[
  {
    "id": "JP4650419B2",
    "text": "Pyrazine derivatives and their pharmaceutical use  Claims (\n3\n)\n\n\nTranslated from \nJapanese\n\n\n\n\n\n\n\n\n \n \n５−［５−アミノ−３−（４−フルオロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン、５−（５−アミノ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン、５−［５−アミノ−３−（４−メトキシフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン、５−［５−アミノ−３−（３−メトキシフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン、５−［５−アミノ−３−（２，３−ジフルオロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン、５−［５−アミノ−３−（２，４−ジフルオロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン、５−［５−アミノ−３−（２，５−ジフルオロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン、５−［５−アミノ−３−（４−フルオロフェニル）−２−ピラジニル］−１−メチル−２（１Ｈ）−ピリドン、５−［５−アミノ−３−（２−フルオロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン、５−［５−アミノ−３−（３−フルオロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン、５−［５−アミノ−３−（３−クロロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン、５−［５−アミノ−３−（４−クロロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン、５−［５−アミノ−３−（３，４−ジフルオロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン、５−［５−アミノ−３−（３，５−ジフルオロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン、及び５−（５−アミノ−３−フェニル−２−ピラジニル）−１−メチル−２（１Ｈ）−ピリドンからなる群から選択される化合物\nまたはその塩。\n \n5- [5-Amino-3- (4-fluorophenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone, 5- (5-amino-3-phenyl-2-pyrazinyl) -1- Isopropyl-2 (1H) -pyridone, 5- [5-amino-3- (4-methoxyphenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone, 5- [5-amino-3- (3-methoxyphenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone, 5- [5-amino-3- (2,3-difluorophenyl) -2-pyrazinyl] -1-isopropyl- 2 (1H) -pyridone, 5- [5-amino-3- (2,4-difluorophenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone, 5- [5-amino-3- (2,5-di Fluorophenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone, 5- [5-amino-3- (4-fluorophenyl) -2-pyrazinyl] -1-methyl-2 (1H) -pyridone 5- [5-amino-3- (2-fluorophenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone, 5- [5-amino-3- (3-fluorophenyl) -2 -Pyrazinyl] -1-isopropyl-2 (1H) -pyridone, 5- [5-amino-3- (3-chlorophenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone, 5- [5 -Amino-3- (4-chlorophenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone, 5- [5-amino-3- (3,4-difluorophenyl) -2-pyrazinyl -1-isopropyl-2 (1H) -pyridone, 5- [5-amino-3- (3,5-difluorophenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone, and 5- ( A compound selected from the group consisting of 5-amino-3-phenyl-2-pyrazinyl) -1-methyl-2 (1H) -pyridone\n or a salt thereof.\n\n\n\n\n\n\n\n\n\n\n \n \n５−［５−アミノ−３−（４−フルオロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\nまたはその塩。\n \n5- [5-amino-3- (4-fluorophenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone\n or a salt thereof.\n\n\n\n\n\n\n\n\n\n\n\n\n \n請求項１乃至２の何れか一項に記載の化合物または医薬として許容されるその塩を有効成分として含有する医薬組成物。\nA pharmaceutical composition comprising the compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof as an active ingredient. Description\n\n\nTranslated from \nJapanese\n\n\n\n\n\n\n\n\n \n\n  本発明は、医薬として有用である新規ピラジン誘導体およびその塩に関する。\n\n\n  The present invention relates to novel pyrazine derivatives and salts thereof that are useful as pharmaceuticals.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  アデノシンは普遍的生化学メッセンジャーである。アデノシンは、７回膜貫通Ｇタンパク質共役受容体と結合し、それらを活性化し、種々の生理的反応を誘発する。アデノシン受容体は既知の４亜型（即ちＡ\nｌ\n、Ａ\n２ａ\n、Ａ\n２ｂ\nおよびＡ\n３\n）に分類される。これらの受容体亜型は、異なる作用、時には相反する作用を媒介する。アデノシンＡ\nｌ\n受容体の活性化は、たとえば腎血管抵抗の増加を誘発するが、アデノシンＡ\n２ａ\n受容体の活性化は、腎血管抵抗の減少を誘発する。したがって、アデノシン拮抗剤は、心疾患および循環障害、中枢神経系の変性疾患、呼吸器疾患および利尿治療が適切となる多くの疾患などの多数の疾患の予防および／または治療に有用である。\n\nAdenosine is a universal biochemical messenger. Adenosine binds to 7-transmembrane G protein coupled receptors and activates them to elicit various physiological responses. Adenosine receptors are classified into four known subtypes (ie, A \n1\n , A \n2a\n , A \n2b\n and A \n3\n ). These receptor subtypes mediate different actions and sometimes conflicting actions. Activation of the adenosine A \nl\n receptor, for example, induces an increase in renal vascular resistance, the activation of the adenosine A \n2a\n receptor elicits a decrease in renal vascular resistance. Thus, adenosine antagonists are useful for the prevention and / or treatment of a number of diseases, such as heart diseases and circulatory disorders, central nervous system degenerative diseases, respiratory diseases and many diseases for which diuretic treatment is appropriate.\n\n\n\n\n\n\n \n\n  アデノシン受容体拮抗作用を示すいくつかの２−アミノピリジン化合物が知られており（ＷＯ０２／１４２８２、ＷＯ０１／２５２１０など）、さらにいくつかの２−アミノピリミジン化合物も知られている（ＵＳ２００１／００２７１９６など）。\n\n しかしながら、概して、四種の置換基で置換されるピラジンを生成することは困難であり、たとえば式Ａ\n\nSome 2-aminopyridine compounds showing adenosine receptor antagonistic activity are known (WO02 / 14282, WO01 / 25210, etc.), and some 2-aminopyrimidine compounds are also known (US2001 / 0027196, etc.). ). \n However, in general, it is difficult to produce pyrazines that are substituted with four substituents, for example the formula A\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n（式中、ＡｒおよびＡｒ’は、それぞれ同じまたは異なるアリール；\n\n  Ｒ、Ｒ’およびＭは、それぞれ水素または適当な置換基；\n\nをそれぞれ意味する。）\n\nで表されるピラジン化合物の合成が報告されている（たとえば（１）Ｊ．Ｏｒｇ．Ｃｈｅｍ．，４０，２３４１（１９７５），（２）Ｊ．Ｈｅｔｅｒｏｃｙｃｌｉｃ  Ｃｈｅｍ．，１５，６６５（１９７８），（３）Ｊ．Ｃｈｅｍ．Ｓｏｃ．，Ｐｅｒｋｉｎ  Ｔｒａｎｓ．１，８８５（１９９４），（４）Ｓｙｎｔｈｅｓｉｓ，９３１（１９９４），（５）ＷＯ０２／０８８０８４など）；しかしながら、そのＡｒとＡｒ’は同じであり、ＡｒとＡｒ’が異なるピラジン化合物の選択的合成は、周知の限りでは示されておらず、２−アミノ−６−アリール−５−（６−オキソ−１，６−ジヒドロ−ピリド−３−イル）−ピラジン化合物およびその誘導体は新規であり、これらの化合物は、今までのところ知られていない。さらに、アデノシンＡ\nｌ\nとＡ\n２ａ\nの両方の阻害活性を有するいかなるピラジン誘導体も知られていない。\n\nWherein Ar and Ar ′ are each the same or different aryl; \n R, R ′ and M are each hydrogen or a suitable substituent; \n Means each. ) \n (For example, (1) J. Org. Chem., 40, 2341 (1975), (2) J. Heterocyclic Chem., 15, 665 (1978), (3) ) J. Chem. Soc., Perkin Trans. 1, 885 (1994), (4) Synthesis, 931 (1994), (5) WO 02/088804, etc.); Selective synthesis of pyrazine compounds in which Ar ′ and Ar ′ are different is not shown to the extent that it is well known, 2-amino-6-aryl-5- (6-oxo-1,6-dihydro-pyrid-3-yl) -Pyrazine compounds and their derivatives are novel and these compounds are not known so far. Furthermore, no known any pyrazine derivatives having the inhibitory activity of both adenosine A \nl\n and A \n2a.\n \n\n\n\n\n\n\n\n\n\n\n \n\n  本発明は、医薬として有用であって、毒性（特に痙攣性毒性）の無いあるいは少ない新規ピラジン誘導体および医薬として許容されるその塩；当該ピラジン誘導体およびその塩の製造方法；有効成分として当該ピラジン誘導体または医薬として許容されるその塩を含有する医薬組成物；当該ピラジン誘導体または医薬として許容されるその塩の医薬としての使用；ならびに、ヒトまたは動物に当該ピラジン誘導体または医薬として許容されるその塩を投与することからなる、当該ピラジン誘導体または医薬として許容されるその塩を治療目的のために使用する方法に関する。\n\n\n  The present invention is a novel pyrazine derivative that is useful as a medicament and has little or no toxicity (particularly convulsive toxicity) and a pharmaceutically acceptable salt thereof; a method for producing the pyrazine derivative and a salt thereof; the pyrazine derivative as an active ingredient Or a pharmaceutical composition containing a pharmaceutically acceptable salt thereof; use of the pyrazine derivative or pharmaceutically acceptable salt thereof as a medicine; and a human or animal with the pyrazine derivative or pharmaceutically acceptable salt thereof. It relates to a method of using the pyrazine derivative or a pharmaceutically acceptable salt thereof for therapeutic purposes.\n\n\n\n\n\n\n\n \n\n  ピラジン誘導体およびその塩は、アデノシン拮抗剤（特にＡ\n１\n受容体およびＡ\n２\n（特にＡ\n２ａ\n）受容体デュアル拮抗剤）であり、抗カタレプシー作用、認識増強作用、鎮痛作用、自発運動量増加作用、抗うつ作用、利尿作用、心臓保護作用、強心作用、血管拡張作用（たとえば脳血管拡張作用など）、腎血流量増加作用、腎保護作用、腎機能改善作用、脂肪分解増強作用、アナフィラキシー性気管支収縮の阻害作用、インスリン分泌促進作用、エリスロポエチン産生増加作用、血小板凝集抑制作用などの種々の薬理作用を有する。\n\nPyrazine derivatives and salts thereof are adenosine antagonists (especially A \n1\n receptors and A \n2\n (especially A \n2a\n ) receptor dual antagonists), and have an anti-catalepsy action, a cognitive enhancement action, an analgesic action, an increase in locomotor activity, Depressive action, diuretic action, cardioprotective action, cardiotonic action, vasodilatory action (eg cerebral vasodilatory action, etc.), renal blood flow increasing action, renal protective action, renal function improving action, lipolysis enhancing action, anaphylactic bronchoconstriction It has various pharmacological actions such as an inhibitory action, an insulin secretion promoting action, an erythropoietin production increasing action, and a platelet aggregation inhibitory action.\n\n\n\n\n\n\n \n\n  それらは、認識増強剤、抗不安剤、抗痴呆薬、精神刺激薬、鎮痛薬、心臓保護剤、抗うつ薬、脳循環改善剤、トランキライザー、心不全用薬剤、強心薬、降圧薬、腎不全（腎機能障害）用薬剤、腎毒性用薬剤、腎保護剤、腎機能改善用薬剤、利尿薬、浮腫用薬剤、抗肥満薬、抗喘息薬、気管支拡張薬、無呼吸用薬剤、痛風用薬剤、高尿酸血症用薬剤、乳幼児突然死症候群（ＳＩＤＳ）用薬剤、アデノシンによる免疫抑制作用の改善薬、抗糖尿病薬、潰瘍用薬剤、膵炎用薬剤、メニエール症候群用薬剤、貧血用薬剤；血栓症用薬剤、心筋梗塞用薬剤、閉塞症用薬剤、閉塞性動脈硬化症用薬剤、血栓静脈炎用薬剤、脳梗塞用薬剤、一過性の虚血発作用薬剤、狭心症用薬剤などとして有用であり；うつ病、痴呆（たとえばアルツハイマー病、脳血管性の痴呆、パーキンソン病に伴う痴呆など）、パーキンソン病、不安、疼痛、脳血管疾患（たとえば卒中など）、心不全；高血圧（たとえば本態性高血圧、腎原性高血圧など）；たとえば虚血／再灌流障害（たとえば心筋虚血／再灌流障害、脳虚血／再灌流障害、末梢虚血／再灌流障害など）、ショック（たとえばエンドトキシンショック、出血性ショックなど）、外科的処置などによって誘発される循環不全（急性循環不全）；蘇生後の収縮不全；徐脈性不整脈；電気機械的機能不全；心血行動態不全；ＳＩＲＳ（全身性炎症反応症候群）；多臓器不全；腎不全（腎機能障害）（たとえば急性腎不全など）、腎毒性［たとえばシスプラチン、ゲンタマイシン、ＦＲ−９００５０６（ＥＰ−０１８４１６２に開示されている）、シクロスポリン（たとえばシクロスポリンＡ）など；グリセロールなどの薬剤によって誘発される腎毒性］、ネフローゼ、腎炎、浮腫（たとえば心臓性浮腫、腎性浮腫、肝性浮腫、特発性浮腫、薬剤性浮腫、急性血管神経性浮腫、遺伝性血管神経性浮腫、癌性の腹水、妊娠浮腫など）；肥満症、気管支喘息、痛風、高尿酸血症、乳幼児突然死症候群、免疫抑制、糖尿病、消化性潰瘍（たとえば胃潰瘍、十二指腸潰瘍など）などの潰瘍、膵炎、メニエール症候群、貧血、透析誘導性の低血圧、便秘症、虚血性の腸疾患、イレウス（たとえば機械的イレウス、麻痺性イレウスなど）；ならびに心筋梗塞、血栓症（たとえば動脈性血栓、脳血栓など）、閉塞症、閉塞性動脈硬化症、血栓静脈炎、脳梗塞、一過性の虚血性発作、狭心症などの予防および／または治療に有用である。\n\n\n  They include cognitive enhancers, anxiolytics, anti-dementia drugs, psychostimulants, analgesics, cardioprotectants, antidepressants, cerebral circulation improvers, tranquilizers, drugs for heart failure, cardiotonic drugs, antihypertensive drugs, renal failure ( Renal dysfunction drugs, nephrotoxic drugs, nephroprotective drugs, renal function improving drugs, diuretics, edema drugs, anti-obesity drugs, anti-asthma drugs, bronchodilator drugs, apnea drugs, gout drugs, Drug for hyperuricemia, drug for sudden infant death syndrome (SIDS), drug for improving immunosuppressive action by adenosine, antidiabetic drug, drug for ulcer, drug for pancreatitis, drug for Meniere syndrome, drug for anemia; Useful as drugs, drugs for myocardial infarction, drugs for obstruction, drugs for obstructive arteriosclerosis, drugs for thrombophlebitis, drugs for cerebral infarction, drugs for transient ischemia, drugs for angina pectoris, etc. Yes; depression, dementia (eg Alzheimer's disease, cerebrovascular Dementia, dementia associated with Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (eg stroke), heart failure; hypertension (eg essential hypertension, nephrogenic hypertension, etc.); eg ischemia / reperfusion injury (Eg, myocardial ischemia / reperfusion injury, cerebral ischemia / reperfusion injury, peripheral ischemia / reperfusion injury, etc.), circulatory failure induced by shock (eg, endotoxin shock, hemorrhagic shock, etc.), surgical procedures, etc. (Acute circulatory failure); systolic dysfunction after resuscitation; bradyarrhythmia; electromechanical dysfunction; cardiovascular dysfunction; SIRS (systemic inflammatory response syndrome); multiple organ failure; renal failure (renal dysfunction) (eg Acute kidney failure, etc.), nephrotoxicity [eg cisplatin, gentamicin, FR-900506 (disclosed in EP-0184162), cyclosporine (Eg, cyclosporin A); nephrotoxicity induced by drugs such as glycerol], nephrosis, nephritis, edema (eg, cardiac edema, renal edema, hepatic edema, idiopathic edema, drug edema, acute vascular neuropathy) Edema, hereditary angioedema, cancerous ascites, pregnancy edema, etc.); obesity, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, peptic ulcer (eg gastric ulcer, duodenum) Ulcers such as ulcers), pancreatitis, Meniere syndrome, anemia, dialysis-induced hypotension, constipation, ischemic bowel disease, ileus (eg mechanical ileus, paralytic ileus, etc.); and myocardial infarction, thrombosis ( Prevention and / or treatment of arterial thrombus, cerebral thrombus, etc.), obstruction, obstructive arteriosclerosis, thrombophlebitis, cerebral infarction, transient ischemic attack, angina Useful for.\n\n\n\n\n\n\n\n \n\n  本発明の新規ピラジン誘導体またはその塩は、下記式（Ｉ）\n\n\n  The novel pyrazine derivative of the present invention or a salt thereof has the following formula (I)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n［式中、Ｒ\n１\nは、\n\n[Wherein R \n1\n is\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n（式中、\n\n  Ｒ\n６\nは水素または任意に置換された低級アルキル；\n\n  Ｒ\n７\nは水素またはハロゲン；\n\n  Ｒ\n８\nは低級アルキル；\n\nをそれぞれ意味する。）\n\n  Ｒ\n２\nは水素；ヒドロキシ；ハロゲン；シアノ；または低級アルキル、低級アルケニル、低級アルキニル、低級アルコキシ、アリールオキシ、アリールチオ、アシル、アリール、複素環基またはアミノ、その各々は置換基で任意に置換される；\n\n  Ｒ\n３\nおよびＲ\n４\nは、それぞれ水素、低級アルキルまたはアシル；\n\n  Ｒ\n５\nは低級アルキル、低級アルケニル、低級アルキニル、シアノ、アリールまたは複素環基、その各々は置換基で任意に置換される；\n\nをそれぞれ意味する。］\n\nで表される化合物またはその塩である。\n\n(Where \n R \n6\n is hydrogen or optionally substituted lower alkyl; \n R \n7\n is hydrogen or halogen; \n R \n8\n is lower alkyl; \n Means each. ) \n R \n2\n is hydrogen; hydroxy; halogen; cyano; or lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, aryloxy, arylthio, acyl, aryl, heterocyclic group or amino, each of which is optionally substituted with a substituent ; \n R \n3\n and R \n4\n are each hydrogen, lower alkyl or acyl; \n R \n5\n is a lower alkyl, lower alkenyl, lower alkynyl, cyano, aryl or heterocyclic group, each of which is optionally substituted with a substituent; \n Means each. ] \n Or a salt thereof.\n\n\n\n\n\n\n \n\n  一般式（Ｉ）で表される本発明のピラジン化合物の好ましい例としては、下記のものを挙げることができる。\n\n（１）  一般式（Ｉ）\n\n［式中、\n\n  Ｒ\n１\nは、\n\nPreferable examples of the pyrazine compound of the present invention represented by the general formula (I) include the following. \n (1) General formula (I) \n [Where: \n R \n1\n is\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n（式中、\n\n  Ｒ\n６\nは水素、低級アルキル、アリール（低級）アルキル、ヘテロアリール（低級）アルキル；\n\n  Ｒ\n７\nは水素またはハロゲン；\n\nをそれぞれ意味する。）\n\n  Ｒ\n２\nは水素，ハロゲン、シアノ、任意に置換された低級アルキル、任意に置換された低級アルキニル、低級アルコキシ、アリールオキシ、アリールチオ、カルバモイル、カルボキシ、保護されたカルボキシまたは任意に置換されたアミノ；\n\n  Ｒ\n３\nおよびＲ\n４\nは、それぞれ水素または低級アルキル；\n\n  Ｒ\n５\nはアリールまたはヘテロアリール、その各々は１個またはそれ以上の置換基で任意に置換される；\n\nをそれぞれ意味する。］\n\nで表されるピラジン化合物またはその塩。\n\n（２）  上記の化合物（１）であって、\n\n（式中、\n\n  Ｒ\n２\nは水素、ハロゲン、シアノ、ヒドロキシル化された（低級）アルキル、低級アルキニル、低級アルコキシ、アリールオキシ、アリールチオ、カルボキシ、エステル化されたカルボキシ、カルバモイル、アミド化されたカルボキシ、アミノまたはモノまたはジ（低級）アルキルアミノ；\n\n  Ｒ\n３\nおよびＲ\n４\nは、それぞれ水素；\n\n  Ｒ\n５\nはアリールまたはヘテロアリール、その各々は、ハロゲンおよび低級アルコキシよりなる群から選択された１個またはそれ以上の置換基で任意に置換される；\n\n  Ｒ\n６\nは水素または低級アルキル；\n\n  Ｒ\n７\nは水素；\n\nをそれぞれ意味する。）\n\nで表されるピラジン化合物またはその塩。\n\n（３）  上記の化合物（２）であって、\n\n（式中、\n\n  Ｒ\n２\nは水素、ブロモ、シアノ、ヒドロキシメチル、ヒドロキシエチル、ヒドロキシプロピル、エチニル、メトキシ、エトキシ、プロポキシ、フェニルオキシ、フェニルチオ、カルボキシ、カルバモイル、モノまたはジメチルアミノカルボニル、ピリジルメチルアミノカルボニル、ヒドロキシメチルアミノカルボニルまたはモノまたはジメチルアミノ；\n\n  Ｒ\n３\nおよびＲ\n４\nは、それぞれ水素；\n\n  Ｒ\n５\nはフェニル、ピリジル、フリル、チエニル、ピロリルまたはピラゾリル、その各々は、フルオロ、クロロおよびメトキシよりなる群から選択された１個またはそれ以上の置換基で任意に置換される；\n\n  Ｒ\n６\nは水素、メチル、エチル、ｎ−プロピル、イソプロピル、ｎ−ブチルまたはｔ−ブチル；\n\n  Ｒ\n７\nは水素；\n\nをそれぞれ意味する。）\n\nで表されるピラジン化合物またはその塩。\n\n（４）  上記の化合物（３）であって、\n\n（式中、\n\n  Ｒ\n２\nは水素、シアノ、エチニル、メトキシ、フェニルオキシ、フェニルチオ、カルボキシ、カルバモイルまたはメチルアミノ；\n\n  Ｒ\n５\nはフェニル、フリルまたはチエニル、その各々は、フルオロ、クロロおよびメトキシよりなる群から選択された１個またはそれ以上の置換基で任意に置換される；\n\nをそれぞれ意味する。）\n\nで表されるピラジン化合物またはその塩。\n\n（５）  上記の化合物（４）であって、\n\n（式中、\n\n  Ｒ\n２\nは水素、シアノ、カルボキシ、カルバモイルまたはメチルアミノ；\n\n  Ｒ\n５\nは、１個またはそれ以上のフルオロで任意に置換されたフェニル；\n\n  Ｒ\n６\nは水素、メチル、エチルまたはイソプロピル；\n\nをそれぞれ意味する。）\n\nで表されるピラジン化合物またはその塩。\n\n(Where \n R \n6\n is hydrogen, lower alkyl, aryl (lower) alkyl, heteroaryl (lower) alkyl; \n R \n7\n is hydrogen or halogen; \n Means each. ) \n R \n2\n is hydrogen, halogen, cyano, optionally substituted lower alkyl, optionally substituted lower alkynyl, lower alkoxy, aryloxy, arylthio, carbamoyl, carboxy, protected carboxy or optionally substituted amino; \n R \n3\n and R \n4\n are each hydrogen or lower alkyl; \n R \n5\n is aryl or heteroaryl, each of which is optionally substituted with one or more substituents; \n Means each. ] \n Or a salt thereof. \n (2) The above compound (1), \n (Where \n R \n2\n is hydrogen, halogen, cyano, hydroxylated (lower) alkyl, lower alkynyl, lower alkoxy, aryloxy, arylthio, carboxy, esterified carboxy, carbamoyl, amidated carboxy, amino or mono or di (Lower) alkylamino; \n R \n3\n and R \n4\n are each hydrogen; \n R \n5\n is aryl or heteroaryl, each of which is optionally substituted with one or more substituents selected from the group consisting of halogen and lower alkoxy; \n R \n6\n is hydrogen or lower alkyl; \n R \n7\n is hydrogen; \n Means each. ) \n Or a salt thereof. \n (3) The above compound (2), \n (Where \n R \n2\n is hydrogen, bromo, cyano, hydroxymethyl, hydroxyethyl, hydroxypropyl, ethynyl, methoxy, ethoxy, propoxy, phenyloxy, phenylthio, carboxy, carbamoyl, mono or dimethylaminocarbonyl, pyridylmethylaminocarbonyl, hydroxymethylaminocarbonyl Or mono or dimethylamino; \n R \n3\n and R \n4\n are each hydrogen; \n R \n5\n is phenyl, pyridyl, furyl, thienyl, pyrrolyl or pyrazolyl, each of which is optionally substituted with one or more substituents selected from the group consisting of fluoro, chloro and methoxy; \n R \n6\n is hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl or t-butyl; \n R \n7\n is hydrogen; \n Means each. ) \n Or a salt thereof. \n (4) Said compound (3), \n (Where \n R \n2\n is hydrogen, cyano, ethynyl, methoxy, phenyloxy, phenylthio, carboxy, carbamoyl or methylamino; \n R \n5\n is phenyl, furyl or thienyl, each of which is optionally substituted with one or more substituents selected from the group consisting of fluoro, chloro and methoxy; \n Means each. ) \n Or a salt thereof. \n (5) The above compound (4), \n (Where \n R \n2\n is hydrogen, cyano, carboxy, carbamoyl or methylamino; \n R \n5\n is phenyl optionally substituted with one or more fluoro; \n R \n6\n is hydrogen, methyl, ethyl or isopropyl; \n Means each. ) \n Or a salt thereof.\n\n\n\n\n\n\n \n\n  本発明の目的化合物（Ｉ）およびその塩は、下記の諸方法によって製造することができる。\n\n\n製造法１\n\n\nThe object compound (I) and salts thereof of the present invention can be produced by the following methods. \n \nManufacturing method 1\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n製造法２\nManufacturing method 2\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n製造法３\nProduction method 3\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n製造法４\nManufacturing method 4\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n製造法５\nManufacturing method 5\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n製造法６\nManufacturing method 6\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n製造法７\nManufacturing method 7\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n製造法８\nManufacturing method 8\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n［式中、Ｒ\n１\n、Ｒ\n２\n、Ｒ\n３\n、Ｒ\n４\n、Ｒ\n５\nおよびＲ\n８\nは、それぞれ前記定義の通りであり；\n\n  Ｒ\n９\nはシアノ、カルバモイルまたはカルボキシ；\n\n  Ｒ\n１０\nは任意に置換された低級アルキル；\n\n  Ｒ\n１１\nおよびＲ\n１２\nは、それぞれ水素、低級アルキル、低級アルコキシまたはシクロ（低級）アルキル、その各々は置換基で任意に置換される；またはＲ\n１１\nおよびＲ\n１２\nは、それらが結合する窒素原子と共に、任意に置換された窒素含有複素環基を表す。\n\n[Wherein R \n1\n , R \n2\n , R \n3\n , R \n4\n , R \n5\n and R \n8\n are as defined above; \n R \n9\n is cyano, carbamoyl or carboxy; \n R \n10\n is an optionally substituted lower alkyl; \n R \n11\n and R \n12\n are each hydrogen, lower alkyl, lower alkoxy or cyclo (lower) alkyl, each of which is optionally substituted with a substituent; or R \n11\n and R \n12\n together with the nitrogen atom to which they are attached, Represents an optionally substituted nitrogen-containing heterocyclic group.\n\n\n\n\n\n\n \n\n  Ｒ\n１３\nは低級アルキル、低級アルケニル、低級アルキニル、低級アルコキシ、アリールオキシ、アリールチオ、アシル、アリール、複素環基またはアミノ、その各々は置換基で任意に置換される；\n\n  Ｙは脱離基；\n\n  Ｈａｌはハロゲン原子；\n\n  Ｚは水素、アルカリ金属（たとえばリチウム、ナトリウム、カリウムなど）、ＳｎＢｕ\n３\n、ＢＷ\n２\nまたはＭｅｔ−Ｈａｌ；\n\n（式中、ＢＷ\n２\nは、Ｂ（ＯＨ）\n２\n、Ｂ（ＣＨＣＨ\n３\nＣＨ（ＣＨ\n３\n）\n２\n）\n２\n、テトラメチル−１，３，２−ジオキサボロラン−２−イル、９−ボラビシクロ［３．３．１］ノナニルなどの有機ホウ素化合物の一部；\n\n  Ｍｅｔ−Ｈａｌは、ＭｇＢｒ、ＺｎＣｌなどの金属ハロゲン化合物の一部；\n\nをそれぞれ意味する。）\n\nをそれぞれ意味する。］\n\n  出発化合物またはその塩は、たとえば下記の反応式にしたがって製造することができる。\n\n\n製造法Ａ\n\n\nR \n13\n is lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, aryloxy, arylthio, acyl, aryl, heterocyclic group or amino, each of which is optionally substituted with a substituent; \n Y is a leaving group; \n Hal is a halogen atom; \n Z is hydrogen, alkali metal (eg, lithium, sodium, potassium, etc.), SnBu \n3\n , BW \n2\n or Met-Hal; \n (In the formula, BW \n2\n represents B (OH) \n2\n , B (CHCH \n3\n CH (CH \n3\n ) \n2\n ) \n2\n , tetramethyl-1,3,2-dioxaborolan-2-yl, 9-borabicyclo [3.3. 1] Some organic boron compounds such as nonanyl; \n Met-Hal is a part of metal halide compounds such as MgBr and ZnCl; \n Means each. ) \n Means each. ] \n The starting compound or a salt thereof can be produced, for example, according to the following reaction formula. \n \nManufacturing method A\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n製造法Ｂ\nManufacturing method B\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n製造法Ｃ\nManufacturing method C\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n製造法Ｄ\nManufacturing method D\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n製造法Ｅ\nManufacturing method E\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n［式中、Ｒ\n１\n、Ｒ\n２\n、Ｒ\n３\n、Ｒ\n４\n、Ｒ\n１０\n、ＹおよびＨａｌは、それぞれ前記定義の通りである．］\n\n  上記の製造法に加えて、目的化合物（Ｉ）およびその塩は、たとえば本明細書中の\n実施例\nで説明される手順またはそれと同様の手順にしたがって製造することができる。\n\n[Wherein R \n1\n , R \n2\n , R \n3\n , R \n4\n , R \n10\n , Y and Hal are as defined above. ] \n In addition to the above production methods, the object compound (I) and salts thereof can be produced, for \nexample\n , according to the procedures described in the \nexamples\n in this specification or procedures similar thereto.\n\n\n\n\n\n\n \n\n  出発化合物は、たとえば本明細書中の\n製造例\nで説明される手順またはそれと同様の手順にしたがって製造することができる。\n\nThe starting compounds can be prepared, for \nexample\n , according to the procedures described in the \npreparation examples\n herein or procedures similar thereto.\n\n\n\n\n\n\n \n\n  目的化合物（Ｉ）およびその塩は、\n製造例\nまたは\n実施例\nに示される方法またはそれと同様の方法にしたがって製造することができる。\n\nThe object compound (I) and a salt thereof can be prepared according to the method or similar methods shown in \nProduction Examples\n or \nExamples.\n \n\n\n\n\n\n\n \n\n  さらに、化合物（Ｉ）の溶媒和形態（たとえば水和物など）および化合物（Ｉ）の結晶のいかなる形態もまた本発明の範囲に含まれる。\n\n\n  Furthermore, solvated forms of compound (I) (such as hydrates) and any form of crystals of compound (I) are also within the scope of the present invention.\n\n\n\n\n\n\n\n \n\n  さらに、生物学的研究に適合する化合物（Ｉ）の放射能標識誘導体もまた本発明の範囲に含まれる。\n\n\n  Furthermore, radiolabeled derivatives of compound (I) that are compatible with biological studies are also within the scope of the present invention.\n\n\n\n\n\n\n\n \n\n  目的化合物（Ｉ）の好適な塩は、慣用の医薬として許容される塩であって、金属塩、たとえばアルカリ金属塩（たとえばナトリウム塩、カリウム塩など）およびアルカリ土類金属塩（たとえばカルシウム塩、マグネシウム塩など）、アンモニウム塩、有機塩基塩（たとえばトリメチルアミン塩、トリエチルアミン塩、ピリジン塩、ピコリン塩、ジシクロヘキシルアミン塩、Ｎ，Ｎ’−ジベンジルエチレンジアミン塩など）、有機酸塩（たとえば酢酸塩、トリフルオロ酢酸塩、マレイン酸塩、酒石酸塩、フマル酸塩、メタンスルホン酸塩、ベンゼンスルホン酸塩、蟻酸塩、トルエンスルホン酸塩など）、無機酸塩（たとえば塩酸塩、臭化水素酸塩、ヨウ化水素酸塩、硫酸塩、燐酸塩など）、アミノ酸との塩（たとえばアルギニン塩、アスパラギン酸塩、グルタミン酸塩など）などを挙げることができる。\n\n\n  Suitable salts of the target compound (I) are conventional pharmaceutically acceptable salts, such as metal salts such as alkali metal salts (eg sodium salts, potassium salts etc.) and alkaline earth metal salts (eg calcium salts, Magnesium salt), ammonium salt, organic base salt (eg trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N, N′-dibenzylethylenediamine salt), organic acid salt (eg acetate, Fluoroacetate, maleate, tartrate, fumarate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate, etc., inorganic acid salt (eg hydrochloride, hydrobromide, iodine Hydrohalides, sulfates, phosphates, etc.), salts with amino acids (eg arginine salts, asparagi) Salt, such as glutamate), and the like.\n\n\n\n\n\n\n\n \n\n  本発明の範囲内に含まれ、本明細書において上記および下記の記載に見られる種々の定義の好適な例および実例を以下に詳細に説明する。\n\n\n  Preferred examples and examples of the various definitions included within the scope of the present invention and found herein above and below are described in detail below.\n\n\n\n\n\n\n\n \n\n  「任意に置換された」とは、「置換されていないまたは置換された」を意味する。\n\n\n  “Optionally substituted” means “unsubstituted or substituted”.\n\n\n\n\n\n\n\n \n\n  「低級」とは、特記ない限り、炭素原子数１ないし６を意味する。\n\n\n  “Lower” means 1 to 6 carbon atoms unless otherwise specified.\n\n\n\n\n\n\n\n \n\n  「モノまたはジ（低級）アルキルアミノ」における好適な「低級アルキル」および「（低級）アルキル」部分としては、直鎖または分枝状のもの、たとえばメチル、エチル、プロピル、イソプロピル、ブチル、第三級ブチル、ペンチル、ヘキシルなどを挙げることができ、好ましいものとしては、メチル、エチルまたはイソプロピルを挙げることができる。\n\n\n  Suitable “lower alkyl” and “(lower) alkyl” moieties in “mono or di (lower) alkylamino” include straight or branched moieties such as methyl, ethyl, propyl, isopropyl, butyl, tertiary Primary butyl, pentyl, hexyl and the like can be mentioned, and preferable examples include methyl, ethyl or isopropyl.\n\n\n\n\n\n\n\n \n\n  好適な「任意に置換された低級アルキル」としては、低級アルコキシ、ヒドロキシ、アリールオキシ、シクロ（低級）アルキル、アミノ、アリール、複素環基、アシルなどの適当な置換基で任意に置換された低級アルキルを挙げることができる。\n\n\n  Suitable “optionally substituted lower alkyl” includes lower alkoxy optionally substituted with an appropriate substituent such as lower alkoxy, hydroxy, aryloxy, cyclo (lower) alkyl, amino, aryl, heterocyclic group, acyl and the like. Mention may be made of alkyl.\n\n\n\n\n\n\n\n \n\n  好適な「低級アルコキシ」としては、直鎖または分枝状のもの、たとえばメトキシ、エトキシ、プロポキシ、イソプロポキシ、ブトキシ、第三級ブトキシ、ペンチルオキシ、ヘキシルオキシなどを挙げることができる。\n\n\n  Suitable “lower alkoxy” includes linear or branched ones such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tertiary butoxy, pentyloxy, hexyloxy and the like.\n\n\n\n\n\n\n\n \n\n  好適な「任意に置換された低級アルコキシ」としては、ヒドロキシ、シクロ（低級）アルキル、アミノ、アリール、複素環基、アシルなどの適当な置換基で任意に置換された低級アルコキシを挙げることができる。\n\n\n  Suitable “optionally substituted lower alkoxy” includes lower alkoxy optionally substituted with a suitable substituent such as hydroxy, cyclo (lower) alkyl, amino, aryl, heterocyclic group, acyl and the like. .\n\n\n\n\n\n\n\n \n\n  好適な「シクロ（低級）アルキル」としては、シクロ（Ｃ３−Ｃ８）アルキル、たとえばシクロプロピル、シクロブチル、シクロペンチル、シクロヘキシル、シクロヘプチル、シクロオクチルなどを挙げることができ、好ましいものとしては、シクロヘキシルを挙げることができる。\n\n\n  Suitable \"cyclo (lower) alkyl\" includes cyclo (C3-C8) alkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like, and preferred is cyclohexyl. be able to.\n\n\n\n\n\n\n\n \n\n  好適な「低級アルケニル」としては、直鎖または分枝状のもの、たとえばビニル、プロペニル、アリル、イソプロペニル、ブテニル、ペンテニル、ヘキセニルなどを挙げることができ、好ましいものとしては、ビニルを挙げることができる。\n\n\n  Suitable “lower alkenyl” may be linear or branched, such as vinyl, propenyl, allyl, isopropenyl, butenyl, pentenyl, hexenyl, etc., with vinyl being preferred. it can.\n\n\n\n\n\n\n\n \n\n  好適な「任意に置換された低級アルケニル」としては、低級アルコキシ、ヒドロキシ、シクロ（低級）アルキル、アミノ、アリール、複素環基、アシルなどの適当な置換基で任意に置換された低級アルケニルを挙げることができる。\n\n\n  Suitable “optionally substituted lower alkenyl” includes lower alkenyl optionally substituted with a suitable substituent such as lower alkoxy, hydroxy, cyclo (lower) alkyl, amino, aryl, heterocyclic group, acyl and the like. be able to.\n\n\n\n\n\n\n\n \n\n  好適な「低級アルキニル」としては、直鎖または分枝状のもの、たとえばエチニル、プロピニル、ブチニル、ペンチニル、ヘキシニルなどを挙げることができ、好ましいものとしては、エチニルを挙げることができる。\n\n\n  Suitable “lower alkynyl” includes linear or branched ones such as ethynyl, propynyl, butynyl, pentynyl, hexynyl and the like, and preferred is ethynyl.\n\n\n\n\n\n\n\n \n\n  好適な「任意に置換された低級アルキニル」としては、低級アルコキシ、ヒドロキシ、シクロ（低級）アルキル、アミノ、アリール、複素環基、アシルなどの適当な置換基で任意に置換された低級アルキニルを挙げることができる。\n\n\n  Suitable “optionally substituted lower alkynyl” includes lower alkynyl optionally substituted with an appropriate substituent such as lower alkoxy, hydroxy, cyclo (lower) alkyl, amino, aryl, heterocyclic group, acyl and the like. be able to.\n\n\n\n\n\n\n\n \n\n  「アリールオキシ」または「アリールチオ」における好適な「アリール」および「アリール」部分としては、フェニル、ナフチル、インデニル、アントリルなどを挙げることができ、好ましいものとしては、（Ｃ６−Ｃ１０）アリールを、より好ましいものとしては、フェニルを挙げることができる。\n\n\n  Suitable “aryl” and “aryl” moieties in “aryloxy” or “arylthio” may include phenyl, naphthyl, indenyl, anthryl and the like, with (C6-C10) aryl being more preferred Preferable examples include phenyl.\n\n\n\n\n\n\n\n \n\n  好適な「アリール（低級）アルキル」としては、フェニル（低級）アルキル（たとえばベンジル、フェネチルなど）、ジフェニル（低級）アルキル（たとえばベンズヒドリルなど）、トリフェニル（低級）アルキル（たとえばトリチルなど）、ナフチル（低級）アルキル、インデニル（低級）アルキルまたはアントリル（低級）アルキルなどを挙げることができ、好ましいものとしては、フェニル（低級）アルキルを、より好ましいものとしては、フェニル（Ｃ１−Ｃ４）アルキルを挙げることができる。\n\n\n  Suitable “aryl (lower) alkyl” includes phenyl (lower) alkyl (eg benzyl, phenethyl etc.), diphenyl (lower) alkyl (eg benzhydryl etc.), triphenyl (lower) alkyl (eg trityl etc.), naphthyl ( (Lower) alkyl, indenyl (lower) alkyl, anthryl (lower) alkyl, etc. may be mentioned, with phenyl (lower) alkyl being preferred, and phenyl (C1-C4) alkyl being more preferred. Can do.\n\n\n\n\n\n\n\n \n\n  好適な「任意に置換されたアリール」としては、低級アルキル、低級アルコキシ、ヒドロキシ、ハロゲンなどの適当な置換基、好ましくは１ないし３個の置換基、で任意に置換されたアリールを挙げることができる。任意に置換されたアリールの好適な例としては、低級アルキルフェニル、低級アルコキシフェニルおよびハロフェニルを挙げることができる。\n\n\n  Suitable “optionally substituted aryl” includes aryl optionally substituted with appropriate substituents such as lower alkyl, lower alkoxy, hydroxy, halogen, preferably 1 to 3 substituents. it can. Suitable examples of optionally substituted aryl include lower alkylphenyl, lower alkoxyphenyl and halophenyl.\n\n\n\n\n\n\n\n \n\n  好適な「複素環基」としては、酸素原子、硫黄原子および窒素原子から選択されたヘテロ原子を少なくとも１個有する飽和または不飽和の単環式または多環式複素環基を挙げることができる。\n\n\n  Suitable “heterocyclic group” includes a saturated or unsaturated monocyclic or polycyclic heterocyclic group having at least one heteroatom selected from an oxygen atom, a sulfur atom and a nitrogen atom.\n\n\n\n\n\n\n\n \n\n  前記複素環基の特に好ましい例としては、\n\n  窒素原子１ないし４個を有する３ないし８員の不飽和複素単環基、たとえばピロリル、ピロリニル、イミダゾリル、ピラゾリル、ピリジルおよびそのＮ−オキサイド、ピリミジル、ピラジニル、ピリダジニル、トリアゾリル（たとえば４Ｈ−１，２，４−トリアゾリル、１Ｈ−１，２，３−トリアゾリル、２Ｈ−１，２，３−トリアゾリルなど）、テトラゾリル（たとえば１Ｈ−テトラゾリル、２Ｈ−テトラゾリルなど）、ジヒドロトリアジニル（たとえば４，５−ジヒドロ−１，２，４−トリアジニル、２，５−ジヒドロ−１，２，４−トリアジニルなど）など；\n\n  窒素原子１ないし４個を有する３ないし８員の飽和複素単環基、たとえばアゼチジニル、ピロリジニル、イミダゾリジニル、ピペリジニル（たとえばピペリジノなど）、ピペラジニルなど；\n\n  窒素原子１ないし５個を有する不飽和縮合複素環基、たとえばインドリル、イソインドリル、インドリジニル、ベンズイミダゾリル、キノリル、イソキノリル、インダゾリル、ベンゾトリアゾリル、テトラゾロピリジル、テトラゾロピリダジニル（たとえばテトラゾロ［１，５−ｂ］ピリダジニルなど）、ジヒドロトリアゾロピリダジニルなど；\n\n  酸素原子１または２個および窒素原子１ないし３個を有する３ないし８員の不飽和複素単環基、たとえばオキサゾリル、イソオキサゾリル、オキサジアゾリル（たとえば１，２，４−オキサジアゾリル、１，３，４−オキサジアゾリル、１，２，５−オキサジアゾリルなど）など；\n\n  酸素原子１または２個および窒素原子１ないし３個を有する３ないし８員の飽和複素単環基、たとえばモルホリニル、オキサゾリジニル（たとえば１，３−オキサゾリジニルなど）など；\n\n  酸素原子１または２個および窒素原子１ないし３個を有する不飽和縮合複素環基、たとえばベンゾオキサゾリル、ベンゾオキサジアゾリルなど；\n\n  硫黄原子１または２個および窒素原子１ないし３個を有する３ないし８員の不飽和複素単環基、たとえばチアゾリル、イソチアゾリル、チアゾリニル、チアジアゾリル（たとえば１，２，４−チアジアゾリル、１，３，４−チアジアゾリル、１，２，５−チアジアゾリル、１，２，３−チアジアゾリルなど）など；\n\n  硫黄原子１または２個および窒素原子１ないし３個を有する３ないし８員の飽和複素単環基、たとえばチアゾリジニルなど；\n\n  硫黄原子１個を有する３ないし８員の不飽和複素環基、たとえばチエニルなど；\n\n  硫黄原子１または２個および窒素原子１ないし３個を有する不飽和縮合複素環基、たとえばベンゾチアゾリル、ベンゾチアジアゾリルなど；\n\n  酸素原子１または２個を有する３ないし８員の不飽和複素単環基、たとえばフリル、ピラニル、ジオキソリルなど；\n\n  酸素原子１または２個を有する３ないし８員の飽和複素単環基、たとえばオキソラニル、テトラヒドロピラニル（たとえばテトラヒドロ−２Ｈ−ピラン−２−イルなど）、ジオキソラニルなど；および\n\n  酸素原子１または２個を有する不飽和縮合複素環基、たとえばイソベンゾフラニル、クロメニル（たとえば２Ｈ−クロメン−３−イルなど）、ジヒドロクロメニル（たとえば３，４−ジヒドロ−２Ｈ−クロメン−４−イルなど）などを挙げることができる。\n\nParticularly preferred examples of the heterocyclic group include \n 3 to 8 membered unsaturated heteromonocyclic groups having 1 to 4 nitrogen atoms such as pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl and its N-oxide, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (for example 4H-1,2, , 4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (eg, 1H-tetrazolyl, 2H-tetrazolyl, etc.), dihydrotriazinyl (eg, 4,5- Dihydro-1,2,4-triazinyl, 2,5-dihydro-1,2,4-triazinyl and the like); \n 3 to 8 membered saturated heteromonocyclic groups having 1 to 4 nitrogen atoms, such as azetidinyl, pyrrolidinyl, imidazolidinyl, piperidinyl (such as piperidino), piperazinyl and the like; \n Unsaturated fused heterocyclic groups having 1 to 5 nitrogen atoms, such as indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridyl, tetrazolopyridazinyl (eg tetrazolo [ 1,5-b] pyridazinyl etc.), dihydrotriazolopyridazinyl etc .; \n 3- to 8-membered unsaturated heteromonocyclic groups having 1 or 2 oxygen atoms and 1 to 3 nitrogen atoms, such as oxazolyl, isoxazolyl, oxadiazolyl (eg 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl) , 1,2,5-oxadiazolyl and the like); \n A 3- to 8-membered saturated heteromonocyclic group having 1 or 2 oxygen atoms and 1 to 3 nitrogen atoms, such as morpholinyl, oxazolidinyl (eg 1,3-oxazolidinyl, etc.); \n Unsaturated condensed heterocyclic groups having 1 or 2 oxygen atoms and 1 to 3 nitrogen atoms, such as benzoxazolyl, benzoxiadiazolyl, etc .; \n 3 to 8 membered unsaturated heteromonocyclic groups having 1 or 2 sulfur atoms and 1 to 3 nitrogen atoms, such as thiazolyl, isothiazolyl, thiazolinyl, thiadiazolyl (eg 1,2,4-thiadiazolyl, 1,3,4) -Thiadiazolyl, 1,2,5-thiadiazolyl, 1,2,3-thiadiazolyl, etc.); \n 3 to 8 membered saturated heteromonocyclic groups having 1 or 2 sulfur atoms and 1 to 3 nitrogen atoms, such as thiazolidinyl; \n A 3- to 8-membered unsaturated heterocyclic group having one sulfur atom, such as thienyl; \n Unsaturated condensed heterocyclic groups having 1 or 2 sulfur atoms and 1 to 3 nitrogen atoms, such as benzothiazolyl, benzothiadiazolyl and the like; \n 3 to 8 membered unsaturated heteromonocyclic groups having 1 or 2 oxygen atoms such as furyl, pyranyl, dioxolyl and the like; \n 3 to 8 membered saturated heteromonocyclic groups having 1 or 2 oxygen atoms such as oxolanyl, tetrahydropyranyl (eg tetrahydro-2H-pyran-2-yl), dioxolanyl etc .; and 1 or 2 oxygen atoms Unsaturated condensed heterocyclic group having, for example, isobenzofuranyl, chromenyl (for example, 2H-chromen-3-yl), dihydrochromenyl (for example, 3,4-dihydro-2H-chromen-4-yl), etc. be able to.\n\n\n\n\n\n\n \n\n  好適な「任意に置換された複素環基」としては、低級アルキル、低級アルコキシ、ヒドロキシ、ハロゲンなどの適当な置換基、好ましくは１ないし３個の置換基、で任意に置換された複素環基を挙げることができる。\n\n\n  Suitable “optionally substituted heterocyclic group” includes a heterocyclic group optionally substituted with a suitable substituent such as lower alkyl, lower alkoxy, hydroxy, halogen, etc., preferably 1 to 3 substituents. Can be mentioned.\n\n\n\n\n\n\n\n \n\n  好適な「窒素含有複素環基」としては、前記の「複素環基」であって、その環員に少なくとも１個の窒素原子を有する基、たとえばピロリル、ピロリニル、イミダゾリル、ピラゾリル、トリアゾリル、テトラゾリル、ジヒドロトリアジニル、アゼチジニル、ピロリジニル、イミダゾリジニル、ピペリジル、ピペラジニル、インドリル、イソインドリル、インダゾリル、ベンゾトリアゾリル、ジヒドロトリアゾロピリダジニル、モルホリニル、オキサゾリジニル、チアゾリニル、チアゾリジニルなどを挙げることができる。\n\n\n  Suitable “nitrogen-containing heterocyclic group” is the above-mentioned “heterocyclic group” having a group having at least one nitrogen atom, such as pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, Dihydrotriazinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, indolyl, isoindolyl, indazolyl, benzotriazolyl, dihydrotriazolopyridazinyl, morpholinyl, oxazolidinyl, thiazolinyl, thiazolidinyl and the like can be mentioned.\n\n\n\n\n\n\n\n \n\n  「ヘテロアリール（低級）アルキル」における好適な「ヘテロアリール」および「ヘテロアリール」部分としては、前記の「複素環基」であって、芳香族複素環基として分類されるもの、たとえばピロリル、ピロリニル、イミダゾリル、ピラゾリル、ピリジル、ピリミジニル、ピラジニル、ピリダジニル、トリアゾリル、テトラゾリル、ジヒドロトリアジニル、インドリル、イソインドリル、インドリジニル、ベンゾイミダゾリル、キノリル、イソキノリル、インダゾリル、ベンゾトリアゾリル、テトラゾロピリジル、テトラゾロピリダジニル、ジヒドロトリアゾロピリダジニル、オキサゾリル、イソオキサゾリル、オキサジアゾリル、ベンズオキサゾリル、ベンズオキサジアゾリル、チアゾリル、イソチアゾリル、チアゾリニル、チアジアゾリル、チエニル、ベンゾチアゾリル、ベンゾチアジアゾリル、フリル、ピラニル、ジオキソリル、イソベンゾフラニル、クロメニル、ジヒドロクロメニルなどを挙げることができる。\n\n\n  Suitable \"heteroaryl\" and \"heteroaryl\" moieties in \"heteroaryl (lower) alkyl\" include those described above as \"heterocyclic groups\" that are classified as aromatic heterocyclic groups, such as pyrrolyl, pyrrolinyl , Imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl, dihydrotriazinyl, indolyl, isoindolyl, indolizinyl, benzoimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridyl, tetrazolopyridazini , Dihydrotriazolopyridazinyl, oxazolyl, isoxazolyl, oxadiazolyl, benzoxazolyl, benzoxdiazolyl, thiazolyl, isothiazolyl, thiazolinyl, thiadia It Lil, thienyl, benzothiazolyl, benzothiadiazolyl, furyl, pyranyl, dioxolyl, isobenzofuranyl, chromenyl, and the like dihydrochloride Mesnil.\n\n\n\n\n\n\n\n \n\n  好適な「アシル」としては、低級アルカノイル、アロイル、カルボキシ、保護されたカルボキシなどを挙げることができる。\n\n\n  Suitable “acyl” may include lower alkanoyl, aroyl, carboxy, protected carboxy, and the like.\n\n\n\n\n\n\n\n \n\n  前記の「低級アルカノイル」の好適な例としては、ホルミル、アセチル、プロピオニル、ブチリル、イソブチリル、ピバロイル、ヘキサノイルなどを挙げることができ、好ましいものとしては、（Ｃ１−Ｃ４）アルカノイルを挙げることができる。\n\n\n  Preferable examples of the “lower alkanoyl” include formyl, acetyl, propionyl, butyryl, isobutyryl, pivaloyl, hexanoyl and the like, and (C1-C4) alkanoyl is preferable.\n\n\n\n\n\n\n\n \n\n  前記の「アロイル」の好適な例としては、ベンゾイル、トルオイルなどを挙げることができる。\n\n\n  Preferred examples of the “aroyl” include benzoyl and toluoyl.\n\n\n\n\n\n\n\n \n\n  前記の「保護されたカルボキシ」の好適な例としては、\n\nｉ）  エステル化されたカルボキシ；好適なエステル化されたカルボキシとしては、低級アルコキシカルボニル（たとえばメトキシカルボニル、エトキシカルボニル、プロポキシカルボニル、ブトキシカルボニル、第三級ブトキシカルボニル、ペンチルオキシカルボニル、ヘキシルオキシカルボニルなど）、アリール（低級）アルコキシカルボニル（たとえばベンジルオキシカルボニル、フェネチルオキシカルボニル、２−フェニルプロポキシカルボニル、４−フェニルブトキシカルボニル、４−フェニルペンチルオキシカルボニル、１，３−ジフェニルヘキシルオキシカルボニルなど）など；\n\nｉｉ）  アミド化されたカルボキシ；好適なアミド化されたカルボキシとしては、カルバモイル、Ｎ−（低級）アルキルカルバモイル（たとえばＮ−メチルカルバモイル、Ｎ−エチルカルバモイル、Ｎ−イソプロピルカルバモイル、Ｎ−ブチルカルバモイル、Ｎ−ペンチルカルバモイル、Ｎ−ヘキシルカルバモイルなど）、Ｎ，Ｎ−ジ（低級）アルキルカルバモイル［たとえばＮ，Ｎ−ジメチルカルバモイル、Ｎ，Ｎ−ジエチルカルバモイル、Ｎ−メチル−Ｎ−エチルカルバモイル、Ｎ，Ｎ−ジプロピルカルバモイル、Ｎ，Ｎ−ジ（第三級ブチル）カルバモイル、Ｎ−ペンチル−Ｎ−ヘキシルカルバモイルなど］、Ｎ−低級アルキル−Ｎ−アリール（低級）アルキルカルバモイル（たとえばＮ−メチル−Ｎ−ベンジルカルバモイルなど）などを挙げることができる。\n\nSuitable examples of the above “protected carboxy” include \n i) Esterified carboxy; suitable esterified carboxy includes lower alkoxycarbonyl (eg methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, tertiary butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, etc.) Aryl (lower) alkoxycarbonyl (eg benzyloxycarbonyl, phenethyloxycarbonyl, 2-phenylpropoxycarbonyl, 4-phenylbutoxycarbonyl, 4-phenylpentyloxycarbonyl, 1,3-diphenylhexyloxycarbonyl, etc.); \n ii) amidated carboxy; suitable amidated carboxy include carbamoyl, N- (lower) alkylcarbamoyl (eg N-methylcarbamoyl, N-ethylcarbamoyl, N-isopropylcarbamoyl, N-butylcarbamoyl, N -Pentylcarbamoyl, N-hexylcarbamoyl, etc.), N, N-di (lower) alkylcarbamoyl [for example, N, N-dimethylcarbamoyl, N, N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, N, N- Dipropylcarbamoyl, N, N-di (tertiarybutyl) carbamoyl, N-pentyl-N-hexylcarbamoyl, etc.], N-lower alkyl-N-aryl (lower) alkylcarbamoyl (eg N-methyl-N-benzyl) Carbamoyl etc.) Can be mentioned.\n\n\n\n\n\n\n \n\n  好適な「ハロゲン」としては、フッ素、塩素、臭素およびヨウ素を挙げることができる。\n\n\n  Suitable “halogen” may include fluorine, chlorine, bromine and iodine.\n\n\n\n\n\n\n\n \n\n  好適な「脱離基」としては、ハロゲン、ヒドロキシ、アルカノイルオキシ（たとえばアセトキシ、プロピオニルオキシなど）などのアシルオキシ、またはスルホニルオキシ（たとえばメシルオキシ、トシルオキシなど）などを挙げることができる。\n\n\n  Suitable “leaving groups” include acyloxy such as halogen, hydroxy, alkanoyloxy (eg acetoxy, propionyloxy, etc.), or sulfonyloxy (eg mesyloxy, tosyloxy etc.) and the like.\n\n\n\n\n\n\n\n \n\n  好適な「任意に置換されたアミノ」としては、アミノ、モノまたはジ（低級）アルキルアミノ（たとえばメチルアミノ、ジメチルアミノ、メチルエチルアミノなど）、アシルアミノ（たとえば低級アルコキシカルボニルアミノ（たとえばメトキシカルボニルアミノ、エトキシカルボニルアミノなど）、スルホニルアミノ（たとえばメシルアミノなど）、ウレイドなど）などを挙げることができる。\n\n\n  Suitable “optionally substituted amino” includes amino, mono- or di (lower) alkylamino (eg, methylamino, dimethylamino, methylethylamino, etc.), acylamino (eg, lower alkoxycarbonylamino (eg, methoxycarbonylamino, Ethoxycarbonylamino etc.), sulfonylamino (eg mesylamino etc.), ureido etc.).\n\n\n\n\n\n\n\n \n\n  目的ピラジン化合物（Ｉ）の製造法を以下に詳細に説明する。\n\n\n製造法１\n \n\n  化合物（Ｉ）またはその塩は、化合物（ＩＩ）またはその塩を化合物（ＩＩＩ）またはその塩とのカップリング反応に付すことによって製造することができる。\n\nThe production method of the target pyrazine compound (I) will be described in detail below. \n \nManufacturing method 1\n \n Compound (I) or a salt thereof can be produced by subjecting compound (II) or a salt thereof to a coupling reaction with compound (III) or a salt thereof.\n\n\n\n\n\n\n \n\n  この反応は、通常、慣用の溶媒、たとえば水、アセトン、ジオキサン、アセトニトリル、１，２−ジメトキシエタン、クロロホルム、ジクロロメタン、１，２−ジクロロエタン、テトラヒドロフラン、酢酸エチル、Ｎ，Ｎ−ジメチルホルムアミド、メタノール、エタノール、ジエチルエーテル、１，３−ジメチル−２−イミダゾリジノン、Ｎ−メチルピロリドン、Ｎ，Ｎ’−ジメチルプロピレンウレア、それらの混合物、または反応に悪影響を及ぼさない他の有機溶媒中で実施される。\n\n\n  This reaction is usually carried out using conventional solvents such as water, acetone, dioxane, acetonitrile, 1,2-dimethoxyethane, chloroform, dichloromethane, 1,2-dichloroethane, tetrahydrofuran, ethyl acetate, N, N-dimethylformamide, methanol, Carried out in ethanol, diethyl ether, 1,3-dimethyl-2-imidazolidinone, N-methylpyrrolidone, N, N′-dimethylpropylene urea, mixtures thereof, or other organic solvents that do not adversely affect the reaction The\n\n\n\n\n\n\n\n \n\n  本反応のいくつかは、有機または無機塩基、たとえばアルカリ金属（たとえばナトリウム、カリウムなど）、アルカリ土類金属（たとえばマグネシウム、カルシウムなど）、それらの水素化物または水酸化物またはアルコキシドまたは炭酸塩または炭酸水素塩またはアルカン酸、トリアルキルアミン（たとえばトリエチルアミン、トリメチルアミンなど）、ヒドラジン、ピリジン化合物（たとえばピリジン、ルチジン、ピコリン、４−ジメチルアミノピリジンなど）、キノリンなどの存在下で実施するのが好ましい。\n\n\n  Some of the reactions may be organic or inorganic bases such as alkali metals (eg sodium, potassium etc.), alkaline earth metals (eg magnesium, calcium etc.), their hydrides or hydroxides or alkoxides or carbonates or carbonates. It is preferably carried out in the presence of a hydrogen salt or alkanoic acid, a trialkylamine (eg, triethylamine, trimethylamine, etc.), hydrazine, a pyridine compound (eg, pyridine, lutidine, picoline, 4-dimethylaminopyridine, etc.), quinoline and the like.\n\n\n\n\n\n\n\n \n\n  本反応のいくつかは、触媒、たとえば酢酸パラジウム（ＩＩ）、テトラキス（トリフェニルホスフィン）パラジウム（０）などの存在下で実施するのが好ましい。\n\n\n  Some of the reactions are preferably carried out in the presence of a catalyst such as palladium (II) acetate, tetrakis (triphenylphosphine) palladium (0), and the like.\n\n\n\n\n\n\n\n \n\n  反応温度は特に限定されず、反応は、通常、室温、加温または加熱下で行われる。\n\n\n製造法２\n \n\n  化合物（Ｉｂａ）またはその塩は、化合物（Ｉａ）またはその塩を加水分解に付すことによって製造することができる。\n\nThe reaction temperature is not particularly limited, and the reaction is usually performed at room temperature, warming or heating. \n \nManufacturing method 2\n \n Compound (Iba) or a salt thereof can be produced by subjecting compound (Ia) or a salt thereof to hydrolysis.\n\n\n\n\n\n\n \n\n  この反応は慣用の方法にしたがって実施される。\n\n\n  This reaction is carried out according to conventional methods.\n\n\n\n\n\n\n\n \n\n  加水分解は、塩基またはルイス酸などの酸の存在下で実施するのが好ましい。\n\n\n  The hydrolysis is preferably carried out in the presence of a base or an acid such as a Lewis acid.\n\n\n\n\n\n\n\n \n\n  好適な塩基としては、無機塩基および有機塩基、たとえばアルカリ金属（たとえばナトリウム、カリウムなど）、アルカリ土類金属（たとえばマグネシウム、カルシウムなど）、それらの水酸化物または炭酸塩または炭酸水素塩、トリアルキルアミン（たとえばトリエチルアミン、トリメチルアミンなど）、ヒドラジン、ピリジン化合物（たとえばピリジン、ルチジン、ピコリン、４−ジメチルアミノピリジンなど）、１，５−ジアザビシクロ［４．３．０］ノン−５−エン、キノリン、１，４−ジアザビシクロ［２．２．２］オクタン、１，８−ジアザビシクロ［５．４．０］ウンデク−７−エンなどを挙げることができる。\n\n\n  Suitable bases include inorganic and organic bases, such as alkali metals (eg, sodium, potassium, etc.), alkaline earth metals (eg, magnesium, calcium, etc.), their hydroxides or carbonates or bicarbonates, trialkyls Amines (eg triethylamine, trimethylamine etc.), hydrazine, pyridine compounds (eg pyridine, lutidine, picoline, 4-dimethylaminopyridine etc.), 1,5-diazabicyclo [4.3.0] non-5-ene, quinoline, 1 , 4-diazabicyclo [2.2.2] octane, 1,8-diazabicyclo [5.4.0] undec-7-ene, and the like.\n\n\n\n\n\n\n\n \n\n  好適な酸としては、有機酸（たとえば蟻酸、酢酸、プロピオン酸、トリクロロ酢酸、トリフルオロ酢酸など）および無機酸（たとえば塩酸、臭化水素酸、硫酸、塩化水素、臭化水素など）を挙げることができる。\n\n\n  Suitable acids include organic acids (eg formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid etc.) and inorganic acids (eg hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide etc.) Can do.\n\n\n\n\n\n\n\n \n\n  三臭化ホウ素、三塩化ホウ素、三フッ化ホウ素、塩化アルミニウムなどのルイス酸を用いる脱離反応は、カチオン捕捉剤たとえば（アニソール、フェノール）の存在下で実施するのが好ましい。\n\n\n  The elimination reaction using a Lewis acid such as boron tribromide, boron trichloride, boron trifluoride or aluminum chloride is preferably carried out in the presence of a cation scavenger such as (anisole, phenol).\n\n\n\n\n\n\n\n \n\n  この場合、加水分解は、通常、ルイス酸などの酸の存在下で実施され、ルイス酸などのこれらの酸は、混合して使用することができ、加水分解の箇所または数は、条件によって異なることがある（詳しくは実施例部（実施例２、７、１０および１５）を参照のこと）。\n\n\n  In this case, the hydrolysis is usually carried out in the presence of an acid such as a Lewis acid, and these acids such as a Lewis acid can be used in combination, and the location or number of hydrolysis depends on the conditions. (For details, see Examples (Examples 2, 7, 10 and 15)).\n\n\n\n\n\n\n\n \n\n  この反応は、通常、溶媒、たとえば水、アルコール（たとえばメタノール、エタノール、イソプロピルアルコールなど）、テトラヒドロフラン、ジオキサン、トルエン、ジクロロメタン、１，２−ジクロロエタン、クロロホルム、Ｎ，Ｎ−ジメチルホルムアミド、Ｎ，Ｎ−ジメチルアセトアミド、または反応に悪影響を及ぼさない他の有機溶媒、またはそれらの混合物中で実施される。\n\n\n  This reaction is usually carried out in a solvent such as water, alcohol (eg, methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, dichloromethane, 1,2-dichloroethane, chloroform, N, N-dimethylformamide, N, N- It is carried out in dimethylacetamide, or other organic solvent that does not adversely influence the reaction, or a mixture thereof.\n\n\n\n\n\n\n\n \n\n  液体の塩基または酸もまた溶媒として使用できる。\n\n\n  Liquid bases or acids can also be used as solvents.\n\n\n\n\n\n\n\n \n\n  反応温度は特に限定されず、反応は、通常、冷却ないし加熱下で行われる。\n\n\n製造法３\n \n\n  化合物（Ｉｃ）またはその塩は、化合物（Ｉｂ）またはその塩を化合物（ＩＶ）またはその塩とのアルキル化反応に付すことによって製造することができる。\n\nThe reaction temperature is not critical and the reaction is usually carried out under cooling to heating. \n \nProduction method 3\n \n Compound (Ic) or a salt thereof can be produced by subjecting compound (Ib) or a salt thereof to an alkylation reaction with compound (IV) or a salt thereof.\n\n\n\n\n\n\n \n\n  化合物（ＩＶ）の好適な塩としては、化合物（Ｉ）で例示したのと同じものを挙げることができる。\n\n\n  Suitable salts of compound (IV) may be the same as those exemplified for compound (I).\n\n\n\n\n\n\n\n \n\n  この反応は、溶媒、たとえば水、燐酸緩衝液、アセトン、クロロホルム、アセトニトリル、ニトロベンゼン、ジクロロメタン、１，２−ジクロロエタン、ホルムアミド、Ｎ，Ｎ−ジメチルホルムアミド、メタノール、エタノール、ｓｅｃ−ブタノール、アミルアルコール、ジエチルエーテル、ジオキサン、１，２−ジメトキシエタン、テトラヒドロフラン、ジメチルスルホキシド、または反応に悪影響を及ぼさない他の有機溶媒、好ましくは強極性を有する溶媒中で実施される。これらの溶媒の内、親和性溶媒は水と混合して用いてもよい。化合物（ＩＶ）が液体の状態にある場合、それもまた溶媒として使用できる。この反応は、塩基、たとえばアルカリ金属水酸化物、アルカリ金属アルコキシド（たとえばカリウム第三級ブトキシド）、アルカリ金属炭酸塩、アルカリ金属重炭酸塩、アルカリ金属水素化物（たとえば水素化ナトリウムなど）などの無機塩基、またはトリアルキルアミン（たとえばトリエチルアミンなど）などの有機塩基、または塩基性樹脂などの存在下で実施するのが好ましい。\n\n\n  This reaction is carried out using a solvent such as water, phosphate buffer, acetone, chloroform, acetonitrile, nitrobenzene, dichloromethane, 1,2-dichloroethane, formamide, N, N-dimethylformamide, methanol, ethanol, sec-butanol, amyl alcohol, diethyl. It is carried out in ether, dioxane, 1,2-dimethoxyethane, tetrahydrofuran, dimethyl sulfoxide, or other organic solvents that do not adversely influence the reaction, preferably those having a strong polarity. Among these solvents, the affinity solvent may be used by mixing with water. When compound (IV) is in a liquid state, it can also be used as a solvent. This reaction can be carried out with a base such as an alkali metal hydroxide, an alkali metal alkoxide (eg, potassium tertiary butoxide), an alkali metal carbonate, an alkali metal bicarbonate, an alkali metal hydride (eg, sodium hydride), etc. It is preferably carried out in the presence of a base or an organic base such as trialkylamine (for example, triethylamine) or a basic resin.\n\n\n\n\n\n\n\n \n\n  反応温度は特に限定されず、反応は、通常、室温、加温または加熱下で行われる。\n\n\n  The reaction temperature is not particularly limited, and the reaction is usually performed at room temperature, warming or heating.\n\n\n\n\n\n\n\n \n\n  この反応は、アルカリ金属ハロゲン化物（たとえばヨウ化ナトリウム、ヨウ化カリウムなど）などの存在下で実施するのが好ましい。\n\n\n  This reaction is preferably carried out in the presence of an alkali metal halide (for example, sodium iodide, potassium iodide, etc.).\n\n\n\n\n\n\n\n \n\n  Ｙが−ＯＨである場合、トリフェニルホスフィンなど、およびアゾジカルボン酸ジ（低級）アルキル（たとえばアゾジカルボン酸ジエチル、アゾジカルボン酸ジイソプロピルなど）などを用いるＯＨの活性化が必要となることがある。\n\n\n製造法４\n \n\n  化合物（Ｉｅ）またはその塩は、化合物（Ｉｄ）またはその塩を、塩基または酸を用いる加水分解に付すことによって製造することができる。\n\nWhen Y is —OH, it may be necessary to activate OH using triphenylphosphine and the like and di (lower) alkyl azodicarboxylate (eg, diethyl azodicarboxylate, diisopropyl azodicarboxylate, etc.). \n \nManufacturing method 4\n \n Compound (Ie) or a salt thereof can be produced by subjecting compound (Id) or a salt thereof to hydrolysis using a base or an acid.\n\n\n\n\n\n\n \n\n  この反応は、\n製造法２\nにおける塩基を用いる前記の加水分解と同一の方法にしたがって実施することができるので、使用する試薬および反応条件（たとえば溶媒、反応温度など）は\n製造法２\nの記載を参照すればよい。\n\n\n製造法５\n \n\n  化合物（Ｉｆ）またはその塩は、化合物（Ｉｅ）またはその塩を脱カルボキシル化することによって製造することができる。\n\nThis reaction, therefore can be carried out according to the hydrolysis in the same manner with a base in the \nproduction method 2,\n the reagents and reaction conditions used (e.g. solvent, reaction temperature, etc.) is referred to the description of the \nproduction method 2\n do it. \n \nManufacturing method 5\n \n Compound (If) or a salt thereof can be produced by decarboxylating compound (Ie) or a salt thereof.\n\n\n\n\n\n\n \n\n  この反応は、熱分解、酸分解などの慣用の方法で実施され；この場合のより好ましい方法は、熱分解である。\n\n\n  This reaction is carried out by a conventional method such as thermal decomposition, acid decomposition or the like; in this case, the more preferable method is thermal decomposition.\n\n\n\n\n\n\n\n \n\n  この反応は、通常、慣用の不活性溶媒、たとえばキノリン、ジクロロベンゼン、メシチレン、ドデカン、Ｄｏｗｔｈｅｒｍ（Ｒ）（フェニルエーテル−ビフェニル共融混合物）、または反応に悪影響を及ぼさない他の有機溶媒、またはそれらの混合物中で実施され；この場合のより好ましい溶媒は、１，２−ジクロロベンゼンである。\n\n\n  This reaction is usually carried out using conventional inert solvents such as quinoline, dichlorobenzene, mesitylene, dodecane, Dowtherm® (phenyl ether-biphenyl eutectic mixture), or other organic solvents that do not adversely affect the reaction, or A more preferred solvent in this case is 1,2-dichlorobenzene.\n\n\n\n\n\n\n\n \n\n  反応温度は特に限定されず、反応は、通常、１００℃〜２００℃の加熱条件で行われる。\n\n\n製造法６\n \n\n  化合物（Ｉｇ）またはその塩は、化合物（Ｉｅ）またはその塩をアミド化することによって製造することができる。\n\nThe reaction temperature is not particularly limited, and the reaction is usually performed under heating conditions of 100 ° C to 200 ° C. \n \nManufacturing method 6\n \n Compound (Ig) or a salt thereof can be produced by amidating compound (Ie) or a salt thereof.\n\n\n\n\n\n\n \n\n  この反応は、通常、慣用の溶媒、たとえば水、アセトン、ジオキサン、アセトニトリル、クロロホルム、ジクロロメタン、１，２−ジクロロエタン、テトラヒドロフラン、酢酸エチル、Ｎ，Ｎ−ジメチルホルムアミド、ピリジン、または反応に悪影響を及ぼさない他の有機溶媒、またはそれらの混合物中で行われる。\n\n\n  This reaction usually does not adversely affect conventional solvents such as water, acetone, dioxane, acetonitrile, chloroform, dichloromethane, 1,2-dichloroethane, tetrahydrofuran, ethyl acetate, N, N-dimethylformamide, pyridine, or the reaction It is carried out in other organic solvents or mixtures thereof.\n\n\n\n\n\n\n\n \n\n  この反応は慣用の縮合剤の存在下で行われることが好ましく、縮合剤の例としては、Ｎ，Ｎ’−ジシクロヘキシルカルボジイミド；Ｎ−シクロヘキシル−Ｎ’−モルホリノエチルカルボジイミド；Ｎ−シクロヘキシル−Ｎ’−（４−ジエチルアミノシクロヘキシル）カルボジイミド；Ｎ，Ｎ’−ジイソプロピルカルボジイミド；Ｎ−エチル−Ｎ’−（３−ジメチルアミノプロピル）カルボジイミド；Ｎ，Ｎ−カルボニル−ビス（２−メチルイミダゾール）；ペンタメチレンケテン−Ｎ−シクロヘキシルイミン；ジフェニルケテン−Ｎ−シクロヘキシルイミン；エトキシアセチレン；１−アルコキシ−１−クロロエチレン；トリアルキル亜燐酸塩；ポリ燐酸イソプロピル；オキシ塩化燐（塩化ホスホリル）；三塩化燐；塩化チオニル；塩化オキサリル；トリフェニルホスフィン；２−エチル−７−ヒドロキシベンズイソキサゾリウム塩；水酸化２−エチル−５−（ｍ−スルホフェニル）イソキサゾリウム分子内塩；１−（ｐ−クロロベンゼンスルホニルオキシ）−６−クロロ−１Ｈ−ベンゾトリアゾール；Ｎ，Ｎ−ジメチルホルムアミドと塩化チオニル、ホスゲン、オキシ塩化燐などと反応させて調製されるいわゆるビルスマイヤー試薬などを挙げることができる。\n\n\n  This reaction is preferably carried out in the presence of a conventional condensing agent. Examples of the condensing agent include N, N′-dicyclohexylcarbodiimide; N-cyclohexyl-N′-morpholinoethylcarbodiimide; N-cyclohexyl-N′-. (4-diethylaminocyclohexyl) carbodiimide; N, N′-diisopropylcarbodiimide; N-ethyl-N ′-(3-dimethylaminopropyl) carbodiimide; N, N-carbonyl-bis (2-methylimidazole); N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-1-chloroethylene; trialkyl phosphite; isopropyl polyphosphate; phosphorous oxychloride (phosphoryl chloride); phosphorous trichloride; thionyl chloride; Oki chloride Triethylphosphine; 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5- (m-sulfophenyl) isoxazolium hydroxide inner salt; 1- (p-chlorobenzenesulfonyloxy) -6 -Chloro-1H-benzotriazole; so-called Vilsmeier reagent prepared by reacting N, N-dimethylformamide with thionyl chloride, phosgene, phosphorus oxychloride and the like.\n\n\n\n\n\n\n\n \n\n  この反応は、アルカリ金属重炭酸塩、トリ（低級）アルキルアミン、ピリジン、Ｎ−（低級）アルキルモルホリン、Ｎ，Ｎ−ジ（低級）アルキルベンジルアミンなどの無機または有機の塩基の存在下でも実施可能である。\n\n\n  This reaction is also carried out in the presence of an inorganic or organic base such as alkali metal bicarbonate, tri (lower) alkylamine, pyridine, N- (lower) alkylmorpholine, N, N-di (lower) alkylbenzylamine. Is possible.\n\n\n\n\n\n\n\n \n\n  反応温度は特に限定されず、反応は、通常、冷却ないし加熱下で行われる。\n\n\n製造法７\n \n\n  化合物（Ｉｈ）またはその塩は、Ｎ−ハロスクシンイミド（たとえばＮ−クロロスクシンイミド、Ｎ−ブロモスクシンイミドなど）などのハロゲン化剤を用いて化合物（Ｉｆ）またはその塩をハロゲン化反応に付すことによって製造することができる。\n\nThe reaction temperature is not critical and the reaction is usually carried out under cooling to heating. \n \nManufacturing method 7\n \n Compound (Ih) or a salt thereof is produced by subjecting compound (If) or a salt thereof to a halogenation reaction using a halogenating agent such as N-halosuccinimide (eg, N-chlorosuccinimide, N-bromosuccinimide, etc.). can do.\n\n\n\n\n\n\n \n\n  この反応は、通常、溶媒、たとえばテトラヒドロフラン、ジオキサン、トルエン、ジクロロメタン、１，２−ジクロロエタン、クロロホルム、Ｎ，Ｎ−ジメチルホルムアミド、Ｎ，Ｎ−ジメチルアセトアミド、または反応に悪影響を及ぼさない他の有機溶媒、またはそれらの混合物中で行われる。\n\n\n製造法８\n \n\n  化合物（Ｉｊ）またはその塩は、化合物（Ｉｈ）またはその塩を化合物（Ｖ）またはその塩とカップリング反応に付すことによって製造することができる。\n\nThis reaction is usually performed in a solvent such as tetrahydrofuran, dioxane, toluene, dichloromethane, 1,2-dichloroethane, chloroform, N, N-dimethylformamide, N, N-dimethylacetamide, or other organic solvents that do not adversely affect the reaction. Or in a mixture thereof. \n \nManufacturing method 8\n \n Compound (Ij) or a salt thereof can be produced by subjecting compound (Ih) or a salt thereof to a coupling reaction with compound (V) or a salt thereof.\n\n\n\n\n\n\n \n\n  この反応は、\n製造法１\nにおける前記のカップリング反応と同一の方法にしたがって実施することができるので、使用する試薬および反応条件（たとえば溶媒、反応温度など）は\n製造法１\nの記載を参照すればよい。\n\n\n製造法Ａ\n \n\n  化合物（ＶＩＩ）またはその塩は、化合物（ＶＩ）またはその塩を、酸を用いる加水分解（工程１に例示されている）に付すことによって製造することができる。この反応は、\n製造法２\nにおける酸を用いる前記の加水分解と同一の方法にしたがって実施することができるので、使用する試薬および反応条件（たとえば溶媒、反応温度など）は\n製造法２\nの記載を参照すればよい。\n\nSince this reaction can be carried out according to the same method as the coupling reaction in \nProduction Method 1\n , the reagents used and reaction conditions (for example, solvent, reaction temperature, etc.) can be referred to the description of \nProduction Method 1.\n Good. \n \nManufacturing method A\n \n Compound (VII) or a salt thereof can be produced by subjecting compound (VI) or a salt thereof to hydrolysis using an acid (exemplified in Step 1). This reaction, therefore can be carried out according to the hydrolysis in the same manner using an acid in the \nproduction method 2,\n the reagents and reaction conditions used (e.g. solvent, reaction temperature, etc.) is referred to the description of the \nproduction method 2\n do it.\n\n\n\n\n\n\n \n\n  さらに、目的化合物（ＶＩＩＩ）は、化合物（ＶＩＩ）またはその塩を、化合物（ＩＶ）またはその塩とのアルキル化反応（工程２に例示されている）に付すことによって製造することができる。この反応は、前記の\n製造法３\nと同一の方法にしたがって実施することができるので、使用する試薬および反応条件（たとえば溶媒、反応温度など）は\n製造法３\nの記載を参照すればよい。\n\n\n製造法Ｂ\n \n\n  化合物（Ｘ）またはその塩は、後述の製造例１に開示されている方法またはそれと同様の方法にしたがって、化合物（ＩＸ）をアセチル化（工程１に例示されている）することによって製造することができる。\n\nFurthermore, the target compound (VIII) can be produced by subjecting compound (VII) or a salt thereof to an alkylation reaction (exemplified in Step 2) with compound (IV) or a salt thereof. This reaction, therefore can be carried out according to the same manner as \nProcess 3,\n the reagents and the reaction conditions used (e.g. solvent, reaction temperature, etc.) can be referred to the description of the \nproduction method 3.\n \n \nManufacturing method B\n \n Compound (X) or a salt thereof is produced by acetylating Compound (IX) (exemplified in Step 1) according to the method disclosed in Production Example 1 described later or a method similar thereto. Can do.\n\n\n\n\n\n\n \n\n  さらに、目的化合物（ＸＩ）は、化合物（Ｘ）を、後述の製造例２に開示されているオキシム生成反応（工程２に例示されている）に付すことによって、またはそれと同様の方法にしたがって製造することができる。\n\n\n製造法Ｃ\n \n\n  化合物（ＸＩＩ）またはその塩は、化合物（ＸＩ）またはその塩をアミノマロニトリルまたはその塩と反応させることによって製造することができる。\n\nFurthermore, the target compound (XI) is produced by subjecting the compound (X) to an oxime-forming reaction (exemplified in Step 2) disclosed in Production Example 2 described later, or according to a method similar thereto. can do. \n \nManufacturing method C\n \n Compound (XII) or a salt thereof can be produced by reacting compound (XI) or a salt thereof with aminomalonitrile or a salt thereof.\n\n\n\n\n\n\n \n\n  この反応は、ｐ−トルエンスルホン酸などの触媒の存在下で実施するのが好ましい。\n\n\n  This reaction is preferably carried out in the presence of a catalyst such as p-toluenesulfonic acid.\n\n\n\n\n\n\n\n \n\n  この反応は、通常、慣用の溶媒、たとえば水、アセトン、ジオキサン、アセトニトリル、１，２−ジメトキシエタン、クロロホルム、ジクロロメタン、１，２−ジクロロエタン、テトラヒドロフラン、酢酸エチル、Ｎ，Ｎ−ジメチルホルムアミド、メタノール、エタノール、イソプロパノール、ｔ−ブタノール、ジエチルエーテル、イソプロピルエーテル、それらの混合物、または反応に悪影響を及ぼさない他の有機溶媒中で実施される。\n\n\n  This reaction is usually carried out using a conventional solvent such as water, acetone, dioxane, acetonitrile, 1,2-dimethoxyethane, chloroform, dichloromethane, 1,2-dichloroethane, tetrahydrofuran, ethyl acetate, N, N-dimethylformamide, methanol, It is carried out in ethanol, isopropanol, t-butanol, diethyl ether, isopropyl ether, mixtures thereof, or other organic solvents that do not adversely affect the reaction.\n\n\n\n\n\n\n\n \n\n  反応温度は特に限定されず、反応は、通常、室温、加温または加熱下で行われる。\n\n\n  The reaction temperature is not particularly limited, and the reaction is usually performed at room temperature, warming or heating.\n\n\n\n\n\n\n\n \n\n  この反応は、後述の製造例３に開示されている方法、またはそれと同様の方法にしたがって実施することができる。\n\n\n製造法Ｄ\n \n\n  化合物（ＸＶＩ）またはその塩は、化合物（ＸＩＩＩ）またはその塩を、酸を用いる加水分解に付すことによって製造することができる。\n\n\n製造法Ｅ\n \n\n  化合物（ＩＩ）またはその塩は、化合物（ＸＶ）またはその塩を化合物（ＸＶＩ）またはその塩と反応させることによって製造することができる。\n\nThis reaction can be carried out according to the method disclosed in Production Example 3 described later or a method similar thereto. \n \nManufacturing method D\n \n Compound (XVI) or a salt thereof can be produced by subjecting compound (XIII) or a salt thereof to hydrolysis using an acid. \n \nManufacturing method E\n \n Compound (II) or a salt thereof can be produced by reacting compound (XV) or a salt thereof with compound (XVI) or a salt thereof.\n\n\n\n\n\n\n \n\n  この反応は、通常、慣用の溶媒、たとえばアセトン、ジオキサン、アセトニトリル、１，２−ジメトキシエタン、クロロホルム、ジクロロメタン、１，２−ジクロロエタン、テトラヒドロフラン、酢酸エチル、Ｎ，Ｎ−ジメチルホルムアミド、ジエチルエーテル、イソプロピルエーテル、それらの混合物、または反応に悪影響を及ぼさない他の有機溶媒中で実施される。\n\n\n  This reaction is usually carried out using conventional solvents such as acetone, dioxane, acetonitrile, 1,2-dimethoxyethane, chloroform, dichloromethane, 1,2-dichloroethane, tetrahydrofuran, ethyl acetate, N, N-dimethylformamide, diethyl ether, isopropyl. It is carried out in ethers, mixtures thereof, or other organic solvents that do not adversely affect the reaction.\n\n\n\n\n\n\n\n \n\n  この反応は、後述の製造例４に開示されている方法、またはそれと同様の方法にしたがって実施することができる。\n\n\n  This reaction can be carried out according to the method disclosed in Production Example 4 described later or a method similar thereto.\n\n\n\n\n\n\n\n \n\n  上記の製造法において、すべての出発材料および生成化合物は塩であってもよい。上記の製造法の化合物は、慣用の方法にしたがって塩に転換することができる。\n\n\n  In the above production method, all starting materials and product compounds may be salts. The compounds of the above production methods can be converted into salts according to conventional methods.\n\n\n\n\n\n\n\n \n\n  本発明の目的化合物（Ｉ）は、アデノシン拮抗剤であり、上述したような種々の薬理作用を有する。\n\n\n  The object compound (I) of the present invention is an adenosine antagonist and has various pharmacological actions as described above.\n\n\n\n\n\n\n\n \n\n  本発明の化合物（Ｉ）の有用性を示すために、本発明の代表的な化合物の薬理試験結果を以下に示す。\n\n\n試験１：アデノシン拮抗活性\n \n\n［Ｉ］試験方法\n\n  試験化合物のアデノシン拮抗活性［Ｋｉ（ｎＭ）］を、ヒトＡ\n１\n受容体については８−シクロペンチル−１，３−ジプロピルキサンチン［ジプロピル−２，３−\n３\nＨ（Ｎ）］（［\n３\nＨ］ＤＰＣＰＸ、４．５ｎＭ）、ヒトＡ\n２ａ\n受容体については［\n３\nＨ］ＣＧＳ２１６８０（２０ｎＭ）を用いる放射リガンド結合法により試験した。\n\n［ＩＩ］試験化合物\n\n  ３−アミノ−６−（１−エチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド（実施例４）\n\n  ３−アミノ−６−（１−メチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボニトリル（実施例１１）\n\n  ３−アミノ−５−（３，４−ジフルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボニトリル（実施例３９）\n\n  ３−アミノ−Ｎ−（シアノメチル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド（実施例４６）\n\n  ５−［５−アミノ−６−（ヒドロキシメチル）−３−フェニル−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（実施例４７）\n\n  ３−アミノ−Ｎ−（２−ヒドロキシエチル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド（実施例４９）\n\n  ５−（５−アミノ−６−ブロモ−３−フェニル−２−ピラジニル）−３−ブロモ−１−イソプロピル−２（１Ｈ）−ピリドン（実施例５３）\n\n  ５−［５−アミノ−３−（２−チエニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（実施例１１５）\n\n  ５−［５−アミノ−３−（３，５−ジフルオロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（実施例１２９）\n\n  ５−（５−アミノ−６−ブロモ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（実施例１４１）\n\n  ５−［５−アミノ−６−（２−フリル）−３−フェニル−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（実施例１４４）\n\n  ５−（５−アミノ−６−フェノキシ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（実施例１５１）\n\n［ＩＩＩ］試験結果\n\nIn order to show the usefulness of the compound (I) of the present invention, the pharmacological test results of representative compounds of the present invention are shown below. \n \nTest 1:\n Adenosine antagonistic activity [Ki (nM)] \nadenosine antagonistic activity\n [I] Test method Test compounds for human \nA 1\n receptors 8-cyclopentyl-1,3-dipropyl xanthine [dipropyl-2,3 \n3\n H (N)] ([ \n3\n H] DPCPX, 4.5 nM) and the human A \n2a\n receptor were tested by the radioligand binding method using [ \n3\n H] CGS 21680 (20 nM). \n [II] Test compound 3-amino-6- (1-ethyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxamide (Example 4) \n 3-Amino-6- (1-methyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarbonitrile (Example 11) \n 3-Amino-5- (3,4-difluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarbonitrile (Example 39) \n 3-Amino-N- (cyanomethyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxamide (Example 46) \n 5- [5-Amino-6- (hydroxymethyl) -3-phenyl-2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone (Example 47) \n 3-Amino-N- (2-hydroxyethyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxamide (Example 49) \n 5- (5-Amino-6-bromo-3-phenyl-2-pyrazinyl) -3-bromo-1-isopropyl-2 (1H) -pyridone (Example 53) \n 5- [5-Amino-3- (2-thienyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone (Example 115) \n 5- [5-Amino-3- (3,5-difluorophenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone (Example 129) \n 5- (5-Amino-6-bromo-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (Example 141) \n 5- [5-Amino-6- (2-furyl) -3-phenyl-2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone (Example 144) \n 5- (5-Amino-6-phenoxy-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (Example 151) \n [III] Test results\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n試験２：マウスにおける抗カタレプシー活性\n \n\n［Ｉ］試験方法\n\n  試験化合物（３．２ｍｇ／ｋｇ）をｄｄＹマウス（ｎ＝７）に経口投与した。当該化合物の投与から３０分後、ハロペリドール（０．３２ｍｇ／ｋｇ）を腹腔注射した。注射から３０分後、マウスのカタレプシー反応を測定した。各マウスの前肢を、高さ３ｃｍ、幅３ｍｍの水平棒に置き、カタレプシー姿勢の持続を最高３０秒間測定した。\n\n［ＩＩ］試験化合物\n\n  ３−アミノ−６−（１−エチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド（実施例４）\n\n  ３−アミノ−６−（１−メチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボニトリル（実施例１１）\n\n  ３−アミノ−５−（３，４−ジフルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボニトリル（実施例３９）\n\n  ３−アミノ−Ｎ−（シアノメチル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド（実施例４６）\n\n  ５−［５−アミノ−６−（ヒドロキシメチル）−３−フェニル−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（実施例４７）\n\n  ３−アミノ−Ｎ−（２−ヒドロキシエチル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド（実施例４９）\n\n  ５−（５−アミノ−６−ブロモ−３−フェニル−２−ピラジニル）−３−ブロモ−１−イソプロピル−２（１Ｈ）−ピリドン（実施例５３）\n\n  ５−［５−アミノ−３−（２−チエニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（実施例１１５）\n\n  ５−［５−アミノ−３−（３，５−ジフルオロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（実施例１２９）\n\n  ５−（５−アミノ−６−ブロモ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（実施例１４１）\n\n  ５−［５−アミノ−６−（２−フリル）−３−フェニル−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（実施例１４４）\n\n  ５−（５−アミノ−６−フェノキシ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（実施例１５１）\n\n［ＩＩＩ］試験結果\n\n \n \nTest 2: Anti-catalepsy activity in mice\n [I] Test method A test compound (3.2 mg / kg) was orally administered to ddY mice (n = 7). 30 minutes after administration of the compound, haloperidol (0.32 mg / kg) was injected intraperitoneally. Thirty minutes after injection, the catalepsy response of the mice was measured. Each mouse's forelimb was placed on a horizontal bar 3 cm high and 3 mm wide, and the duration of the catalepsy posture was measured for a maximum of 30 seconds. \n [II] Test compound 3-amino-6- (1-ethyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxamide (Example 4) \n 3-Amino-6- (1-methyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarbonitrile (Example 11) \n 3-Amino-5- (3,4-difluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarbonitrile (Example 39) \n 3-Amino-N- (cyanomethyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxamide (Example 46) \n 5- [5-Amino-6- (hydroxymethyl) -3-phenyl-2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone (Example 47) \n 3-Amino-N- (2-hydroxyethyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxamide (Example 49) \n 5- (5-Amino-6-bromo-3-phenyl-2-pyrazinyl) -3-bromo-1-isopropyl-2 (1H) -pyridone (Example 53) \n 5- [5-Amino-3- (2-thienyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone (Example 115) \n 5- [5-Amino-3- (3,5-difluorophenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone (Example 129) \n 5- (5-Amino-6-bromo-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (Example 141) \n 5- [5-Amino-6- (2-furyl) -3-phenyl-2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone (Example 144) \n 5- (5-Amino-6-phenoxy-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (Example 151) \n [III] Test results\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n  本発明のピラジン化合物（Ｉ）およびその塩は、アデノシン拮抗剤（特にＡ\n１\n受容体およびＡ\n２\n（特にＡ\n２ａ\n）受容体デュアル拮抗剤）として有用であり、うつ病、痴呆（たとえばアルツハイマー病、脳血管性の痴呆、パーキンソン病に伴う痴呆など）、パーキンソン病、不安、疼痛、脳血管疾患、心不全、高血圧、循環不全、蘇生後の収縮不全、徐脈性不整脈、電気機械的機能不全、心血行動態不全、ＳＩＲＳ（全身性炎症反応症候群）、多臓器不全、腎不全（腎機能障害）、腎毒性、ネフローゼ、腎炎、浮腫、肥満症、気管支喘息、痛風、高尿酸血症、乳幼児突然死症候群、免疫抑制、糖尿病、潰瘍、膵炎、メニエール症候群、貧血、透析誘導性の低血圧、便秘症、虚血性の腸疾患、イレウス、心筋梗塞、血栓症、閉塞症、閉塞性動脈硬化症、血栓静脈炎、脳梗塞、一過性の虚血性発作、狭心症などの予防および／または治療に有用である。\n\nThe pyrazine compounds (I) and salts thereof of the present invention are useful as adenosine antagonists (especially A \n1\n receptors and A \n2\n (especially A \n2a\n ) receptor dual antagonists), and are used for depression, dementia (eg, Alzheimer's disease, Cerebrovascular dementia, dementia associated with Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease, heart failure, hypertension, circulatory failure, post-resuscitation contraction, bradyarrhythmia, electromechanical dysfunction, heart blood Behavioral dysfunction, SIRS (systemic inflammatory response syndrome), multiple organ failure, renal failure (renal dysfunction), nephrotoxicity, nephrosis, nephritis, edema, obesity, bronchial asthma, gout, hyperuricemia, sudden infant death Syndrome, immunosuppression, diabetes, ulcer, pancreatitis, Meniere syndrome, anemia, dialysis-induced hypotension, constipation, ischemic bowel disease, ileus, myocardial infarction, thrombosis, obstruction, obstructive movement Sclerosis, thrombophlebitis, cerebral infarction, useful in the prevention and / or treatment such as transient ischemic attack, angina.\n\n\n\n\n\n\n \n\n  アデノシン拮抗剤は、パーキンソン病用に最も普及している薬剤であるＬ−３，４−ジヒドロキシ−フェニルアラニン（Ｌ−ＤＯＰＡ）と併用することによってパーキンソン病に対して有用となり得る（Ｒ．グロンディンら、Ｎｅｕｒｏｌｏｇｙ、５２，１６７３（１９９９））。したがって、本発明のピラジン化合物（Ｉ）およびその塩のＬ−ＤＯＰＡとの併用は、Ｌ−ＤＯＰＡの長期使用によって誘発されるジスキネジーの発現などの副作用などを減少させるまたは軽減させることにより、パーキンソン病の治療および予防にも有用であろう。\n\n\n  Adenosine antagonists can be useful against Parkinson's disease when used in combination with L-3,4-dihydroxy-phenylalanine (L-DOPA), the most prevalent drug for Parkinson's disease (R. Glondin et al., Neurology, 52, 1673 (1999)). Therefore, the combined use of the pyrazine compound (I) of the present invention and its salt with L-DOPA reduces or alleviates side effects such as the expression of dyskinesia induced by long-term use of L-DOPA, thereby causing Parkinson's disease. It may also be useful for the treatment and prevention.\n\n\n\n\n\n\n\n \n\n  さらに、これらの化合物を医薬として用いる分野を考慮すると、これらの化合物は、ある程度まで作用持続可能であるべきである。本発明のピラジン化合物（Ｉ）またはその塩の作用持続時間は長期であることが予想される。\n\n\n  Furthermore, given the field of use of these compounds as pharmaceuticals, these compounds should be able to sustain action to some extent. The duration of action of the pyrazine compound (I) or a salt thereof of the present invention is expected to be long.\n\n\n\n\n\n\n\n \n\n  本発明の医薬組成物は、直腸、経肺（経鼻またはバッカル吸入）、点鼻、点眼、外用（局所）、経口または非経口（皮下、静脈内および筋肉内を含む）投与または吸入に適した有機または無機の担体または賦形剤との混合物の形で、ピラジン化合物（Ｉ）または医薬として許容されるその塩を有効成分として含有する、たとえば固形、半固形または液状の医薬製剤の形態で使用できる。当該有効成分は、たとえば錠剤、ペレット剤、トローチ剤、カプセル剤、坐剤、クリーム剤、軟膏剤、エアロゾル剤、吸入用散剤、液剤、乳剤、懸濁剤、その他使用に適した任意の他の剤型のための医薬として許容される通常の無毒性担体と調合できる。さらに、補助剤、安定剤、増粘剤、着色剤および香料を必要に応じて用いてもよい。ピラジン化合物（Ｉ）または医薬として許容されるその塩は、疾患の過程または状態に対して所望の前記の医薬的効果を奏するのに十分な量が医薬組成物に含有される。\n\n\n  The pharmaceutical composition of the present invention is suitable for rectal, pulmonary (nasal or buccal inhalation), nasal, ophthalmic, topical (topical), oral or parenteral (including subcutaneous, intravenous and intramuscular) administration or inhalation. Containing the pyrazine compound (I) or a pharmaceutically acceptable salt thereof as an active ingredient in the form of a mixture with another organic or inorganic carrier or excipient, for example in the form of a solid, semi-solid or liquid pharmaceutical preparation Can be used. The active ingredients are for example tablets, pellets, troches, capsules, suppositories, creams, ointments, aerosols, powders for inhalation, solutions, emulsions, suspensions, and any other suitable for use. It can be formulated with conventional non-toxic pharmaceutically acceptable carriers for dosage forms. Furthermore, you may use an adjuvant, a stabilizer, a thickener, a coloring agent, and a fragrance | flavor as needed. The pyrazine compound (I) or a pharmaceutically acceptable salt thereof is contained in the pharmaceutical composition in an amount sufficient to exert the desired pharmaceutical effect on the disease process or condition.\n\n\n\n\n\n\n\n \n\n  当該組成物のヒトまたは動物への適用は、それを静脈内、筋肉内、経肺または経口投与、または吸入により適用するのが好ましい。ピラジン化合物（Ｉ）の治療有効量は、処置すべき各個の患者の年令および状態により変化するが、概して、静脈内投与の場合には、ヒトまたは動物の体重１ｋｇ当たり０．０１〜１００ｍｇのピラジン化合物（Ｉ）を１日量として、筋肉内投与の場合には、ヒトまたは動物の体重１ｋｇ当たり０．１〜１００ｍｇのピラジン化合物（Ｉ）を１日量として、経口投与の場合には、ヒトまたは動物の体重１ｋｇ当たり０．５〜１００ｍｇのピラジン化合物（Ｉ）を１日量として、前記疾患の予防および／または治療のために投与する。\n\n\n  For application of the composition to humans or animals, it is preferably applied by intravenous, intramuscular, pulmonary or oral administration, or by inhalation. The therapeutically effective amount of the pyrazine compound (I) varies depending on the age and condition of each individual patient to be treated, but is generally 0.01-100 mg / kg body weight of a human or animal when administered intravenously. In the case of intramuscular administration of pyrazine compound (I) as a daily dose, 0.1 to 100 mg of pyrazine compound (I) per kg of human or animal body weight as a daily dose, and in the case of oral administration, A daily dose of 0.5 to 100 mg of pyrazine compound (I) per kg of human or animal body weight is administered for the prevention and / or treatment of the disease.\n\n\n\n\n\n\n\n\n\n\n\n \n\n  以下の製造例および実施例は、本発明をより詳細に説明するために示すものである。\n\n\n  The following preparation examples and examples are given to illustrate the present invention in more detail.\n\n\n\n\n\n\n\n \n\n  製造例および実施例で用いられる略語、記号および用語は下記の意味を有する。\n\nＡｃＯＨ                酢酸\n\nＣＨＣｌ\n３            \n  クロロホルム\n\nＣＨ\n２\nＣｌ\n２            \n  ジクロロメタン\n\nＤＭＥ                  １，２−ジメトキシエタン\n\nＤＭＦ                  Ｎ，Ｎ−ジメチルホルムアミド\n\nＤＭＳＯ                ジメチルスルホキシド\n\nＥｔＯＡｃ              酢酸エチル\n\nＥｔＯＨ                エタノール\n\nＩＰＡ                  イソプロピルアルコール\n\nＩＰＥ                  イソプロピルエーテル\n\nＭｅＯＨ                メタノール\n\nＭｅＣＮ                アセトニトリル\n\nＮＭＰ                  Ｎ−メチルピロリドン\n\nＴＨＦ                  テトラヒドロフラン\n\nＨＣｌ                  塩酸\n\nＮＥｔ\n３              \n  トリエチルアミン\n\nｔ−ＢｕＯＫ              カリウム第三級ブトキシド\n\nＫ\n２\nＣＯ\n３            \n  炭酸カリウム\n\nＭｇＳＯ\n４            \n  硫酸マグネシウム\n\nＮａＯＡｃ              酢酸ナトリウム\n\nＮａ\n２\nＣＯ\n３            \n  炭酸ナトリウム\n\nＮａＨ                  水素化ナトリウム\n\nＮａＨＣＯ\n３            \n  重炭酸ナトリウム\n\nＮａＯＨ                水酸化ナトリウム\n\nＥｔＩ                  ヨウ化エチル\n\nＭｅＩ                      ヨウ化メチル\n\nｎ−ＰｒＢｒ              ｎ−臭化プロピル\n\nｉ−ＰｒＩ              ヨウ化イソプロピル\n\nＣｕＩ                  ヨウ化第一銅（ヨウ化銅（Ｉ））\n\nＰｄＣｌ\n２\n（ＰＰｈ\n３\n）\n２\n  ジクロロビス（トリフェニルホスフィン）パラジウム（ＩＩ）\n\nＰｄ（ＯＡｃ）\n２      \n  酢酸パラジウム（ＩＩ）\n\nＰｄ（ＰＰｈ\n３\n）\n４    \n  テトラキス（トリフェニルホスフィン）パラジウム（ＩＩ）\n\nａｑ．                  水溶液\n\nｃｏｎｃ．              濃縮\n\nｓａｔ．                飽和\n\nAbbreviations, symbols and terms used in the production examples and examples have the following meanings. \n AcOH Acetic acid CHCl \n3\n Chloroform CH \n2\n Cl \n2\n Dichloromethane DME 1,2-Dimethoxyethane DMF N, N-dimethylformamide DMSO Dimethyl sulfoxide EtOAc Ethyl acetate EtOH Ethanol IPA Isopropyl alcohol IPE Isopropyl ether MeOH Methanol MeCN Acetonitrile NMP N-Methylpyrrolidone THF Tetrahydrofuran HCl Hydrochloric acid NEt \n3\n triethylamine t-BuOK potassium tertiary butoxide K \n2\n CO \n3\n potassium carbonate MgSO \n4\n magnesium sulfate NaOAc sodium acetate Na \n2\n CO \n3\n sodium carbonate NaH sodium hydride NaHCO \n3\n sodium bicarbonate NaOH sodium hydroxide EtI ethyl iodide MeI iodo Methyl n-PrBr n-propyl bromide i- rI isopropyl iodide CuI cuprous iodide (iodide (I)) \n PdCl \n2\n \n(PPh\n \n3) 2\n dichlorobis (triphenylphosphine) palladium (II) \n Pd \n(OAc) 2\n palladium (II) acetate \n Pd \n(PPh\n \n3) 4\n tetrakis (triphenylphosphine) palladium (II) \n aq. Aqueous solution conc. Concentrated sat. Saturation\n\n\n\n\n\n\n \n \n製造例１\n \n\n  ２−メトキシブロモピリジン（２５ｇ）とｎ−ブチルビニルエーテル（６６．６ｇ）をＤＭＦ（２５０ｍｌ）に溶解した。溶液に、１，３−ビス（ジフェニルホスフィノ）プロパン（３．６２ｇ）とＰｄ（ＯＡｃ）\n２\n（８９６ｍｇ）とＫ\n２\nＣＯ\n３\n水溶液を窒素雰囲気下に加えた。反応混合物を１００〜１２０℃で２時間攪拌した。混合物を２５℃まで冷却した。溶液に１ＮＨＣｌ水溶液（６２５ｍｌ）を加えた。溶液を２５〜３０℃で１時間攪拌した。溶液をＥｔＯＡｃと水に分配した。有機層を分離した。水層をＥｔＯＡｃで抽出した。合わせた有機溶液を水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を真空留去して、油状残留物を得た。残留物をシリカゲルクロマトグラフィー（ＥｔＯＡｃ：ｎ−ヘキサン＝１：５、ｖ／ｖ）で精製して、２−メトキシ−５−アセチルピリジンを固形物（１２．１４ｇ）として得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 2.56 (3H, s), 3.95 (3H, s), 6.92 (1H, d, J=8.4 Hz), 8.17 (1H, dd, J=2.4, 8.4 Hz), 8.30 (1H, d, J=2.4 Hz)\n\nMS(ESI\n+\n) : 152[M+H]\n+\n\n\n \nProduction Example 1\n \n 2-Methoxybromopyridine (25 g) and n-butyl vinyl ether (66.6 g) were dissolved in DMF (250 ml). To the solution, 1,3-bis (diphenylphosphino) propane (3.62 g), Pd (OAc) \n2\n (896 mg) and an aqueous K \n2\n CO \n3\n solution were added under a nitrogen atmosphere. The reaction mixture was stirred at 100-120 ° C. for 2 hours. The mixture was cooled to 25 ° C. To the solution was added 1N aqueous HCl (625 ml). The solution was stirred at 25-30 ° C. for 1 hour. The solution was partitioned between EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with water and brine and dried over MgSO \n4\n . The solvent was removed in vacuo to give an oily residue. The residue was purified by silica gel chromatography (EtOAc: n-hexane = 1: 5, v / v) to give 2-methoxy-5-acetylpyridine as a solid (12.14 g). \n \n1\n H-NMR (DMSO-d \n6\n δ): 2.56 (3H, s), 3.95 (3H, s), 6.92 (1H, d, J = 8.4 Hz), 8.17 (1H, dd, J = 2.4, 8.4 Hz) ), 8.30 (1H, d, J = 2.4 Hz) \n MS (ESI \n+\n ): 152 [M + H] \n+\n \n\n\n\n\n\n\n \n \n製造例２\n \n\n  ２−メトキシ−５−アセチルピリジン（１２．１ｇ）と第三級ブチル二トリル（９．９２ｇ）をＴＨＦ（１２０ｍｌ）に溶解した。溶液を０〜５℃に冷却した。溶液にｔ−ＢｕＯＫ（１０．８ｇ）を５〜２５℃で加えた。反応混合物を２５℃で２時間攪拌した。混合物に１ＮＨＣｌ（１０５ｍｌ）を加えた。溶液をＥｔＯＡｃと水に分配した。有機層を分離した。水層をＥｔＯＡｃで抽出した。合わせた有機溶液を１０％ＮａＯＡｃ水溶液と食塩水で順次洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を真空留去して固形残留物を得た。残留物をＩＰＥ（１５０ｍｌ）で粉末化した。沈殿結晶を濾取して、（１Ｅ）−（６−メトキシ−３−ピリジル）（オキソ）アセトアルデヒドオキシムを固形物（５．４５ｇ）（アンチ、シン混合物（アンチ：シン＝１：１））として得た。濾液中の溶媒を留去して、残留物を得た。残留物をＩＰＥで粉末化した。沈殿結晶を濾取して、（１Ｅ）−（６−メトキシ−３−ピリジル）（オキソ）アセトアルデヒドオキシムを固形物（２．５ｇ）（アンチ、シン混合物（アンチ：シン＝１：１））として得た。\n\nアンチ形\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.95 (3H, s), 6.95 (1H, d, J=8.4 Hz), 8.00 (1H, s), 8.23 (1H, dd, J=2.4, 8.4 Hz), 8.85 (1H, d, J=2.4 Hz), 12.7 (1H, s)\n\nMS(ESI\n+\n) : 181[M+H]\n+\n, 203[M+Na]\n+\n \n\nシン形\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.96 (3H, s), 7.00 (1H, d, J=8.4 Hz), 7.59 (1H, s), 8.09 (1H, dd, J=2.4, 8.4 Hz), 8.64 (1H, d, J=2.4 Hz), 11.8 (1H, s),\n\nMS(ESI\n+\n) : 181[M+H]\n+\n, 203[M+Na]\n+\n\n\n \nProduction Example 2\n \n 2-Methoxy-5-acetylpyridine (12.1 g) and tertiary butyl nitrile (9.92 g) were dissolved in THF (120 ml). The solution was cooled to 0-5 ° C. To the solution was added t-BuOK (10.8 g) at 5-25 ° C. The reaction mixture was stirred at 25 ° C. for 2 hours. To the mixture was added 1N HCl (105 ml). The solution was partitioned between EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed successively with 10% aqueous NaOAc solution and brine and dried over MgSO \n4\n . The solvent was removed in vacuo to give a solid residue. The residue was triturated with IPE (150 ml). The precipitated crystals were collected by filtration to give (1E)-(6-methoxy-3-pyridyl) (oxo) acetaldehyde oxime as a solid (5.45 g) (anti, syn mixture (anti: sin = 1: 1)). Obtained. The solvent in the filtrate was distilled off to obtain a residue. The residue was triturated with IPE. The precipitated crystals were collected by filtration to give (1E)-(6-methoxy-3-pyridyl) (oxo) acetaldehyde oxime as a solid (2.5 g) (anti, syn mixture (anti: sin = 1: 1)). Obtained. \n Anti form \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.95 (3H, s), 6.95 (1H, d, J = 8.4 Hz), 8.00 (1H, s), 8.23 (1H, dd, J = 2.4, 8.4 Hz) ), 8.85 (1H, d, J = 2.4 Hz), 12.7 (1H, s) \n MS (ESI \n+\n ): 181 [M + H] \n+\n , 203 [M + Na] \n+\n \n Thin \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.96 (3H, s), 7.00 (1H, d, J = 8.4 Hz), 7.59 (1H, s), 8.09 (1H, dd, J = 2.4, 8.4 Hz) ), 8.64 (1H, d, J = 2.4 Hz), 11.8 (1H, s), \n MS (ESI \n+\n ): 181 [M + H] \n+\n , 203 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n製造例３\n \n\n  （１Ｅ）−（６−メトキシ−３−ピリジル）（オキソ）アセトアルデヒドオキシム（５．４ｇ）とｐ−トルエンスルホン酸アミノマロニトリル（７．６ｇ）を２−プロパノール（１０８ｍｌ）中に懸濁し、２５℃で攪拌した。混合物にｐ−トルエンスルホン酸（５．７１ｇ）を加えた。混合物を５０℃で２時間、次いで室温で１時間加熱した。上記の反応混合物を真空濃縮した。濃縮溶液にＮａＯＡｃ飽和水溶液を加えた。結晶を沈殿させた。懸濁液を２０℃で１５時間攪拌した。結晶を濾取し、真空乾燥して、３−アミノ−６−（６−メトキシ−３−ピリジル）−２−ピラジンカルボニトリル・４−オキシドを粉末（６．６５ｇ）として得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.90 (3H, s), 6.92 (1H, d, J=8.6 Hz), 8.06 (2H, brs), 8.23 (1H, dd, J=2.4, 8.6 Hz), 8.74 (1H, d, J=2.4 Hz), 9.21 (1H, s)\n\nMS(ESI\n+\n) : 244[M+H]\n+\n,\n\nIR(KBr) : 3386, 3186, 2238, 1639, 1610, 1489, 1189 cm\n-1\n\n\n \nProduction Example 3\n \n (1E)-(6-Methoxy-3-pyridyl) (oxo) acetaldehyde oxime (5.4 g) and p-toluenesulfonic acid aminomalonitrile (7.6 g) were suspended in 2-propanol (108 ml). Stir at ° C. To the mixture was added p-toluenesulfonic acid (5.71 g). The mixture was heated at 50 ° C. for 2 hours and then at room temperature for 1 hour. The above reaction mixture was concentrated in vacuo. To the concentrated solution was added a saturated aqueous solution of NaOAc. Crystals precipitated. The suspension was stirred at 20 ° C. for 15 hours. The crystals were collected by filtration and dried in vacuo to give 3-amino-6- (6-methoxy-3-pyridyl) -2-pyrazinecarbonitrile 4-oxide as a powder (6.65 g). \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.90 (3H, s), 6.92 (1H, d, J = 8.6 Hz), 8.06 (2H, brs), 8.23 (1H, dd, J = 2.4, 8.6 Hz) ), 8.74 (1H, d, J = 2.4 Hz), 9.21 (1H, s) \n MS (ESI \n+\n ): 244 [M + H] \n+\n , \n IR (KBr): 3386, 3186, 2238, 1639, 1610, 1489, 1189 cm \n-1\n \n\n\n\n\n\n\n \n \n製造例４\n \n\n  ３−アミノ−６−（６−メトキシ−３−ピリジル）−２−ピラジンカルボニトリル・４−オキシド（６．６５ｇ）をＤＭＦ（１３３ｍｌ）に溶解した。溶液にオキシ塩化燐（１２．６ｇ）を２５℃で加えた。混合物を室温で２時間攪拌した。混合物に水（５２０ｍｌ）を加えた。溶液を２０〜２５℃で１５時間攪拌した。沈殿結晶を濾取し、真空乾燥して、３−アミノ−５−クロロ−６−（６−メトキシ−３−ピリジル）−２−ピラジンカルボニトリルを粉末（４．６ｇ）として得た。濾液をＥｔＯＡｃで抽出した。有機溶液を食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を真空留去して、油状残留物を得た。残留物をシリカゲルクロマトグラフィー（ＥｔＯＡｃ：ｎ−ヘキサン＝１：１、ｖ／ｖ）で精製して、３−アミノ−５−クロロ−６−（６−メトキシ−３−ピリジル）−２−ピラジンカルボニトリルを粉末（１．０ｇ）として得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.93 (3H, s), 6.92 (1H, d, J=8.6 Hz), 7.88 (2H, s), 7.95 (1H, dd, J=2.4, 8.6 Hz), 8.43 (1H, d, J=2.4 Hz)\n\nMS(ESI\n+\n) : 262[M+H]\n+\n, 284[M+Na]\n+\n \n\nIR(KBr) : 3384, 3187, 2227, 1656, 1610, 1475, 1209 cm\n-1\n\n\n \nProduction Example 4\n \n 3-Amino-6- (6-methoxy-3-pyridyl) -2-pyrazinecarbonitrile 4-oxide (6.65 g) was dissolved in DMF (133 ml). To the solution was added phosphorus oxychloride (12.6 g) at 25 ° C. The mixture was stirred at room temperature for 2 hours. Water (520 ml) was added to the mixture. The solution was stirred at 20-25 ° C. for 15 hours. The precipitated crystals were collected by filtration and dried in vacuo to give 3-amino-5-chloro-6- (6-methoxy-3-pyridyl) -2-pyrazinecarbonitrile as a powder (4.6 g). The filtrate was extracted with EtOAc. The organic solution was washed with brine and dried over MgSO \n4\n . The solvent was removed in vacuo to give an oily residue. The residue was purified by silica gel chromatography (EtOAc: n-hexane = 1: 1, v / v) to give 3-amino-5-chloro-6- (6-methoxy-3-pyridyl) -2-pyrazinecarbo The nitrile was obtained as a powder (1.0 g). \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.93 (3H, s), 6.92 (1H, d, J = 8.6 Hz), 7.88 (2H, s), 7.95 (1H, dd, J = 2.4, 8.6 Hz) ), 8.43 (1H, d, J = 2.4 Hz) \n MS (ESI \n+\n ): 262 [M + H] \n+\n , 284 [M + Na] \n+\n \n IR (KBr): 3384, 3187, 2227, 1656, 1610, 1475, 1209 cm \n-1\n \n\n\n\n\n\n\n \n \n製造例５\n \n\n  ２−メトキシ−５−ブロモ−ピリジン（６１５ｇ）を６ＮＨＣｌ（３Ｌ）に溶解した。溶液を９９〜１０５℃に加熱した。混合物を還流し、５時間攪拌した。上記の反応混合物を５℃まで冷却した。溶液のｐＨを１０％ＮａＯＨ水溶液で６．５に調整した。沈殿結晶を濾取し、水（５００ｍｌ）で洗浄し、真空乾燥して、５−ブロモ−２（１Ｈ）−ピリドン（５７０ｇ）を結晶として得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 6.36 (1H, d, J=9.8 Hz), 7.55 (1H, dd, J=2.8, 9.8 Hz), 7.69 (1H, d, J=2.4 Hz), 11.7 (1H, s)\n\nMS(ESI\n+\n) : 196 および 198[M+Na]\n+\n\n\n \nProduction Example 5\n \n 2-Methoxy-5-bromo-pyridine (615 g) was dissolved in 6N HCl (3 L). The solution was heated to 99-105 ° C. The mixture was refluxed and stirred for 5 hours. The above reaction mixture was cooled to 5 ° C. The pH of the solution was adjusted to 6.5 with 10% aqueous NaOH. Precipitated crystals were collected by filtration, washed with water (500 ml), and dried under vacuum to give 5-bromo-2 (1H) -pyridone (570 g) as crystals. \n \n1\n H-NMR (DMSO-d \n6\n δ): 6.36 (1H, d, J = 9.8 Hz), 7.55 (1H, dd, J = 2.8, 9.8 Hz), 7.69 (1H, d, J = 2.4 Hz), 11.7 (1H, s) \n MS (ESI \n+\n ): 196 and 198 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n製造例６\n \n\n  ｔ−ＢｕＯＫ（３２．２ｇ）を５−ブロモ−２（１Ｈ）−ピリドン（５０ｇ）のＤＭＥ（５００ｍｌ）中の懸濁液に加えた。混合物を３０分間攪拌した。混合物にＫ\n２\nＣＯ\n３\n（２７．８ｇ）と２−ヨードプロパン（８１．６ｇ）を加えた。反応混合物を攪拌しながら３時間還流した。上記の混合物を２０〜２５℃まで冷却した。沈殿塩を濾去し、ＤＭＥ（１００ｍｌ）で洗浄した。溶媒を真空留去して、固形残留物を得た。残留物をＣＨＣｌ\n３\n（１５０ｍｌ）に溶解した。溶液を０．１ＮＨＣｌと食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を真空留去して、固形残留物を得た。残留物にｎ−ヘキサン（１５０ｍｌ）を加えて、残留物を粉末化した。沈殿物を濾取し、真空乾燥して、５−ブロモ−１−イソプロピル−２（１Ｈ）−ピリドン（４１．２ｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.29 (6H, d, J=6.8 Hz), 4.99 (1H, m), 6.36 (1H, d, J=9.6 Hz), 7.48 (1H, dd, J=2.4, 9.6 Hz), 7.96 (1H, d, J=2.4 Hz)\n\nMS(ESI\n+\n) : 216 および 218[M+H]\n+\n, 238 および 240[M+Na]\n+\n\n\n \nProduction Example 6\n \n t-BuOK (32.2 g) was added to a suspension of 5-bromo-2 (1H) -pyridone (50 g) in DME (500 ml). The mixture was stirred for 30 minutes. To the mixture was added K \n2\n CO \n3\n (27.8 g) and 2-iodopropane (81.6 g). The reaction mixture was refluxed for 3 hours with stirring. The above mixture was cooled to 20-25 ° C. The precipitated salt was removed by filtration and washed with DME (100 ml). The solvent was removed in vacuo to give a solid residue. The residue was dissolved in CHCl \n3\n (150 ml). The solution was washed with 0.1N HCl and brine and dried over MgSO \n4\n . The solvent was removed in vacuo to give a solid residue. N-Hexane (150 ml) was added to the residue to powder the residue. The precipitate was collected by filtration and dried in vacuo to give 5-bromo-1-isopropyl-2 (1H) -pyridone (41.2 g). \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.29 (6H, d, J = 6.8 Hz), 4.99 (1H, m), 6.36 (1H, d, J = 9.6 Hz), 7.48 (1H, dd, J = 2.4, 9.6 Hz), 7.96 (1H, d, J = 2.4 Hz) \n MS (ESI \n+\n ): 216 and 218 [M + H] \n+\n , 238 and 240 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n製造例７\n \n\n  ５−ブロモ−１−イソプロピル−２（１Ｈ）−ピリドン（５０ｇ）をｎ−ブチルビニルエーテル（２５０ｍｌ）に溶解した。溶液に１，３−ビス（ジフェニルホスフィノ）プロパン（６．３ｇ）、粉末化したＫ\n２\nＣＯ\n３\n（３８．２ｇ）とＰｄ（ＯＡｃ）\n２\n（１．５６ｇ）を２５℃で加えた。混合物を攪拌しながら９０〜９５\nｏ\nＣで８時間加熱した。反応混合物を２５〜３０℃まで冷却した。冷却混合物にＣＨＣｌ\n３\n（１２５ｍｌ）を加えた。沈殿塩を濾去し、ＣＨＣｌ\n３\n（１２５ｍｌ）で洗浄した。濾液中の溶媒を真空留去して、油状残留物を得た。残留物をＣＨＣｌ\n３\n（１２５ｍｌ）に溶解した。溶液に１ＮＨＣｌ（１２５ｍｌ）を加えた。反応混合物を２５〜３０℃で１時間攪拌した。有機層を分離した。水層をＣＨＣｌ\n３\n（１００ｍｌ）で抽出した。合わせた有機層を１０％ＮａＨＣＯ\n３\n水溶液（５０ｍｌ）で洗浄し、ＭｇＳＯ\n４\n（２５ｇ）とシリカゲル（２５ｇ）で乾燥した。ＭｇＳＯ\n４\nとシリカゲルを濾去し、ＣＨＣｌ\n３\nで洗浄した。濾液中の溶媒を真空留去して、油状残留物を得て、これをｎ−ヘキサン（５００ｍｌ）から結晶化した。結晶を濾取し、４０℃で真空乾燥して、５−アセチル−１−イソプロピル−２（１Ｈ）−ピリドン（３２．３５ｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.37 (6H, d, J=6.8 Hz), 2.47 (3H, s), 5.02 (1H, m), 6.44 (1H, d, J=9.6 Hz), 7.82 (1H, dd, J=2.6, 9.6 Hz), 8.41 (1H, d, J=2.6 Hz)\n\nMS(ESI\n+\n) : 180[M+H]\n+\n, 202[M+Na]\n+\n\n\n \nProduction Example 7\n \n 5-Bromo-1-isopropyl-2 (1H) -pyridone (50 g) was dissolved in n-butyl vinyl ether (250 ml). To the solution was added 1,3-bis (diphenylphosphino) propane (6.3 g), powdered K \n2\n CO \n3\n (38.2 g) and Pd (OAc) \n2\n (1.56 g) at 25 ° C. The mixture was heated at 90-95 \n°\n C. with stirring for 8 hours. The reaction mixture was cooled to 25-30 ° C. To the cooled mixture was added CHCl \n3\n (125 ml). The precipitated salt was filtered off and washed with CHCl \n3\n (125 ml). The solvent in the filtrate was removed in vacuo to give an oily residue. The residue was dissolved in CHCl \n3\n (125 ml). To the solution was added 1N HCl (125 ml). The reaction mixture was stirred at 25-30 ° C. for 1 hour. The organic layer was separated. The aqueous layer was extracted with CHCl \n3\n (100 ml). The combined organic layers were washed with 10% aqueous NaHCO \n3\n (50 ml) and dried over MgSO \n4\n (25 g) and silica gel (25 g). MgSO \n4\n and silica gel were filtered off and washed with CHCl \n3\n . The solvent in the filtrate was removed in vacuo to give an oily residue which was crystallized from n-hexane (500 ml). The crystals were collected by filtration and dried in vacuo at 40 ° C. to give 5-acetyl-1-isopropyl-2 (1H) -pyridone (32.35 g). \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.37 (6H, d, J = 6.8 Hz), 2.47 (3H, s), 5.02 (1H, m), 6.44 (1H, d, J = 9.6 Hz), 7.82 (1H, dd, J = 2.6, 9.6 Hz), 8.41 (1H, d, J = 2.6 Hz) \n MS (ESI \n+\n ): 180 [M + H] \n+\n , 202 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n製造例８\n \n\n  ５−アセチル−１−イソプロピル−２（１Ｈ）−ピリドンをＣＨ\n２\nＣｌ\n２\n（３００ｍｌ）に溶解した。溶液を−３０〜−２５℃まで冷却した。冷却溶液にジオキサン中４Ｎ塩化水素（５５．３ｍｌ）と第三級ブチルニトリル（１０．４ｇ）を−３０〜−２５℃で加えた。反応混合物の温度を２０〜２５℃まで上げた。混合物を同温で３時間攪拌した。沈殿結晶を濾取し、室温で空気乾燥して、（１Ｅ）−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）（オキソ）アセトアルデヒドオキシム（１４．０ｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.35 (6H, d, J=6.8 Hz), 5.02 (1H, m), 6.47 (1H, d, J=9.6 Hz), 7.89 (1H, dd, J=2.4, 9.6 Hz), 8.00 (1H, s), 8.69 (1H, d, J=2.4 Hz), 12.65 (1H, brs)\n\nMS(ESI\n+\n) : 209[M+H]\n+\n, 231[M+Na]\n+\n \n\nIR(KBr) : 3129, 1660, 1617, 1529, 1018 cm\n-1\n\n\n \nProduction Example 8\n \n 5-Acetyl-1-isopropyl-2 (1H) -pyridone was dissolved in CH \n2\n Cl \n2\n (300 ml). The solution was cooled to -30 to -25 ° C. To the cooled solution was added 4N hydrogen chloride in dioxane (55.3 ml) and tert-butylnitrile (10.4 g) at -30 to -25 ° C. The temperature of the reaction mixture was raised to 20-25 ° C. The mixture was stirred at the same temperature for 3 hours. Precipitated crystals were collected by filtration and air dried at room temperature to obtain (1E)-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) (oxo) acetaldehyde oxime (14.0 g). . \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.35 (6H, d, J = 6.8 Hz), 5.02 (1H, m), 6.47 (1H, d, J = 9.6 Hz), 7.89 (1H, dd, J = 2.4, 9.6 Hz), 8.00 (1H, s), 8.69 (1H, d, J = 2.4 Hz), 12.65 (1H, brs) \n MS (ESI \n+\n ): 209 [M + H] \n+\n , 231 [M + Na] \n+\n \n IR (KBr): 3129, 1660, 1617, 1529, 1018 cm \n-1\n \n\n\n\n\n\n\n \n \n製造例９\n \n\n  （１Ｅ）−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）（オキソ）アセトアルデヒドオキシム（１４ｇ）とｐ−トルエンスルホン酸アミノマロニトリル（１７ｇ）とＩＰＡ（２１０ｍｌ）の混合物を７５〜８０℃に加熱し、同温で２時間攪拌した。反応混合物を０〜５℃まで冷却し、２時間攪拌した。沈殿物を濾取し、真空乾燥して、３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボニトリル・４−オキシド（９．２ｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.36 (6H, d, J=6.8 Hz), 5.09 (1H, m), 6.48 (1H, d, J=9.6 Hz), 7.92-7.99 (3H, m), 8.28 (1H, d, J=2.6 Hz), 9.25 (1H, s)\n\nMS(ESI\n+\n) : 293[M+Na]\n+\n \n\nIR(KBr) : 3122, 2200, 1656, 1598, 1531, 1174 cm\n-1\n\n\n \nProduction Example 9\n \n (1E)-(1-Isopropyl-6-oxo-1,6-dihydro-3-pyridyl) (oxo) acetaldehyde oxime (14 g), p-toluenesulfonic acid aminomalonitrile (17 g) and IPA (210 ml) mixture Was heated to 75-80 ° C. and stirred at the same temperature for 2 hours. The reaction mixture was cooled to 0-5 ° C. and stirred for 2 hours. The precipitate was collected by filtration and dried in vacuo to give 3-amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarbonitrile 4-oxide (9. 2 g) was obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.36 (6H, d, J = 6.8 Hz), 5.09 (1H, m), 6.48 (1H, d, J = 9.6 Hz), 7.92-7.99 (3H, m ), 8.28 (1H, d, J = 2.6 Hz), 9.25 (1H, s) \n MS (ESI \n+\n ): 293 [M + Na] \n+\n \n IR (KBr): 3122, 2200, 1656, 1598, 1531, 1174 cm \n-1\n \n\n\n\n\n\n\n \n \n製造例１０\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボニトリル・４−オキシド（９ｇ）をＡｃＯＨの２５％臭化水素溶液（９０ｍｌ）に２０〜２５℃で溶解した。反応混合物を室温で２時間攪拌した。反応混合物にジオキサン（１８０ｍｌ）を加えた。懸濁液を室温で２時間攪拌した。沈殿物を濾取し、ジオキサンで洗浄し、室温で空気乾燥した。上記の粉末を水（９０ｍｌ）中に懸濁した。懸濁液のｐＨを１ＮＮａＯＨ（７０ｍｌ）で８〜８．５に調整した。懸濁液を室温で攪拌した。沈殿物を濾取し、水で洗浄し、５０℃で真空乾燥して、３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド・４−オキシド（８．８０ｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.39 (6H, d, J=6.8 Hz), 5.10 (1H, m), 6.46 (1H, d, J=9.4 Hz), 7.88 (2H, s), 7.89 (1H, s), 8.32 (1H, dd, J=2.4, 9.4 Hz),8.41 (1H, d, J=2.4 Hz), 8.51 (1H, s), 9.15 (1H, s)\n\nMS(ESI\n+\n) : 312[M+Na]\n+\n \n\nIR(KBr) : 3440, 1660, 1596, 1554, 1186 cm\n-1\n\n\n \nProduction Example 10\n \n 3-amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarbonitrile 4-oxide (9 g) in AcOH in 25% hydrogen bromide (90 ml) Was dissolved at 20-25 ° C. The reaction mixture was stirred at room temperature for 2 hours. Dioxane (180 ml) was added to the reaction mixture. The suspension was stirred at room temperature for 2 hours. The precipitate was collected by filtration, washed with dioxane and air dried at room temperature. The above powder was suspended in water (90 ml). The pH of the suspension was adjusted to 8-8.5 with 1N NaOH (70 ml). The suspension was stirred at room temperature. The precipitate was collected by filtration, washed with water and dried in vacuo at 50 ° C. to give 3-amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide. -4-oxide (8.80g) was obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.39 (6H, d, J = 6.8 Hz), 5.10 (1H, m), 6.46 (1H, d, J = 9.4 Hz), 7.88 (2H, s), 7.89 (1H, s), 8.32 (1H, dd, J = 2.4, 9.4 Hz), 8.41 (1H, d, J = 2.4 Hz), 8.51 (1H, s), 9.15 (1H, s) \n MS (ESI \n+\n ): 312 [M + Na] \n+\n \n IR (KBr): 3440, 1660, 1596, 1554, 1186 cm \n-1\n \n\n\n\n\n\n\n \n \n製造例１１\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド・４−オキシド（８ｇ）をＤＭＦ（８０ｍｌ）に溶解した。溶液を−３０℃まで冷却した。冷却溶液に塩化ホスホリル（１２．７ｇ）を−３０〜−４０℃で滴下した。塩化ホスホリルを加えた後、反応混合物の温度を−１０〜−５℃まで上げた。混合物を−１０〜−５℃で１時間攪拌した。反応混合物に水（４００ｍｌ）を加えた。懸濁液を３０〜３５℃で１５時間攪拌した。懸濁液のｐＨを４．５に調整した。懸濁液を０〜５℃まで冷却し、同温で２時間攪拌した。沈殿物を濾取し、水で洗浄し、４０〜５０℃で真空乾燥して、３−アミノ−５−クロロ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド（７．１ｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.34 (6H, d, J=7.0 Hz), 5.09 (1H, m), 6.44 (1H, d, J=9.4 Hz), 7.74 (1H, s), 7.85 (1H, dd, J=2.4, 9.4 Hz), 7.85 (2H, s), 8.13 (1H, d, J=2.4 Hz), 8.13 (1H, s)\n\nMS(ESI\n+\n) : 330 および 332[M+Na]\n+\n \n\nIR(KBr) : 3284, 1673, 1604, 1461, 1187 cm\n-1\n\n\n \nProduction Example 11\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide 4-oxide (8 g) was dissolved in DMF (80 ml). The solution was cooled to -30 ° C. Phosphoryl chloride (12.7 g) was added dropwise to the cooled solution at −30 to −40 ° C. After the phosphoryl chloride was added, the temperature of the reaction mixture was raised to -10 to -5 ° C. The mixture was stirred at −10 to −5 ° C. for 1 hour. Water (400 ml) was added to the reaction mixture. The suspension was stirred at 30-35 ° C. for 15 hours. The pH of the suspension was adjusted to 4.5. The suspension was cooled to 0-5 ° C. and stirred at the same temperature for 2 hours. The precipitate was filtered off, washed with water and dried in vacuo at 40-50 ° C. to give 3-amino-5-chloro-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl ) -2-pyrazinecarboxamide (7.1 g) was obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.34 (6H, d, J = 7.0 Hz), 5.09 (1H, m), 6.44 (1H, d, J = 9.4 Hz), 7.74 (1H, s), 7.85 (1H, dd, J = 2.4, 9.4 Hz), 7.85 (2H, s), 8.13 (1H, d, J = 2.4 Hz), 8.13 (1H, s) \n MS (ESI \n+\n ): 330 and 332 [M + Na] \n+\n \n IR (KBr): 3284, 1673, 1604, 1461, 1187 cm \n-1\n \n\n\n\n\n\n\n \n \n製造例１２\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド・４−オキシド（２９．１ｇ）をＤＭＦ（２９０ｍｌ）に溶解した。溶液を−３０℃まで冷却した。冷却溶液に塩化ホスホリル（４６．３ｇ）を−３０〜−４０℃で滴下した。塩化ホスホリルを加えた後、反応混合物の温度を４０〜４５℃に上げた。混合物を４０〜４５℃で１時間攪拌した。反応混合物に水（１１６０ｍｌ）を加えた。懸濁液を３０〜３５℃で１５時間攪拌した。懸濁液のｐＨを１２％ＮａＯＨ水溶液（４００ｍｌ）で７に調整した。懸濁液を０〜５℃まで冷却し、同温で２時間攪拌した。沈殿物を濾取し、水で洗浄し、４０〜５０℃で真空乾燥して、３−アミノ−５−クロロ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボニトリル（１７．２ｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.34 (6H, d, J=7.0 Hz), 5.09 (1H, m), 6.44 (1H, d, J=9.4 Hz), 7.74 (1H, s), 7.85 (1H, dd, J=2.4, 9.4 Hz), 7.85 (2H, s), 8.13 (1H, d, J=2.4 Hz), 8.13 (1H, s)\n\nMS(ESI\n+\n) : 330[M+Na]\n+\n \n\nIR(KBr) : 3291, 1662, 1600, 1465, 1182 cm\n-1\n\n\n \nProduction Example 12\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide 4-oxide (29.1 g) was dissolved in DMF (290 ml). The solution was cooled to -30 ° C. Phosphoryl chloride (46.3 g) was added dropwise to the cooled solution at −30 to −40 ° C. After the phosphoryl chloride was added, the temperature of the reaction mixture was raised to 40-45 ° C. The mixture was stirred at 40-45 ° C. for 1 hour. Water (1160 ml) was added to the reaction mixture. The suspension was stirred at 30-35 ° C. for 15 hours. The pH of the suspension was adjusted to 7 with 12% aqueous NaOH (400 ml). The suspension was cooled to 0-5 ° C. and stirred at the same temperature for 2 hours. The precipitate was collected by filtration, washed with water and dried in vacuo at 40-50 ° C. to give 3-amino-5-chloro-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl ) -2-pyrazinecarbonitrile (17.2 g) was obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.34 (6H, d, J = 7.0 Hz), 5.09 (1H, m), 6.44 (1H, d, J = 9.4 Hz), 7.74 (1H, s), 7.85 (1H, dd, J = 2.4, 9.4 Hz), 7.85 (2H, s), 8.13 (1H, d, J = 2.4 Hz), 8.13 (1H, s) \n MS (ESI \n+\n ): 330 [M + Na] \n+\n \n IR (KBr): 3291, 1662, 1600, 1465, 1182 cm \n-1\n \n\n\n\n\n\n\n \n \n製造例１３\n \n\n  １−（ジフェニルメチル）−３−アゼチジノール塩酸塩（５．０ｇ）のＤＭＦ（２５ｍｌ）中の溶液に、水素化ナトリウムを氷浴冷却下に加えた。同温で１０分間攪拌後、混合物を２５℃まで加温させ、次いで１５時間攪拌した。ＥｔＯＡｃ（５００ｍｌ）と水（２００ｍｌ）を混合物に注いだ。有機層を分離し、水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去した。残留物をカラムクロマトグラフィー（シリカゲル；２００ｍｌ、トルエン：ＥｔＯＡｃ＝１５：１〜８：１）で精製して、１−（ジフェニルメチル）−３−メトキシアゼチジン（３．４１ｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 2.7-2.9 (2H, m), 3.12 (3H, s), 3.3-3.5 (2H, m), 3.99 (1H, m), 4.40 (1H, s), 7.1-7.4 (6H, m), 7.3-7.5 (4H, m)\n\nMS(ESI\n+\n) : 254[M+H]\n+\n\n\n \nProduction Example 13\n \n To a solution of 1- (diphenylmethyl) -3-azetidinol hydrochloride (5.0 g) in DMF (25 ml) was added sodium hydride with ice bath cooling. After stirring at the same temperature for 10 minutes, the mixture was warmed to 25 ° C. and then stirred for 15 hours. EtOAc (500 ml) and water (200 ml) were poured into the mixture. The organic layer was separated, washed with water and brine and dried over MgSO \n4\n . The solvent was removed under reduced pressure. The residue was purified by column chromatography (silica gel; 200 ml, toluene: EtOAc = 15: 1 to 8: 1) to give 1- (diphenylmethyl) -3-methoxyazetidine (3.41 g). \n \n1\n H-NMR (DMSO-d \n6\n δ): 2.7-2.9 (2H, m), 3.12 (3H, s), 3.3-3.5 (2H, m), 3.99 (1H, m), 4.40 (1H, s) , 7.1-7.4 (6H, m), 7.3-7.5 (4H, m) \n MS (ESI \n+\n ): 254 [M + H] \n+\n \n\n\n\n\n\n\n \n \n製造例１４\n \n\n  １−（ジフェニルメチル）−３−メトキシ−アゼチジン（３．４ｇ）のＭｅＯＨ（３５ｍｌ）中の溶液に、２０％水酸化パラジウム炭（０．７ｇ）を加えた。次いで混合物を水素雰囲気下に２．５時間攪拌した。１ＮＨＣｌ（２０ｍｌ）を混合物に加え、触媒を濾去し、１ＮＨＣｌで洗浄した。溶媒を減圧除去した。水とＥｔＯＡｃを残留物に注ぎ、水層を分離し、ＥｔＯＡｃで洗浄した。溶媒を減圧除去し、残留物をＥｔＯＨと共沸し、真空乾燥した。ｎ−ヘキサンを残留物に注ぎ、結晶を濾過分離し、ｎ−ヘキサンで洗浄し、真空乾燥して、３−メトキシアゼチジン塩酸塩（１．５８ｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.21 (3H, s), 3.6-3.9 (2H, m), 4.0-4.4 (3H, m)\n\nMS(ESI\n+\n) : 88[M+H]\n+\n (遊離型)\n\n \nProduction Example 14\n \n To a solution of 1- (diphenylmethyl) -3-methoxy-azetidine (3.4 g) in MeOH (35 ml) was added 20% palladium hydroxide charcoal (0.7 g). The mixture was then stirred under a hydrogen atmosphere for 2.5 hours. 1N HCl (20 ml) was added to the mixture and the catalyst was filtered off and washed with 1N HCl. The solvent was removed under reduced pressure. Water and EtOAc were poured into the residue and the aqueous layer was separated and washed with EtOAc. The solvent was removed under reduced pressure and the residue azeotroped with EtOH and dried in vacuo. n-Hexane was poured into the residue and the crystals were separated by filtration, washed with n-hexane and dried in vacuo to give 3-methoxyazetidine hydrochloride (1.58 g). \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.21 (3H, s), 3.6-3.9 (2H, m), 4.0-4.4 (3H, m) \n MS (ESI \n+\n ): 88 [M + H] \n+\n (free form)\n\n\n\n\n\n\n \n \n製造例１５\n \n\n  ５−ブロモ−２（１Ｈ）−ピリドン（２００ｇ）、ＭｅＩ（３２４ｇ）とＫ\n２\nＣＯ\n３\n（３１８ｇ）のＤＭＥ（２Ｌ）中の混合物を攪拌しながら８０℃で２時間加熱した。上記の混合物を室温まで冷却した。沈殿塩を濾去し、ＤＭＥで洗浄した。濾液中の溶媒を真空留去して、油状残留物を得た。残留物をＥｔＯＡｃと水に分配した。有機層を分離した。水層をＥｔＯＡｃで二回抽出した。合わせた有機溶液をＭｇＳＯ\n４\nで乾燥した。溶媒を真空留去して、結晶残留物を得た。残留物をＩＰＥとｎ−ヘキサン（１：３、１０００ｍｌ）で粉末化した。沈殿物を濾取し、真空乾燥して、５−ブロモ−１−メチル−２（１Ｈ）−ピリドンを白色粉末（１８２．５ｇ）として得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.40 (3H, s), 6.36 (1H, d, J=9.6 Hz), 7.51 (1H, dd, J=2.8, 9.6 Hz), 8.03 (1H, d, J=2.8 Hz)\n\nMS(ESI\n+\n) : 210 および 212[M+Na]\n+\n\n\n \nProduction Example 15\n \n A mixture of 5-bromo-2 (1H) -pyridone (200 g), MeI (324 g) and K \n2\n CO \n3\n (318 g) in DME (2 L) was heated at 80 ° C. with stirring for 2 hours. The above mixture was cooled to room temperature. The precipitated salt was removed by filtration and washed with DME. The solvent in the filtrate was removed in vacuo to give an oily residue. The residue was partitioned between EtOAc and water. The organic layer was separated. The aqueous layer was extracted twice with EtOAc. The combined organic solution was dried over MgSO \n4\n . The solvent was removed in vacuo to give a crystalline residue. The residue was triturated with IPE and n-hexane (1: 3, 1000 ml). The precipitate was collected by filtration and dried in vacuo to give 5-bromo-1-methyl-2 (1H) -pyridone as a white powder (182.5 g). \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.40 (3H, s), 6.36 (1H, d, J = 9.6 Hz), 7.51 (1H, dd, J = 2.8, 9.6 Hz), 8.03 (1H, d , J = 2.8 Hz) \n MS (ESI \n+\n ): 210 and 212 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n製造例１６\n \n\n  ５−ブロモ−１−メチル−２（１Ｈ）−ピリドン（１５０ｇ）をＤＭＦ（１５００ｍｌ）に溶解した。溶液に１，３−ビス（ジフェニルホスフィノ）プロパン（２１．７ｇ）、ｎ−ブチルビニルエーテル（４００ｇ）、３Ｍ炭酸カリウム水溶液（２６２．５ｍｌ）とＰｄ（ＯＡｃ）\n２\n（１０．２ｇ）を加えた。混合物を８０℃に加熱し、同温で３時間攪拌した。反応混合物を２５〜３０℃まで冷却し、１ＮＨＣｌ（１４８５ｍｌ）に注いだ。混合物を３０〜４０\nｏ\nＣで２時間攪拌した。溶液をＥｔＯＡｃ（１５００ｍｌ、三回）で抽出した。水層をＣＨ\n２\nＣｌ\n２\n（１０００ｍｌ、三回）で抽出した。採取した有機溶液をＭｇＳＯ\n４\nで乾燥した。溶媒を留去して固形残留物を得て、これをＩＰＡ（１５０ｍｌ）とＩＰＥ（１５００ｍｌ）で粉末化した。懸濁液を冷蔵庫に一夜放置した。沈殿物を濾取し、真空乾燥して、５−アセチル−１−メチル−２（１Ｈ）−ピリドンを白色粉末（１２８ｇ）として得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 2.41 (3H, s), 3.52 (3H, s), 6.42 (1H, d, J=9.6 Hz), 7.84 (1H, dd, J=2.4, 9.6 Hz), 8.66 (1H, d, J=2.4 Hz)\n\nMS(ESI\n+\n) : 152[M+H]\n+\n, 174[M+Na]\n+\n\n\n \nProduction Example 16\n \n 5-Bromo-1-methyl-2 (1H) -pyridone (150 g) was dissolved in DMF (1500 ml). To the solution was added 1,3-bis (diphenylphosphino) propane (21.7 g), n-butyl vinyl ether (400 g), 3M aqueous potassium carbonate solution (262.5 ml) and Pd (OAc) \n2\n (10.2 g). . The mixture was heated to 80 ° C. and stirred at the same temperature for 3 hours. The reaction mixture was cooled to 25-30 ° C. and poured into 1N HCl (1485 ml). The mixture was stirred at 30-40 \n°\n C. for 2 hours. The solution was extracted with EtOAc (1500 ml, 3 times). The aqueous layer was extracted with CH \n2\n Cl \n2\n (1000 ml, 3 times). The collected organic solution was dried over MgSO \n4\n . The solvent was distilled off to obtain a solid residue, which was triturated with IPA (150 ml) and IPE (1500 ml). The suspension was left in the refrigerator overnight. The precipitate was collected by filtration and dried in vacuo to give 5-acetyl-1-methyl-2 (1H) -pyridone as a white powder (128 g). \n \n1\n H-NMR (DMSO-d \n6\n δ): 2.41 (3H, s), 3.52 (3H, s), 6.42 (1H, d, J = 9.6 Hz), 7.84 (1H, dd, J = 2.4, 9.6 Hz) ), 8.66 (1H, d, J = 2.4 Hz) \n MS (ESI \n+\n ): 152 [M + H] \n+\n , 174 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n製造例１７\n \n\n  （１Ｅ）−（１−メチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）（オキソ）アセトアルデヒドオキシム\n\n  表題の化合物を製造例８と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.57 (3H, s), 6.47 (1H, d, J=9.6 Hz), 7.93 (1H, dd, J=2.4, 9.6 Hz), 8.03 (1H, s), 8.76 (1H, d, J=2.4 Hz), 12.62 (1H, s)\n\nMS(ESI\n+\n) : 203[M+Na]\n+\n\n\n \nProduction Example 17\n \n (1E)-(1-Methyl-6-oxo-1,6-dihydro-3-pyridyl) (oxo) acetaldehyde oxime The title compound was obtained in the same manner as in Production Example 8. \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.57 (3H, s), 6.47 (1H, d, J = 9.6 Hz), 7.93 (1H, dd, J = 2.4, 9.6 Hz), 8.03 (1H, s ), 8.76 (1H, d, J = 2.4 Hz), 12.62 (1H, s) \n MS (ESI \n+\n ): 203 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n製造例１８\n \n\n  ３−アミノ−６−（１−メチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボニトリル・４−オキシド\n\n  表題の化合物を製造例９と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.50 (3H, s), 6.47 (1H, d, J=9.6 Hz), 7.96 (2H, s), 7.96-8.02 (1H, m), 8.43 (1H, d, J=2.4 Hz), 9.04 (1H, s)\n\nMS(ESI\n+\n) : 244[M+Na]\n+\n\n\n \nProduction Example 18\n \n 3-Amino-6- (1-methyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarbonitrile 4-oxide The title compound was obtained in the same manner as in Production Example 9. . \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.50 (3H, s), 6.47 (1H, d, J = 9.6 Hz), 7.96 (2H, s), 7.96-8.02 (1H, m), 8.43 (1H , d, J = 2.4 Hz), 9.04 (1H, s) \n MS (ESI \n+\n ): 244 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n製造例１９\n \n\n  ３−アミノ−６−（１−メチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボニトリル・４−オキシド（９７ｇ）をＡｃＯＨの２５％臭化水素溶液（７００ｍｌ）に２５〜３０℃で加えた。混合物を室温で２時間攪拌した。混合物に１２％ＮａＯＨ水溶液（２１００ｍｌ）と水（１０００ｍｌ）を加えた。混合物を冷蔵庫で一夜攪拌した。生じた沈殿結晶を濾取し、水で洗浄し、真空乾燥して、３−アミノ−６−（１−メチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド・４−オキシドを粉末（５２ｇ）として得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.52 (3H, s), 6.45 (1H, d, J=9.6 Hz), 7.82 (2H, s), 7.92 (1H, s), 8.26( 1H, dd, J=2.6, 9.6 Hz), 8.54 (1H, s), 8.72 (1H, d, J=2.6 Hz), 8.97 (1H, s)\n\nMS(ESI\n+\n) : 262[M+H]\n+\n, 284[M+Na]\n+\n\n\n \nProduction Example 19\n \n 3-Amino-6- (1-methyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarbonitrile 4-oxide (97 g) was added to AcOH in 25% hydrogen bromide solution (700 ml). At 25-30 ° C. The mixture was stirred at room temperature for 2 hours. To the mixture was added 12% aqueous NaOH (2100 ml) and water (1000 ml). The mixture was stirred overnight in the refrigerator. The resulting precipitated crystals were collected by filtration, washed with water, and dried under vacuum to give 3-amino-6- (1-methyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide. 4-Oxide was obtained as a powder (52 g). \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.52 (3H, s), 6.45 (1H, d, J = 9.6 Hz), 7.82 (2H, s), 7.92 (1H, s), 8.26 (1H, dd , J = 2.6, 9.6 Hz), 8.54 (1H, s), 8.72 (1H, d, J = 2.6 Hz), 8.97 (1H, s) \n MS (ESI \n+\n ): 262 [M + H] \n+\n , 284 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n製造例２０\n \n\n  ３−アミノ−５−クロロ−６−（１−メチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボニトリル\n\n  表題の化合物を製造例１２と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.25 (3H, s), 6.45 (1H, d, J=9.4 Hz), 7.70 (1H, dd, J=2.6, 9.4 Hz), 7.83 (2H, s), 8.06 (1H, d, J=2.6 Hz)\n\nMS(ESI\n+\n) : 262 および 263[M+H]\n+\n, 284 および 286[M+Na]\n+\n\n\n \nProduction Example 20\n \n 3-Amino-5-chloro-6- (1-methyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarbonitrile The title compound was obtained in the same manner as in Production Example 12. . \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.25 (3H, s), 6.45 (1H, d, J = 9.4 Hz), 7.70 (1H, dd, J = 2.6, 9.4 Hz), 7.83 (2H, s ), 8.06 (1H, d, J = 2.6 Hz) \n MS (ESI \n+\n ): 262 and 263 [M + H] \n+\n , 284 and 286 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n製造例２１\n \n\n  ３−アミノ−６−（１−メチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド・４−オキシド（１．０ｇ）のＤＭＦ中の懸濁液に、三塩化燐（１．０７ｍｌ）を−４０℃で２０分間かけて加えた。この反応混合物を−１０℃まで加温し、１時間攪拌した。この溶液に水（４０ｍｌ）を加え、４０℃で１４時間攪拌した。生じた懸濁液のｐＨを３０％で４．５に調整した。混合物の水溶液のｐＨを１２％ＮａＯＨ水溶液で６〜７に調整した。沈殿物を濾取し、水で洗浄して、３−アミノ−５−クロロ−６−（１−メチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド（２６３ｍｇ）を黄色粉末として得た。\n\nMS(ESI\n+\n) : 280[M+H]\n+\n\n\n \nProduction Example 21\n \n To a suspension of 3-amino-6- (1-methyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide 4-oxide (1.0 g) in DMF was added trichloride. Phosphorus (1.07 ml) was added at −40 ° C. over 20 minutes. The reaction mixture was warmed to −10 ° C. and stirred for 1 hour. Water (40 ml) was added to this solution and stirred at 40 ° C. for 14 hours. The pH of the resulting suspension was adjusted to 4.5 with 30%. The pH of the aqueous solution of the mixture was adjusted to 6-7 with 12% NaOH aqueous solution. The precipitate was filtered off and washed with water to give 3-amino-5-chloro-6- (1-methyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide (263 mg) Was obtained as a yellow powder. \n MS (ESI \n+\n ): 280 [M + H] \n+\n \n\n\n\n\n\n\n \n \n実施例１\n \n\n  ３−アミノ−５−クロロ−６−（６−メトキシ−３−ピリジル）−２−ピラジンカルボニトリル（１．３５ｇ）をジオキサン（１３５ｍｌ）に溶解した。溶液に水（２７ｍｌ）中のフェニルホウ素酸（１．８９ｇ）、Ｐｄ（ＰＰｈ\n３\n）\n４\n（１７９ｍｇ）とＮａ\n２\nＣＯ\n３\n（２．１９ｇ）を２５℃で加えた。反応混合物を８０℃で２時間、次いで室温で３時間加熱した。上記の混合物をＥｔＯＡｃと水に分配した。有機層を分離し、Ｎａ\n２\nＣＯ\n３\n水溶液と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を真空留去して、油状残留物を得て、これをシリカゲルクロマトグラフィー（ＥｔＯＡｃ：ｎ−ヘキサン＝１：１、ｖ／ｖ）で精製して、３−アミノ−６−（６−メトキシ−３−ピリジル）−５−フェニル−２−ピラジンカルボニトリルをＥｔＯＡｃから結晶化した黄色結晶（１．１５ｇ）として得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.81 (3H, s), 6.73 (1H, d, J=8.6 Hz), 7.35 (5H, s), 7.51 (2H, s), 7.54 (1H, dd, J=2.4, 8.6 Hz), 7.99 (1H, d, J=2.4 Hz)\n\nMS(ESI\n+\n) : 304[M+H]\n+\n, 326[M+Na]\n+\n \n\nIR(KBr) : 3357, 3183, 2238, 1648, 1598, 1544, 1195 cm\n-1\n \n\nm.p. : 201-205℃ (IPE)\n\n \nExample 1\n \n 3-Amino-5-chloro-6- (6-methoxy-3-pyridyl) -2-pyrazinecarbonitrile (1.35 g) was dissolved in dioxane (135 ml). To the solution was added phenylboronic acid (1.89 g), Pd (PPh \n3\n ) \n4\n (179 mg) and Na \n2\n CO \n3\n (2.19 g) in water (27 ml) at 25 ° C. The reaction mixture was heated at 80 ° C. for 2 hours and then at room temperature for 3 hours. The above mixture was partitioned between EtOAc and water. The organic layer was separated, washed with aqueous Na \n2\n CO \n3\n and brine, and dried over MgSO \n4\n . The solvent was removed in vacuo to give an oily residue which was purified by silica gel chromatography (EtOAc: n-hexane = 1: 1, v / v) to give 3-amino-6- (6-methoxy -3-Pyridyl) -5-phenyl-2-pyrazinecarbonitrile was obtained as yellow crystals (1.15 g) crystallized from EtOAc. \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.81 (3H, s), 6.73 (1H, d, J = 8.6 Hz), 7.35 (5H, s), 7.51 (2H, s), 7.54 (1H, dd , J = 2.4, 8.6 Hz), 7.99 (1H, d, J = 2.4 Hz) \n MS (ESI \n+\n ): 304 [M + H] \n+\n , 326 [M + Na] \n+\n \n IR (KBr): 3357, 3183, 2238, 1648, 1598, 1544, 1195 cm \n-1\n \n mp: 201-205 ° C (IPE)\n\n\n\n\n\n\n \n \n実施例２\n \n\n  ３−アミノ−６−（６−メトキシ−３−ピリジル）−５−フェニル−２−ピラジンカルボニトリル（５００ｍｇ）をジオキサン（１０ｍｌ）と濃ＨＣｌ（５ｍｌ）に溶解した。溶液を８０℃で５時間攪拌した。反応混合物を２５〜３０℃まで冷却し、真空濃縮して、残留物を得た。残留物に水と１ＮＮａＯＨを加えて、混合物の水溶液のｐＨを６〜７に調整した。沈殿結晶を濾取し、真空乾燥して、３−アミノ−６−（６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド（３９０ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 6.16 (1H, d, J=9.4 Hz), 7.26-7.70 (10H, m), 8.23 (1H, s), 11.66 (1H, s)\n\nMS(ESI\n+\n) : 330[M+Na]\n+\n \n\nMS(ESI\n-\n) : 306[M-H]\n-\n \n\nIR(KBr) : 3309, 1656, 1610, 1544, 1201 cm\n-1\n \n\nm.p. : 215-220℃ (H\n2\nO)\n\n \nExample 2\n \n 3-Amino-6- (6-methoxy-3-pyridyl) -5-phenyl-2-pyrazinecarbonitrile (500 mg) was dissolved in dioxane (10 ml) and concentrated HCl (5 ml). The solution was stirred at 80 ° C. for 5 hours. The reaction mixture was cooled to 25-30 ° C. and concentrated in vacuo to give a residue. Water and 1N NaOH were added to the residue to adjust the pH of the aqueous solution of the mixture to 6-7. Precipitated crystals were collected by filtration and dried in vacuo to give 3-amino-6- (6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxamide (390 mg). \n \n1\n H-NMR (DMSO-d \n6\n δ): 6.16 (1H, d, J = 9.4 Hz), 7.26-7.70 (10H, m), 8.23 (1H, s), 11.66 (1H, s) \n MS (ESI \n+\n ): 330 [M + Na] \n+\n \n \nMS (ESI -): 306 [\n MH] - \n IR (KBr): 3309, 1656, 1610, 1544, 1201 cm \n-1\n \n mp: 215-220 ° C (H \n2\n O)\n\n\n\n\n\n\n \n \n実施例３\n \n\n  ３−アミノ−６−（６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド（６１．４ｍｇ）をＤＭＦ（１ｍｌ）に溶解した。溶液にＤＭＦ中１ＭＭｅＩ溶液（０．２２ｍｌ）とＤＭＦ中０．１Ｍｔ−ＢｕＯＫ溶液（２．２ｍｌ）を加えた。混合物を２０〜３０℃で２時間攪拌した。反応混合物をＥｔＯＡｃと水に分配した。有機層を分離した。水層をＥｔＯＡｃで抽出した。合わせた有機溶液を食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を留去して、油状残留物を得た。上記の残留物をシリカゲルクロマトグラフィー（ＥｔＯＡｃのみ−ＥｔＯＡｃ：ＭｅＯＨ＝９３：７、ｖ／ｖ）で精製して、３−アミノ−６−（１−メチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミドを得て、これをＥｔＯＡｃから結晶化した（２０ｍｇ）。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.45 (3H, s), 6.12 (1H, d, J=9.4 Hz), 6.97 (1H, dd, J=2.4, 9.4 Hz), 7.41-7.62 (8H, m), 8.14 (1H, d, J=2.4 Hz), 8.29 (1H, s)\n\nMS(ESI\n+\n) : 344[M+Na]\n+\n \n\nIR(KBr) : 3353, 1664, 1599, 1531, 1438 cm\n-1\n \n\nm.p. : >250℃ (EtOAc)\n\n \nExample 3\n \n 3-Amino-6- (6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxamide (61.4 mg) was dissolved in DMF (1 ml). To the solution was added 1 M MeI solution in DMF (0.22 ml) and 0.1 Mt-BuOK solution in DMF (2.2 ml). The mixture was stirred at 20-30 ° C. for 2 hours. The reaction mixture was partitioned between EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with brine and dried over MgSO \n4\n . The solvent was distilled off to give an oily residue. The above residue was purified by silica gel chromatography (EtOAc only—EtOAc: MeOH = 93: 7, v / v) to give 3-amino-6- (1-methyl-6-oxo-1,6-dihydro- 3-Pyridyl) -5-phenyl-2-pyrazinecarboxamide was obtained, which was crystallized from EtOAc (20 mg). \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.45 (3H, s), 6.12 (1H, d, J = 9.4 Hz), 6.97 (1H, dd, J = 2.4, 9.4 Hz), 7.41-7.62 (8H , m), 8.14 (1H, d, J = 2.4 Hz), 8.29 (1H, s) \n MS (ESI \n+\n ): 344 [M + Na] \n+\n \n IR (KBr): 3353, 1664, 1599, 1531, 1438 cm \n-1\n \n mp:> 250 ° C (EtOAc)\n\n\n\n\n\n\n \n \n実施例４\n \n\n  ３−アミノ−６−（１−エチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド\n\n  表題の化合物を実施例３と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.12 (3H, t, J=7.0 Hz), 3.84 (2H, q, J=7.0 Hz),6.18 (1H, d, J=9.4 Hz), 7.21 (1H, dd, J=2.4, 9.4 Hz), 7.40-7.72 (8H, m), 7.89 (1H, d, J=2.4 Hz), 8.27 (1H, s)\n\nMS(ESI\n+\n) : 336[M+H]\n+\n, 358[M+Na]\n+\n \n\nIR(KBr) : 3154, 1679, 1597, 1535, 1444 cm\n-1\n \n\nm.p. : >250℃ (EtOAc)\n\n \nExample 4\n \n 3-Amino-6- (1-ethyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxamide The title compound was obtained in the same manner as in Example 3. \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.12 (3H, t, J = 7.0 Hz), 3.84 (2H, q, J = 7.0 Hz), 6.18 (1H, d, J = 9.4 Hz), 7.21 ( 1H, dd, J = 2.4, 9.4 Hz), 7.40-7.72 (8H, m), 7.89 (1H, d, J = 2.4 Hz), 8.27 (1H, s) \n MS (ESI \n+\n ): 336 [M + H] \n+\n , 358 [M + Na] \n+\n \n IR (KBr): 3154, 1679, 1597, 1535, 1444 cm \n-1\n \n mp:> 250 ° C (EtOAc)\n\n\n\n\n\n\n \n \n実施例５\n \n\n  ３−アミノ−６−（６−オキソ−１−プロピル−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド\n\n  表題の化合物を製造例３と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.77 (3H, t, J=7.4 Hz), 1.52 (2H, m), 3.76 (2H, t, J=7.2 Hz), 6.20 (1H, d, J=9.4 Hz), 7.34-7.47 (8H, m), 7.66-7.72 (2H, m), 8.19 (1H, s)\n\nMS(ESI\n+\n) : 350[M+H]\n+\n, 372[M+Na]\n+\n \n\nIR(KBr) : 3421, 1650, 1571, 1515, 1417cm\n-1\n \n\nm.p. : >250℃ (EtOAc)\n\n \nExample 5\n \n 3-Amino-6- (6-oxo-1-propyl-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxamide The title compound was obtained in the same manner as in Production Example 3. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.77 (3H, t, J = 7.4 Hz), 1.52 (2H, m), 3.76 (2H, t, J = 7.2 Hz), 6.20 (1H, d, J = 9.4 Hz), 7.34-7.47 (8H, m), 7.66-7.72 (2H, m), 8.19 (1H, s) \n MS (ESI \n+\n ): 350 [M + H] \n+\n , 372 [M + Na] \n+\n \n IR (KBr): 3421, 1650, 1571, 1515, 1417cm \n-1\n \n mp:> 250 ° C (EtOAc)\n\n\n\n\n\n\n \n \n実施例６\n \n\n  ３−アミノ−６−（６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド（９２．１ｍｇ）をＤＭＦ（１ｍｌ）に溶解した。溶液にＤＭＦ中１Ｍｉ−ＰｒＩ溶液（０．３３ｍｌ）とＤＭＦ中０．１Ｍｔ−ＢｕＯＫ溶液（３．３ｍｌ）を加えた。混合物を２０〜３０℃で２時間攪拌した。反応混合物をＥｔＯＡｃと水に分配した。有機層を分離した。水層をＥｔＯＡｃで抽出した。合わせた有機溶液を食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を留去して油状残留物を得た。上記の残留物をシリカゲルクロマトグラフィー（ＥｔＯＡｃのみ−ＥｔＯＡｃ：ＭｅＯＨ＝９６：４、ｖ／ｖ）で精製して、３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド（１８ｍｇ）と３−アミノ−６−（６−イソプロポキシ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド（４２ｍｇ）を得た。\n\n \nExample 6\n \n 3-Amino-6- (6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxamide (92.1 mg) was dissolved in DMF (1 ml). To the solution was added 1 Mi-PrI solution in DMF (0.33 ml) and 0.1 Mt-BuOK solution in DMF (3.3 ml). The mixture was stirred at 20-30 ° C. for 2 hours. The reaction mixture was partitioned between EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with brine and dried over MgSO \n4\n . The solvent was distilled off to obtain an oily residue. The residue was purified by silica gel chromatography (EtOAc only—EtOAc: MeOH = 96: 4, v / v) to give 3-amino-6- (1-isopropyl-6-oxo-1,6-dihydro- 3-Pyridyl) -5-phenyl-2-pyrazinecarboxamide (18 mg) and 3-amino-6- (6-isopropoxy-3-pyridyl) -5-phenyl-2-pyrazinecarboxamide (42 mg) were obtained.\n\n\n\n\n\n\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.97 (6H, d, J=6.8 Hz), 4.90 (1H, m), 6.20 (1H, d, J=9.4 Hz), 7.34-7.47 (8H, m), 7.66-7.72 (2H, m), 8.19 (1H, s)\n\nMS(ESI\n+\n) : 350 [M+H]\n+\n, 372 [M+Na]\n+\n \n\nIR(KBr) : 3417, 1664, 1591, 1533, 1450 cm\n-1\n \n\nm.p. : 240-245℃ (EtOAc)\n\n  ３−アミノ−６−（６−イソプロポキシ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.26 (6H, d, J=6.8 Hz), 5.20 (1H, m), 6.60 (1H, d, J=8.6 Hz), 7.42 (5H, s), 7.60-7.67 (3H, m), 8.17 (2H, s)\n\nMS(ESI\n+\n) : 350 [M+H]\n+\n, 372 [M+Na]\n+\n \n\nIR(KBr) : 3471, 1683, 1656, 1600, 1488 cm\n-1\n\n\n3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.97 (6H, d, J = 6.8 Hz), 4.90 (1H, m), 6.20 (1H, d, J = 9.4 Hz), 7.34-7.47 (8H, m ), 7.66-7.72 (2H, m), 8.19 (1H, s) \n MS (ESI \n+\n ): 350 [M + H] \n+\n , 372 [M + Na] \n+\n \n IR (KBr): 3417, 1664, 1591, 1533, 1450 cm \n-1\n \n mp: 240-245 ° C (EtOAc) \n 3-Amino-6- (6-isopropoxy-3-pyridyl) -5-phenyl-2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.26 (6H, d, J = 6.8 Hz), 5.20 (1H, m), 6.60 (1H, d, J = 8.6 Hz), 7.42 (5H, s), 7.60-7.67 (3H, m), 8.17 (2H, s) \n MS (ESI \n+\n ): 350 [M + H] \n+\n , 372 [M + Na] \n+\n \n IR (KBr): 3471, 1683, 1656, 1600, 1488 cm \n-1\n \n\n\n\n\n\n\n \n \n実施例７\n \n\n  ３−アミノ−６−（６−メトキシ−３−ピリジル）−５−フェニル−２−ピラジンカルボニトリル（８００ｍｇ）をジオキサンと濃ＨＣｌに溶解した。溶液を８０℃で１５時間攪拌した。ジオキサンを留去した。反応混合物を室温まで冷却し、真空濃縮して、残留物を得た。残留物に１ＮＮａＯＨを加えて、混合物の水溶液のｐＨを６〜７に調整した。結晶を濾取し、真空乾燥して、３−アミノ−６−（６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボン酸を粉末（６００ｍｇ）として得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 6.18 (1H, d, J=9.4 Hz), 7.25-7.65 (9H, m), 11.8 (2H, brs)\n\nMS(ESI\n-\n) : 307[M-H]\n-\n\n\n \nExample 7\n \n 3-Amino-6- (6-methoxy-3-pyridyl) -5-phenyl-2-pyrazinecarbonitrile (800 mg) was dissolved in dioxane and concentrated HCl. The solution was stirred at 80 ° C. for 15 hours. Dioxane was distilled off. The reaction mixture was cooled to room temperature and concentrated in vacuo to give a residue. 1N NaOH was added to the residue to adjust the pH of the aqueous solution of the mixture to 6-7. The crystals were collected by filtration and dried in vacuo to give 3-amino-6- (6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxylic acid as a powder (600 mg). . \n \n1\n H-NMR (DMSO-d \n6\n δ): 6.18 (1H, d, J = 9.4 Hz), 7.25-7.65 (9H, m), 11.8 (2H, brs) \n \nMS (ESI -): 307 [\n MH] -\n\n\n\n\n\n\n \n \n実施例８\n \n\n  ３−アミノ−６−（６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボン酸（１５４ｍｇ）をＤＭＦ（５ｍｌ）に溶解した。溶液にＥｔＩ（８６．１ｍｇ）とｔ−ＢｕＯＫ（６１．９ｍｇ）を加えた。混合物を２０〜３０℃で２時間攪拌した。反応混合物をＥｔＯＡｃと水に分配した。有機層を分離した。水層をＥｔＯＡｃで抽出した。合わせた有機溶液を食塩水で洗浄し、ＭｇＳＯ\n４\nで燥乾した。溶媒を留去して、油状残留物を得た。上記の残留物をシリカゲルクロマトグラフィー（ＥｔＯＡｃのみ−ＥｔＯＡｃ：ＭｅＯＨ＝９５：５、ｖ／ｖ）で精製して、３−アミノ−６−（６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボン酸エチル（８４ｍｇ）と３−アミノ−６−（１−エチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボン酸エチル（２８ｍｇ）を得た。\n\n \nExample 8\n \n 3-Amino-6- (6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxylic acid (154 mg) was dissolved in DMF (5 ml). EtI (86.1 mg) and t-BuOK (61.9 mg) were added to the solution. The mixture was stirred at 20-30 ° C. for 2 hours. The reaction mixture was partitioned between EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with brine and dried over MgSO \n4\n . The solvent was distilled off to give an oily residue. The above residue was purified by silica gel chromatography (EtOAc only—EtOAc: MeOH = 95: 5, v / v) to give 3-amino-6- (6-oxo-1,6-dihydro-3-pyridyl) Ethyl-5-phenyl-2-pyrazinecarboxylate (84 mg) and 3-amino-6- (1-ethyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxylic acid Ethyl (28 mg) was obtained.\n\n\n\n\n\n\n \n\n  ３−アミノ−６−（６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボン酸エチル\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.34 (3H, t, J=7.0 Hz), 4.37 (2H, q, J=7.0 Hz), 6.23 (1H, d, J=9.4 Hz), 7.19 (1H, d, J=2.4 Hz), 7.25 (1H, dd, J=2.4, 9.4 Hz), 7.40-7.52 (5H, m)\n\nMS(ESI\n+\n) : 359[M+Na]\n+\n \n\nIR(KBr) : 3400, 1697, 1614, 1434, 1130 cm\n-1\n \n\nm.p. : 230-238℃ (EtOAc)\n\n  ３−アミノ−６−（１−エチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボン酸エチル\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.00 (3H, t, J=7.0 Hz), 1.34 (3H, t, J=7.0 Hz), 3.76 (2H, q, J=7.0 Hz), 4.37 (2H, q, J=7.0 Hz), 6.32 (1H, d, J=9.4 Hz), 7.32 (1H, dd, J=2.6, 9.4 Hz), 7.36-7.5 (8H, m)\n\nMS(ESI\n+\n) : 365[M+H]\n+\n, 387[M+Na]\n+\n \n\nIR(KBr) : 3400, 1662, 1600, 1440, 1122 cm\n-1\n \n\nm.p. : 175-179℃ (EtOAc)\n\nEthyl 3-amino-6- (6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxylate \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.34 (3H, t, J = 7.0 Hz), 4.37 (2H, q, J = 7.0 Hz), 6.23 (1H, d, J = 9.4 Hz), 7.19 ( 1H, d, J = 2.4 Hz), 7.25 (1H, dd, J = 2.4, 9.4 Hz), 7.40-7.52 (5H, m) \n MS (ESI \n+\n ): 359 [M + Na] \n+\n \n IR (KBr): 3400, 1697, 1614, 1434, 1130 cm \n-1\n \n mp: 230-238 ° C (EtOAc) \n Ethyl 3-amino-6- (1-ethyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxylate \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.00 (3H, t, J = 7.0 Hz), 1.34 (3H, t, J = 7.0 Hz), 3.76 (2H, q, J = 7.0 Hz), 4.37 ( 2H, q, J = 7.0 Hz), 6.32 (1H, d, J = 9.4 Hz), 7.32 (1H, dd, J = 2.6, 9.4 Hz), 7.36-7.5 (8H, m) \n MS (ESI \n+\n ): 365 [M + H] \n+\n , 387 [M + Na] \n+\n \n IR (KBr): 3400, 1662, 1600, 1440, 1122 cm \n-1\n \n mp: 175-179 ° C (EtOAc)\n\n\n\n\n\n\n \n \n実施例９\n \n\n  ３−アミノ−６−（６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボン酸（２８３ｍｇ）をＤＭＦ（１０ｍｌ）に溶解した。溶液にｉ−ＰｒＩ（１７２ｍｇ）とｔ−ＢｕＯＫ（１１４ｍｇ）を加えた。混合物を２０〜３０℃で２時間攪拌した。反応混合物をＥｔＯＡｃと水に分配した。有機層を分離した。水層をＥｔＯＡｃで抽出した。合わせた有機溶液を食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を留去して、油状残留物を得た。上記の残留物をシリカゲルクロマトグラフィー（ＥｔＯＡｃのみ−ＥｔＯＡｃ：ＭｅＯＨ＝９６：４、ｖ／ｖ）で精製して、３−アミノ−６−（６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボン酸イソプロピルを黄色結晶（６４ｍｇ）として得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.35 (6H, d, J=6.2 Hz), 5.20 (1H, m), 6.23 (1H, d, J=9.4Hz), 7.19 (1H, d, J=2.2 Hz), 7.22 (1H, dd, J=2.2, 9.4 Hz), 7.40 (5H, m), 11.6 (1H, s)\n\nMS(ESI\n+\n) : 351[M+H]\n+\n, 373[M+Na]\n+\n \n\nIR(KBr) : 3425, 1666, 1612, 1434, 1101 cm\n-1\n \n\nm.p. : 250-256℃ (EtOAc)\n\n \nExample 9\n \n 3-Amino-6- (6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxylic acid (283 mg) was dissolved in DMF (10 ml). I-PrI (172 mg) and t-BuOK (114 mg) were added to the solution. The mixture was stirred at 20-30 ° C. for 2 hours. The reaction mixture was partitioned between EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with brine and dried over MgSO \n4\n . The solvent was distilled off to give an oily residue. The above residue was purified by silica gel chromatography (EtOAc only—EtOAc: MeOH = 96: 4, v / v) to give 3-amino-6- (6-oxo-1,6-dihydro-3-pyridyl) Isopropyl-5-phenyl-2-pyrazinecarboxylate was obtained as yellow crystals (64 mg). \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.35 (6H, d, J = 6.2 Hz), 5.20 (1H, m), 6.23 (1H, d, J = 9.4 Hz), 7.19 (1H, d, J = 2.2 Hz), 7.22 (1H, dd, J = 2.2, 9.4 Hz), 7.40 (5H, m), 11.6 (1H, s) \n MS (ESI \n+\n ): 351 [M + H] \n+\n , 373 [M + Na] \n+\n \n IR (KBr): 3425, 1666, 1612, 1434, 1101 cm \n-1\n \n mp: 250-256 ° C (EtOAc)\n\n\n\n\n\n\n \n \n実施例１０\n \n\n  ３−アミノ−６−（６−メトキシ−３−ピリジル）−５−フェニル−２−ピラジンカルボニトリル（３７０ｍｇ）を１，２−ジクロロエタン（３７ｍｌ）に溶解した。溶液にＣＨ\n２\nＣｌ\n２\n中１Ｍ三臭化ホウ素溶液（１２．２ｍｌ）を加えた。混合物を８０℃で２４時間攪拌した。混合物を２０〜２５℃まで冷却し、ＥｔＯＡｃと水に分配した。有機層を分離した。水層をＥｔＯＡｃで抽出した。合わせた有機層を食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を真空留去して、赤色固形残留物を得た。残留物を水で粉末化して、３−アミノ−６−（６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボニトリルを粉末（２５４ｍｇ）として得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 6.21 (1H, d, J=9.4 Hz), 7.20-7.98 (7H, m), 11.6 (1H, s)\n\nMS(ESI\n+\n) : 312[M+Na]\n+\n \n\nIR(KBr) : 3326, 2221, 1656, 1610, 1544, 1201 cm\n-1\n \n\nm.p. : 243-248℃ (H\n2\nO)\n\n \nExample 10\n \n 3-Amino-6- (6-methoxy-3-pyridyl) -5-phenyl-2-pyrazinecarbonitrile (370 mg) was dissolved in 1,2-dichloroethane (37 ml). To the solution was added 1M boron tribromide solution in CH \n2\n Cl \n2\n (12.2 ml). The mixture was stirred at 80 ° C. for 24 hours. The mixture was cooled to 20-25 ° C. and partitioned between EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine and dried over MgSO \n4\n . The solvent was removed in vacuo to give a red solid residue. The residue was triturated with water to give 3-amino-6- (6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarbonitrile as a powder (254 mg). \n \n1\n H-NMR (DMSO-d \n6\n δ): 6.21 (1H, d, J = 9.4 Hz), 7.20-7.98 (7H, m), 11.6 (1H, s) \n MS (ESI \n+\n ): 312 [M + Na] \n+\n \n IR (KBr): 3326, 2221, 1656, 1610, 1544, 1201 cm \n-1\n \n mp: 243-248 ° C (H \n2\n O)\n\n\n\n\n\n\n \n \n実施例１１\n \n\n  ３−アミノ−６−（６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボニトリル（５８ｍｇ）をＤＭＦ（１ｍｌ）に溶解した。溶液にＤＭＦ中１ＭＭｅＩ溶液（０．２２ｍｌ）とＤＭＦ中０．１Ｍｔ−ＢｕＯＫ溶液（２．２ｍｌ）を加えた。混合物を２０〜３０℃で２時間攪拌した。反応混合物をＥｔＯＡｃと水に分配した。有機層を分離した。水層をＥｔＯＡｃで抽出した。合わせた有機溶液を食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を留去して、油状残留物を得た。上記の残留物をシリカゲルクロマトグラフィー（ＥｔＯＡｃのみ−ＥｔＯＡｃ：ＭｅＯＨ＝９３：７、ｖ／ｖ）で精製して、３−アミノ−６−（１−メチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボニトリルを得て、これをＥｔＯＡｃから結晶化した（１８ｍｇ）。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.40 (3H, s), 6.17 (1H, d, J=9.4 Hz), 6.97 (1H, dd, J=2.6, 9.4 Hz), 7.40-7.50 (7H, m), 7.81 (1H, d, J=2.6 Hz)\n\nMS(ESI\n+\n) : 304[M+H]\n+\n, 326[M+Na]\n+\n \n\nIR(KBr) : 3386, 2221, 1670, 1590, 1542, 1205 cm\n-1\n \n\nm.p. : >250℃ (EtOAc)\n\n \nExample 11\n \n 3-Amino-6- (6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarbonitrile (58 mg) was dissolved in DMF (1 ml). To the solution was added 1 M MeI solution in DMF (0.22 ml) and 0.1 Mt-BuOK solution in DMF (2.2 ml). The mixture was stirred at 20-30 ° C. for 2 hours. The reaction mixture was partitioned between EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with brine and dried over MgSO \n4\n . The solvent was distilled off to give an oily residue. The above residue was purified by silica gel chromatography (EtOAc only—EtOAc: MeOH = 93: 7, v / v) to give 3-amino-6- (1-methyl-6-oxo-1,6-dihydro- 3-Pyridyl) -5-phenyl-2-pyrazinecarbonitrile was obtained, which was crystallized from EtOAc (18 mg). \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.40 (3H, s), 6.17 (1H, d, J = 9.4 Hz), 6.97 (1H, dd, J = 2.6, 9.4 Hz), 7.40-7.50 (7H , m), 7.81 (1H, d, J = 2.6 Hz) \n MS (ESI \n+\n ): 304 [M + H] \n+\n , 326 [M + Na] \n+\n \n IR (KBr): 3386, 2221, 1670, 1590, 1542, 1205 cm \n-1\n \n mp:> 250 ° C (EtOAc)\n\n\n\n\n\n\n \n \n実施例１２\n \n\n  ３−アミノ−６−（１−エチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボニトリル\n\n  表題の化合物を実施例１１と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.03 (3H, t, J=7.0 Hz), 3.79 (2H, q, J=7.0 Hz), 6.25 (1H, d, J=9.4 Hz), 7.19 (1H, dd, J=2.6, 9.4 Hz), 7.44-7.47 (7H, m), 7.58 (1H, d, J=2.6 Hz)\n\nMS(ESI\n+\n) : 318[M+H]\n+\n, 340[M+Na]\n+\n \n\nIR(KBr) : 3180, 2221, 1657, 1587, 1535, 1203 cm\n-1\n \n\nm.p. : 193-199℃ (IPE)\n\n \nExample 12\n \n 3-Amino-6- (1-ethyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarbonitrile The title compound was obtained in a similar manner as Example 11. . \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.03 (3H, t, J = 7.0 Hz), 3.79 (2H, q, J = 7.0 Hz), 6.25 (1H, d, J = 9.4 Hz), 7.19 ( 1H, dd, J = 2.6, 9.4 Hz), 7.44-7.47 (7H, m), 7.58 (1H, d, J = 2.6 Hz) \n MS (ESI \n+\n ): 318 [M + H] \n+\n , 340 [M + Na] \n+\n \n IR (KBr): 3180, 2221, 1657, 1587, 1535, 1203 cm \n-1\n \n mp: 193-199 ° C (IPE)\n\n\n\n\n\n\n \n \n実施例１３\n \n\n  ３−アミノ−６−（６−オキソ−１−プロピル−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボニトリル（１７ｍｇ）\n\n  表題の化合物を実施例１１と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.71 (3H, t, J=7.4 Hz), 1.44 (2H, m), 3.73 (2H, t, J=7.2 Hz), 6.26 (1H, d, J=9.4 Hz), 7.20 (1H, dd, J=2.6, 9.4 Hz), 7.38-7.47 (7H, m), 7.54 (1H, d, J=2.6 Hz)\n\nMS(ESI\n+\n) : 332[M+H]\n+\n, 354[M+Na]\n+\n \n\nIR(KBr) : 3311, 2220, 1658, 1536, 1463, 1201 cm\n-1\n \n\nm.p. : 180-183℃ (IPE)\n\n \nExample 13\n \n 3-Amino-6- (6-oxo-1-propyl-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarbonitrile (17 mg) \n The title compound was obtained according to the same method as in Example 11. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.71 (3H, t, J = 7.4 Hz), 1.44 (2H, m), 3.73 (2H, t, J = 7.2 Hz), 6.26 (1H, d, J = 9.4 Hz), 7.20 (1H, dd, J = 2.6, 9.4 Hz), 7.38-7.47 (7H, m), 7.54 (1H, d, J = 2.6 Hz) \n MS (ESI \n+\n ): 332 [M + H] \n+\n , 354 [M + Na] \n+\n \n IR (KBr): 3311, 2220, 1658, 1536, 1463, 1201 cm \n-1\n \n mp: 180-183 ℃ (IPE)\n\n\n\n\n\n\n \n \n実施例１４\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボニトリル\n\n  表題の化合物を実施例１１と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.94 (6H, d, J=6.8 Hz), 4.85-4.92 (1H, m), 6.35 (1H, d, J=9.4 Hz), 7.28 (1H, d, J=2.4 Hz), 7.38-7.49 (8H, m)\n\nMS(ESI\n+\n) : 332[M+H]\n+\n, 354[M+Na]\n+\n \n\nIR(KBr) : 3426, 2225, 1664, 1621, 15521, 1106 cm\n-1\n \n\nm.p. : 204.5℃ (95%２−プロパノール水溶液)\n\n \nExample 14\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarbonitrile The title compound was obtained in a similar manner as Example 11. . \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.94 (6H, d, J = 6.8 Hz), 4.85-4.92 (1H, m), 6.35 (1H, d, J = 9.4 Hz), 7.28 (1H, d , J = 2.4 Hz), 7.38-7.49 (8H, m) \n MS (ESI \n+\n ): 332 [M + H] \n+\n , 354 [M + Na] \n+\n \n IR (KBr): 3426, 2225, 1664, 1621, 15521, 1106 cm \n-1\n \n mp: 204.5 ° C (95% 2-propanol aqueous solution)\n\n\n\n\n\n\n \n \n実施例１５\n \n\n  ３−アミノ−６−（６−メトキシ−３−ピリジル）−５−フェニル−２−ピラジンカルボニトリル（１００ｍｇ）をＡｃＯＨ中３０％臭化水素溶液（１ｍｌ）に溶解した。溶液を２５〜３０℃で３時間攪拌した。溶液に水を加えた。混合物の水溶液のｐＨを１２％ＮａＯＨ水溶液で６〜７に調整した。結晶を沈殿させた。懸濁液を２５〜３０℃で３時間攪拌し、冷蔵庫に１０時間放置した。結晶を濾取し、真空乾燥して、３−アミノ−６−（６−メトキシ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド（９２．５ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.82 (3H, s), 6.69 (1H, d, J=6.6 Hz), 7.39 (5H, s), 7.64-7.70 (3H, m), 8.17 (2H, s)\n\nMS(ESI\n+\n) : 322[M+H]\n+\n, 344[M+Na]\n+\n \n\nIR(KBr) : 3411, 3276, 1689, 1598,1496,1286 cm\n-1\n \n\nm.p. : 208-212℃ (H\n2\nO)\n\n  下記の２４個の化合物を実施例１と同様の方法にしたがって得た。\n\n \nExample 15\n \n 3-Amino-6- (6-methoxy-3-pyridyl) -5-phenyl-2-pyrazinecarbonitrile (100 mg) was dissolved in 30% hydrogen bromide solution in AcOH (1 ml). The solution was stirred at 25-30 ° C. for 3 hours. Water was added to the solution. The pH of the aqueous solution of the mixture was adjusted to 6-7 with 12% NaOH aqueous solution. Crystals precipitated. The suspension was stirred at 25-30 ° C. for 3 hours and left in the refrigerator for 10 hours. The crystals were collected by filtration and dried in vacuo to give 3-amino-6- (6-methoxy-3-pyridyl) -5-phenyl-2-pyrazinecarboxamide (92.5 mg). \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.82 (3H, s), 6.69 (1H, d, J = 6.6 Hz), 7.39 (5H, s), 7.64-7.70 (3H, m), 8.17 (2H , s) \n MS (ESI \n+\n ): 322 [M + H] \n+\n , 344 [M + Na] \n+\n \n IR (KBr): 3411, 3276, 1689, 1598,1496,1286 cm \n-1\n \n mp: 208-212 ° C (H \n2\n O) \n The following 24 compounds were obtained in the same manner as in Example 1.\n\n\n\n\n\n\n \n \n実施例１６\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.97 (6H, d, J=6.8 Hz), 4.90 (1H, m), 6.32 (1H, d, J=9.4 Hz), 7.34-7.46 (6H, m), 7.66-7.72 (4H, m), 8.19 (1H, s)\n\nMS(ESI\n+\n) : 350[M+H]\n+\n, 372[M+Na]\n+\n \n\nIR(KBr) : 3417, 1664, 1590, 1533, 1450 cm\n-1\n \n\nmp : 245℃ (IPA-H\n2\nO)\n\n \nExample 16\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.97 (6H, d, J = 6.8 Hz), 4.90 (1H, m), 6.32 (1H, d, J = 9.4 Hz), 7.34-7.46 (6H, m ), 7.66-7.72 (4H, m), 8.19 (1H, s) \n MS (ESI \n+\n ): 350 [M + H] \n+\n , 372 [M + Na] \n+\n \n IR (KBr): 3417, 1664, 1590, 1533, 1450 cm \n-1\n \n mp: 245 ° C (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例１７\n \n\n  ３−アミノ−５−（２−フルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.93 (6H, d, J=6.8 Hz), 4.89 (1H, m), 6.35 (1H, d, J=9.4 Hz), 7.22-7.81 (9H, m), 8.22 (1H, s)\n\nMS(ESI\n+\n) : 368[M+H]\n+\n, 390[M+Na]\n+\n \n\nIR(KBr) : 3367, 1664, 1600, 1446, 1205 cm\n-1\n \n\nmp : 251.7℃ (IPA-H\n2\nO)\n\n \nExample 17\n \n 3-Amino-5- (2-fluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.93 (6H, d, J = 6.8 Hz), 4.89 (1H, m), 6.35 (1H, d, J = 9.4 Hz), 7.22-7.81 (9H, m ), 8.22 (1H, s) \n MS (ESI \n+\n ): 368 [M + H] \n+\n , 390 [M + Na] \n+\n \n IR (KBr): 3367, 1664, 1600, 1446, 1205 cm \n-1\n \n mp: 251.7 ℃ (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例１８\n \n\n  ３−アミノ−５−（３−フルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.01 (6H, d, J=6.8 Hz), 4.93 (1H, m), 6.35 (1H, d, J=9.4 Hz), 7.21-7.71 (9H, m), 8.22 (1H, s)\n\nMS(ESI\n+\n) : 368[M+H]\n+\n, 390[M+Na]\n+\n \n\nIR(KBr) : 3394, 1658, 1590, 1533, 1452 cm\n-1\n \n\nmp : 258.8℃ (IPA-H\n2\nO)\n\n \nExample 18\n \n 3-Amino-5- (3-fluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.01 (6H, d, J = 6.8 Hz), 4.93 (1H, m), 6.35 (1H, d, J = 9.4 Hz), 7.21-7.71 (9H, m ), 8.22 (1H, s) \n MS (ESI \n+\n ): 368 [M + H] \n+\n , 390 [M + Na] \n+\n \n IR (KBr): 3394, 1658, 1590, 1533, 1452 cm \n-1\n \n mp: 258.8 ℃ (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例１９\n \n\n  ３−アミノ−５−（４−フルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.97 (6H, d, J=6.8 Hz), 4.90 (1H, m), 6.32 (1H, d, J=9.4 Hz), 7.34-7.46 (6H, m), 7.66-7.72 (3H, m), 8.19 (1H, s)\n\nMS(ESI\n+\n) : 390[M+Na]\n+\n \n\nIR(KBr) : 3293, 1660, 1583, 1450, 1153 cm\n-1\n \n\nmp : 235.6℃ (IPA-H\n2\nO)\n\n \nExample 19\n \n 3-Amino-5- (4-fluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.97 (6H, d, J = 6.8 Hz), 4.90 (1H, m), 6.32 (1H, d, J = 9.4 Hz), 7.34-7.46 (6H, m ), 7.66-7.72 (3H, m), 8.19 (1H, s) \n MS (ESI \n+\n ): 390 [M + Na] \n+\n \n IR (KBr): 3293, 1660, 1583, 1450, 1153 cm \n-1\n \n mp: 235.6 ° C (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例２０\n \n\n  ３−アミノ−５−（２−クロロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.90 (6H, m), 4.87 (1H, m), 6.34 (1H, d, J=9.4 Hz),7.16 (1H, d, J=2.4 Hz), 7.48-7.68 (6H, m), 7.73 (1H, s), 7.82 (1H, dd, J=2.4, 9.4 Hz), 8.24 (1H, s)\n\nMS(ESI\n+\n) : 384[M+H]\n+\n, 406[M+Na]\n+\n \n\nIR(KBr) : 3367, 1666, 1604, 1454, 1157 cm\n-1\n \n\nmp: 254.5℃ (IPA-H\n2\nO) \n\n \nExample 20\n \n 3-Amino-5- (2-chlorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.90 (6H, m), 4.87 (1H, m), 6.34 (1H, d, J = 9.4 Hz), 7.16 (1H, d, J = 2.4 Hz), 7.48-7.68 (6H, m), 7.73 (1H, s), 7.82 (1H, dd, J = 2.4, 9.4 Hz), 8.24 (1H, s) \n MS (ESI \n+\n ): 384 [M + H] \n+\n , 406 [M + Na] \n+\n \n IR (KBr): 3367, 1666, 1604, 1454, 1157 cm \n-1\n \n mp: 254.5 ℃ (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例２１\n \n\n  ３−アミノ−５−（３−クロロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.01 (6H, d, J=6.8 Hz), 4.93 (1H, m), 6.35 (1H, d, J=9.4 Hz), 7.35-7.46 (5H, m), 7.49 (2H, s), 7.57-7.72 (3H, m), 8.21 (1H,s)\n\nMS(ESI\n+\n) : 384[M+H]\n+\n, 406[M+Na]\n+\n \n\nIR(KBr) : 3396, 1658, 1589, 1452, 1250 cm\n-1\n \n\nmp: 232.6℃ (IPA-H\n2\nO)\n\n \nExample 21\n \n 3-Amino-5- (3-chlorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.01 (6H, d, J = 6.8 Hz), 4.93 (1H, m), 6.35 (1H, d, J = 9.4 Hz), 7.35-7.46 (5H, m ), 7.49 (2H, s), 7.57-7.72 (3H, m), 8.21 (1H, s) \n MS (ESI \n+\n ): 384 [M + H] \n+\n , 406 [M + Na] \n+\n \n IR (KBr): 3396, 1658, 1589, 1452, 1250 cm \n-1\n \n mp: 232.6 ° C (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例２２\n \n\n  ３−アミノ−５−（４−クロロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.02 (6H, d, J=6.8 Hz), 4.94 (1H, m), 6.34 (1H, d, J=9.4 Hz), 7.40 (1H, d, J=2.4Hz), 7.49 (6H, s), 7.6 5(1H, dd, J=2.4, 9.4 Hz), 7.70 (1H, s), 8.21 (1H, s)\n\nMS(ESI\n+\n) : 406[M+Na]\n+\n \n\nIR(KBr) : 3278, 1664, 1587, 1450, 1093 cm\n-1\n \n\nmp: 246.2℃ (IPA-H\n2\nO)\n\n \nExample 22\n \n 3-Amino-5- (4-chlorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.02 (6H, d, J = 6.8 Hz), 4.94 (1H, m), 6.34 (1H, d, J = 9.4 Hz), 7.40 (1H, d, J = 2.4Hz), 7.49 (6H, s), 7.6 5 (1H, dd, J = 2.4, 9.4 Hz), 7.70 (1H, s), 8.21 (1H, s) \n MS (ESI \n+\n ): 406 [M + Na] \n+\n \n IR (KBr): 3278, 1664, 1587, 1450, 1093 cm \n-1\n \n mp: 246.2 ℃ (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例２３\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（２−メトキシフェニル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.89-1.05 (6H, m), 3.48 (3H, s), 4.88 (1H, m), 6.32 (1H, d, J=9.4 Hz), 6.99-7.13 (2H, m), 7.22 (1H, d, J=2.4 Hz), 7.37-7.65 (2H, m), 7.59 (2H, brs), 7.66 (1H, s), 7.75 (1H, dd, J=2.4, 9.4 Hz), 8.16 (1H, s)\n\nMS(ESI\n+\n) : 380[M+H]\n+\n, 402[M+Na]\n+\n \n\nIR(KBr) : 3259, 1662, 1596, 1452, 1259 cm\n-1\n \n\nmp : 263.1℃ (IPA-H\n2\nO)\n\n \nExample 23\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (2-methoxyphenyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.89-1.05 (6H, m), 3.48 (3H, s), 4.88 (1H, m), 6.32 (1H, d, J = 9.4 Hz), 6.99-7.13 (2H, m), 7.22 (1H, d, J = 2.4 Hz), 7.37-7.65 (2H, m), 7.59 (2H, brs), 7.66 (1H, s), 7.75 (1H, dd, J = 2.4 , 9.4 Hz), 8.16 (1H, s) \n MS (ESI \n+\n ): 380 [M + H] \n+\n , 402 [M + Na] \n+\n \n IR (KBr): 3259, 1662, 1596, 1452, 1259 cm \n-1\n \n mp: 263.1 ℃ (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例２４\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（３−メトキシフェニル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.01 (6H, d, J=6.8 Hz), 3.71 (3H, s), 4.90 (1H, m), 6.33 (1H, d, J=9.4 Hz), 6.94-7.02 (3H, m), 7.30-7.39 (2H, m), 7.65-7.71 (3H, m), 8.19 (1H, s)\n\nMS(ESI\n+\n) : 380[M+H]\n+\n, 402[M+Na]\n+\n \n\nIR(KBr) : 3442, 1660, 1581, 1444, 1268 cm\n-1\n \n\nIR(KBr) : 3442, 1660, 1581, 1444, 1268 cm-1\n\nmp : 192.3℃ (IPA-H\n2\nO)\n\n \nExample 24\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (3-methoxyphenyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.01 (6H, d, J = 6.8 Hz), 3.71 (3H, s), 4.90 (1H, m), 6.33 (1H, d, J = 9.4 Hz), 6.94-7.02 (3H, m), 7.30-7.39 (2H, m), 7.65-7.71 (3H, m), 8.19 (1H, s) \n MS (ESI \n+\n ): 380 [M + H] \n+\n , 402 [M + Na] \n+\n \n IR (KBr): 3442, 1660, 1581, 1444, 1268 cm \n-1\n \n IR (KBr): 3442, 1660, 1581, 1444, 1268 cm-1 \n mp: 192.3 ℃ (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例２５\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（４−メトキシフェニル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.05 (6H, d, J=6.8 Hz), 3.77 (3H, s), 4.94 (1H, m), 6.32 (1H, d, J=9.4 Hz), 6.97 (2H, d, J=8.8 Hz), 7.42 (2H, d, J=8.8 Hz), 7.45-7.64 (5H, m), 8.15 (1H, s)\n\nMS(ESI\n+\n) : 380[M+H]\n+\n, 402[M+Na]\n+\n \n\nIR(KBr) : 3266, 1664, 1600, 1448, 1255 cm\n-1\n \n\nmp : 243.9℃ (IPA-H\n2\nO)\n\n \nExample 25\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (4-methoxyphenyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.05 (6H, d, J = 6.8 Hz), 3.77 (3H, s), 4.94 (1H, m), 6.32 (1H, d, J = 9.4 Hz), 6.97 (2H, d, J = 8.8 Hz), 7.42 (2H, d, J = 8.8 Hz), 7.45-7.64 (5H, m), 8.15 (1H, s) \n MS (ESI \n+\n ): 380 [M + H] \n+\n , 402 [M + Na] \n+\n \n IR (KBr): 3266, 1664, 1600, 1448, 1255 cm \n-1\n \n mp: 243.9 ° C (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例２６\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−［２−（トリフルオロメトキシ）フェニル］−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.90 (6H, m), 4.88 (1H, m), 6.34 (1H, d, J=9.4 Hz),7.20 (1H, d, J=2.4 Hz), 7.34-7.39 (1H, m), 7.54-7.78 (7H, m), 8.24 (1H, s)\n\nMS(ESI\n+\n) : 434[M+H]\n+\n, 456[M+Na]\n+\n \n\nIR(KBr) : 3386, 1662, 1596, 1257, 1162 cm\n-1\n \n\nmp : 206.5℃ (IPA-H\n2\nO)\n\n \nExample 26\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- [2- (trifluoromethoxy) phenyl] -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.90 (6H, m), 4.88 (1H, m), 6.34 (1H, d, J = 9.4 Hz), 7.20 (1H, d, J = 2.4 Hz), 7.34-7.39 (1H, m), 7.54-7.78 (7H, m), 8.24 (1H, s) \n MS (ESI \n+\n ): 434 [M + H] \n+\n , 456 [M + Na] \n+\n \n IR (KBr): 3386, 1662, 1596, 1257, 1162 cm \n-1\n \n mp: 206.5 ° C (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例２７\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−［３−（トリフルオロメトキシ）フェニル］−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.98 (6H, d, J=6.8 Hz), 4.88 (1H, m), 6.35 (1H, d, J=9.4 Hz), 7.37-7.81 (9H, m), 8.22 (1H,s)\n\nMS(ESI\n+\n) : 434[M+H]\n+\n, 456[M+Na]\n+\n \n\nIR(KBr) : 3403, 1660, 1592, 1452, 1263 cm\n-1\n \n\nmp : 265.5℃ (IPA-H\n2\nO)\n\n \nExample 27\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- [3- (trifluoromethoxy) phenyl] -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.98 (6H, d, J = 6.8 Hz), 4.88 (1H, m), 6.35 (1H, d, J = 9.4 Hz), 7.37-7.81 (9H, m ), 8.22 (1H, s) \n MS (ESI \n+\n ): 434 [M + H] \n+\n , 456 [M + Na] \n+\n \n IR (KBr): 3403, 1660, 1592, 1452, 1263 cm \n-1\n \n mp: 265.5 ° C (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例２８\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−［４−（トリフルオロメトキシ）フェニル］−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.98 (6H, d, J=6.8 Hz), 4.91 (1H, m), 6.37 (1H, d, J=9.4 Hz),7.30 (1H, d, J=2.4Hz), 7.42 (2H, d, J=8.2Hz), 7.58 (2H, d, J=8.2Hz), 7.70 (3H, m), 7.78 (1H, dd, J=2.4, 9.4Hz), 8.21 (1H,s)\n\nMS(ESI\n+\n) : 434[M+H]\n+\n, 456[M+Na]\n+\n \n\nIR(KBr) : 3403, 1660, 1592, 1452, 1263 cm\n-1\n \n\nmp : 264.0℃ (IPA-H\n2\nO)\n\n \nExample 28\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- [4- (trifluoromethoxy) phenyl] -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.98 (6H, d, J = 6.8 Hz), 4.91 (1H, m), 6.37 (1H, d, J = 9.4 Hz), 7.30 (1H, d, J = 2.4Hz), 7.42 (2H, d, J = 8.2Hz), 7.58 (2H, d, J = 8.2Hz), 7.70 (3H, m), 7.78 (1H, dd, J = 2.4, 9.4Hz), 8.21 (1H, s) \n MS (ESI \n+\n ): 434 [M + H] \n+\n , 456 [M + Na] \n+\n \n IR (KBr): 3403, 1660, 1592, 1452, 1263 cm \n-1\n \n mp: 264.0 ℃ (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例２９\n \n\n  ３−アミノ−５−（３，４−ジフルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.05 (6H, d, J=6.8 Hz), 4.96 (1H, m), 6.35 (1H, d, J=9.2 Hz), 7.28 (1H, d, J=6.4 Hz), 7.46-7.65 (6H, m), 7.71 (1H, s), 8.21 (1H, s)\n\nMS(ESI\n+\n) : 386[M+H]\n+\n, 408[M+Na]\n+\n \n\nIR(KBr) : 3382, 1662, 1602, 1444, 1191 cm\n-1\n \n\nmp : 225.8℃ (IPA-H\n2\nO)\n\n \nExample 29\n \n 3-Amino-5- (3,4-difluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.05 (6H, d, J = 6.8 Hz), 4.96 (1H, m), 6.35 (1H, d, J = 9.2 Hz), 7.28 (1H, d, J = 6.4 Hz), 7.46-7.65 (6H, m), 7.71 (1H, s), 8.21 (1H, s) \n MS (ESI \n+\n ): 386 [M + H] \n+\n , 408 [M + Na] \n+\n \n IR (KBr): 3382, 1662, 1602, 1444, 1191 cm \n-1\n \n mp: 225.8 ℃ (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例３０\n \n\n  ３−アミノ−５−（３，５−ジフルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.05 (6H, d, J=6.8 Hz), 4.95 (1H, m), 6.37 (1H, d, J=9.4 Hz), 7.14-7.37 (3H, m), 7.46 (1H, d, J=2.4Hz), 7.66 (1H, dd, J=2.4,9.4Hz)), 7.73 (3H, m), 8.23 (1H, s)\n\nMS(ESI\n+\n) : 408[M+Na]\n+\n \n\nIR(KBr) : 3284, 1664, 1587, 1446, 1120 cm\n-1\n \n\nmp : 248.8℃ (IPA-H\n2\nO)\n\n \nExample 30\n \n 3-Amino-5- (3,5-difluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.05 (6H, d, J = 6.8 Hz), 4.95 (1H, m), 6.37 (1H, d, J = 9.4 Hz), 7.14-7.37 (3H, m ), 7.46 (1H, d, J = 2.4Hz), 7.66 (1H, dd, J = 2.4, 9.4Hz)), 7.73 (3H, m), 8.23 (1H, s) \n MS (ESI \n+\n ): 408 [M + Na] \n+\n \n IR (KBr): 3284, 1664, 1587, 1446, 1120 cm \n-1\n \n mp: 248.8 ℃ (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例３１\n \n\n  ３−アミノ−５−（４−シアノフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.98 (6H, d, J=6.8 Hz), 4.92 (1H, m), 6.35 (1H, d, J=9.4 Hz), 7.38 (1H, d, J=2.4 Hz), 7.65 (2H, d, J=8.4 Hz), 7.65-7.69 (4H, m), 7.74 (1H, s), 7.90 (1H, d, J=8.4 Hz), 8.24 (1H, s) \n\nMS(ESI\n+\n) : 397[M+Na]\n+\n \n\nIR(KBr) : 3432, 2223, 1671, 1606, 1450 cm\n-1\n \n\nmp : 292℃ (IPA-H\n2\nO)\n\n \nExample 31\n \n 3-Amino-5- (4-cyanophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.98 (6H, d, J = 6.8 Hz), 4.92 (1H, m), 6.35 (1H, d, J = 9.4 Hz), 7.38 (1H, d, J = 2.4 Hz), 7.65 (2H, d, J = 8.4 Hz), 7.65-7.69 (4H, m), 7.74 (1H, s), 7.90 (1H, d, J = 8.4 Hz), 8.24 (1H, s ) \n MS (ESI \n+\n ): 397 [M + Na] \n+\n \n IR (KBr): 3432, 2223, 1671, 1606, 1450 cm \n-1\n \n mp: 292 ℃ (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例３２\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボニトリル\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.94 (6H, d, J=6.8 Hz), 4.89 (1H, m), 6.35 (1H, d, J=9.4 Hz), 7.28 (1H, d, J=2.4 Hz), 7.39-7.49 (8H, m)\n\nMS(ESI\n+\n) : 332[M+H]\n+\n, 354[M+Na]\n+\n \n\nIR(KBr) : 3357, 2219, 1652, 1579, 1465, 1203 cm\n-1\n \n\nmp : 205.4℃ (IPA-H\n2\nO)\n\n \nExample 32\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarbonitrile \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.94 (6H, d, J = 6.8 Hz), 4.89 (1H, m), 6.35 (1H, d, J = 9.4 Hz), 7.28 (1H, d, J = 2.4 Hz), 7.39-7.49 (8H, m) \n MS (ESI \n+\n ): 332 [M + H] \n+\n , 354 [M + Na] \n+\n \n IR (KBr): 3357, 2219, 1652, 1579, 1465, 1203 cm \n-1\n \n mp: 205.4 ° C (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例３３\n \n\n  ３−アミノ−５−（２−フルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボニトリル\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.91 (6H, d, J=6.8 Hz), 4.87 (1H, m), 6.37 (1H, d, J=9.4 Hz), 7.18-7.63 (8H, m)\n\nMS(ESI\n+\n) : 350[M+H]\n+\n, 372[M+Na]\n+\n \n\nIR(KBr) : 3366, 2214, 1615, 1516, 1200 cm\n-1\n \n\nmp : 210.6℃ (IPA-H\n2\nO)\n\n \nExample 33\n \n 3-Amino-5- (2-fluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarbonitrile \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.91 (6H, d, J = 6.8 Hz), 4.87 (1H, m), 6.37 (1H, d, J = 9.4 Hz), 7.18-7.63 (8H, m ) \n MS (ESI \n+\n ): 350 [M + H] \n+\n , 372 [M + Na] \n+\n \n IR (KBr): 3366, 2214, 1615, 1516, 1200 cm \n-1\n \n mp: 210.6 ° C (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例３４\n \n\n  ３−アミノ−５−（３−フルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボニトリル\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.98 (6H, d, J=6.8 Hz), 4.92 (1H, m), 6.37 (1H, d, J=9.4 Hz), 7.22-7.53 (8H, m)\n\nMS(ESI\n+\n) : 350[M+H]\n+\n, 372[M+Na]\n+\n \n\nIR(KBr) : 3360, 2214, 1660, 1570, 1205 cm\n-1\n \n\nmp : 210.6℃ (IPA-H\n2\nO)\n\n \nExample 34\n \n 3-Amino-5- (3-fluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarbonitrile \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.98 (6H, d, J = 6.8 Hz), 4.92 (1H, m), 6.37 (1H, d, J = 9.4 Hz), 7.22-7.53 (8H, m ) \n MS (ESI \n+\n ): 350 [M + H] \n+\n , 372 [M + Na] \n+\n \n IR (KBr): 3360, 2214, 1660, 1570, 1205 cm \n-1\n \n mp: 210.6 ° C (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例３５\n \n\n  ３−アミノ−５−（４−フルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボニトリル\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.98 (6H, d, J=6.8 Hz), 4.92 (1H, m), 6.37 (1H, d, J=9.4 Hz), 7.22-7.68 (8H, m)\n\nMS(ESI\n+\n) : 350[M+H]\n+\n \n\nIR(KBr) : 3364, 2214, 1660, 1572, 1200 cm\n-1\n \n\nmp : 207.0℃ (IPA-H\n2\nO)\n\n \nExample 35\n \n 3-Amino-5- (4-fluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarbonitrile \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.98 (6H, d, J = 6.8 Hz), 4.92 (1H, m), 6.37 (1H, d, J = 9.4 Hz), 7.22-7.68 (8H, m ) \n MS (ESI \n+\n ): 350 [M + H] \n+\n \n IR (KBr): 3364, 2214, 1660, 1572, 1200 cm \n-1\n \n mp: 207.0 ° C (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例３６\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（２−メトキシフェニル）−２−ピラジンカルボニトリル\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.97 (6H, brs), 3.46 (3H, s), 4.86 (1H, m), 6.34 (1H, d, J=9.4 Hz), 6.99 (1H, d, 8.2 Hz), 7.10 (1H, t, 7.6 Hz), 7.18 (1H, d, 2.5 Hz), 7.37-7.50 (5H, m)\n\nMS(ESI\n+\n) : 362[M+H]\n+\n, 384[M+Na]\n+\n \n\nIR(KBr) : 3266, 2214, 1600, 1448, 1255 cm\n-1\n \n\nmp : 222.6℃ (IPA-H\n2\nO)\n\n \nExample 36\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (2-methoxyphenyl) -2-pyrazinecarbonitrile \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.97 (6H, brs), 3.46 (3H, s), 4.86 (1H, m), 6.34 (1H, d, J = 9.4 Hz), 6.99 (1H, d , 8.2 Hz), 7.10 (1H, t, 7.6 Hz), 7.18 (1H, d, 2.5 Hz), 7.37-7.50 (5H, m) \n MS (ESI \n+\n ): 362 [M + H] \n+\n , 384 [M + Na] \n+\n \n IR (KBr): 3266, 2214, 1600, 1448, 1255 cm \n-1\n \n mp: 222.6 ℃ (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例３７\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（３−メトキシフェニル）−２−ピラジンカルボニトリル\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.98 (6H, d, J=6.8 Hz), 3.69 (3H, s), 4.91 (1H, m), 6.35 (1H, d, J=9.4 Hz), 6.95-6.97 (1H, m), 7.00 (2H, s), 7.30-7.47 (5H, m)\n\nMS(ESI\n+\n) : 362[M+H]\n+\n, 384[M+Na]\n+\n \n\nIR(KBr) : 3360, 2215, 1655, 1570, 1205 cm\n-1\n \n\nmp : 192.3℃ (IPA-H\n2\nO)\n\n \nExample 37\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (3-methoxyphenyl) -2-pyrazinecarbonitrile \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.98 (6H, d, J = 6.8 Hz), 3.69 (3H, s), 4.91 (1H, m), 6.35 (1H, d, J = 9.4 Hz), 6.95-6.97 (1H, m), 7.00 (2H, s), 7.30-7.47 (5H, m) \n MS (ESI \n+\n ): 362 [M + H] \n+\n , 384 [M + Na] \n+\n \n IR (KBr): 3360, 2215, 1655, 1570, 1205 cm \n-1\n \n mp: 192.3 ℃ (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例３８\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（４−メトキシフェニル）−２−ピラジンカルボニトリル\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.02 (6H, d, J=6.8 Hz), 3.76 (3H, s), 4.93 (1H, m), 6.35 (1H, d, J=9.4 Hz), 6.98 (2H, d, 7.2Hz), 7.38-7.43 (6H, m)\n\nMS(ESI\n+\n) : 362[M+H]\n+\n, 384[M+Na]\n+\n \n\nIR(KBr) : 3357, 2218, 1650, 1570, 1200 cm\n-1\n \n\nmp : 243.9℃ (IPA-H\n2\nO)\n\n \nExample 38\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (4-methoxyphenyl) -2-pyrazinecarbonitrile \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.02 (6H, d, J = 6.8 Hz), 3.76 (3H, s), 4.93 (1H, m), 6.35 (1H, d, J = 9.4 Hz), 6.98 (2H, d, 7.2Hz), 7.38-7.43 (6H, m) \n MS (ESI \n+\n ): 362 [M + H] \n+\n , 384 [M + Na] \n+\n \n IR (KBr): 3357, 2218, 1650, 1570, 1200 cm \n-1\n \n mp: 243.9 ° C (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例３９\n \n\n  ３−アミノ−５−（３，４−ジフルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボニトリル\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.02 (6H, d, J=6.8 Hz), 4.95 (1H, m), 6.38 (1H, d, J=9.0 Hz), 7.26 (1H, m), 7.38-7.58 (6H, m), \n\nMS(ESI\n+\n) : 368[M+H]\n+\n, 390[M+Na]\n+\n \n\nIR(KBr) : 3166, 2210, 1658, 1461, 1201 cm\n-1\n \n\nmp : 180℃ (IPA-H\n2\nO)\n\n \nExample 39\n \n 3-Amino-5- (3,4-difluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarbonitrile \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.02 (6H, d, J = 6.8 Hz), 4.95 (1H, m), 6.38 (1H, d, J = 9.0 Hz), 7.26 (1H, m), 7.38-7.58 (6H, m), \n MS (ESI \n+\n ): 368 [M + H] \n+\n , 390 [M + Na] \n+\n \n IR (KBr): 3166, 2210, 1658, 1461, 1201 cm \n-1\n \n mp: 180 ° C (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例４０\n \n\n  ３−アミノ−５−（４−フルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド（３０ｇ）をジオキサン（６０ｍｌ）と２ＮＮａＯＨ水溶液（６００ｍｌ）に懸濁した。混合物を攪拌しながら９０℃で４時間加熱した。上記の反応混合物を２５〜３０℃まで冷却した。懸濁液のｐＨを３５％ＨＣｌ（１０５ｍｌ）で２．５に調整した。沈殿物を濾取し、水で洗浄し、５０℃で１５時間真空乾燥して、３−アミノ−５−（４−フルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボン酸を黄色粉末（２９．６ｇ）として得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.00 (6H, d, J=6.8 Hz), 4.93 (1H, m), 6.37 (1H, d, J=9.4 Hz), 7.22-7.36 (3H, m), 7.48-7.68 (5H, m), 13.00 (1H, s)\n\nIR(KBr) : 3266, 1725, 1662, 1600, 1455 cm\n-1\n \n\nmp : 222.2℃ (IPA-H\n2\nO)\n\n \nExample 40\n \n 3-amino-5- (4-fluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide (30 g) in dioxane (60 ml) and 2N aqueous NaOH solution (600 ml). The mixture was heated at 90 ° C. with stirring for 4 hours. The reaction mixture was cooled to 25-30 ° C. The pH of the suspension was adjusted to 2.5 with 35% HCl (105 ml). The precipitate was collected by filtration, washed with water and dried in vacuo at 50 ° C. for 15 hours to give 3-amino-5- (4-fluorophenyl) -6- (1-isopropyl-6-oxo-1,6- Dihydro-3-pyridyl) -2-pyrazinecarboxylic acid was obtained as a yellow powder (29.6 g). \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.00 (6H, d, J = 6.8 Hz), 4.93 (1H, m), 6.37 (1H, d, J = 9.4 Hz), 7.22-7.36 (3H, m ), 7.48-7.68 (5H, m), 13.00 (1H, s) \n IR (KBr): 3266, 1725, 1662, 1600, 1455 cm \n-1\n \n mp: 222.2 ° C (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例４１\n \n\n  ３−アミノ−５−（４−フルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボン酸（２５ｇ）を１，２−ジクロロベンゼン（１２５ｍｌ）に懸濁した。懸濁液を攪拌しながら１６５〜１７０℃で４時間加熱した。反応混合物を２０〜２５℃まで冷却した。冷却混合物にＩＰＥ（２５０ｍｌ）を加えた。懸濁液を２５〜３０℃で３時間攪拌した。沈殿物を濾取し、真空乾燥した。上記の乾燥沈殿物を、ＣＨＣｌ\n３\n：ＭｅＯＨ（９：１、２Ｌ）を溶離溶媒として用いるシリカゲル（５００ｇ）クロマトグラフィーで精製した。溶媒を真空留去して、黄色結晶残留物を得て、これを７０％ＥｔＯＨ（３２２ｍｌ）から再結晶して、５−［５−アミノ−３−（４−フルオロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドンを黄色結晶（１９．４ｇ）として得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.00 (6H, d, J=6.8 Hz), 4.93 (1H, m), 6.33 (1H, d, J=9.2 Hz), 6.63 (2H, s), 7.17-7.26 (3H, m), 7.38-7.46 (3H, m), 7.93 (1H, s)\n\nMS(ESI\n+\n) : 325[M+H]\n+\n, 347[M+Na]\n+\n \n\nIR(KBr) : 3166, 1666, 1604, 1533, 1467, 1222 cm\n-1\n \n\nmp : 257.7℃ (IPA-H\n2\nO)\n\n \nExample 41\n \n 3-Amino-5- (4-fluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxylic acid (25 g) was converted into 1,2-dichlorobenzene. (125 ml). The suspension was heated with stirring at 165-170 ° C. for 4 hours. The reaction mixture was cooled to 20-25 ° C. To the cooled mixture was added IPE (250 ml). The suspension was stirred at 25-30 ° C. for 3 hours. The precipitate was collected by filtration and dried in vacuo. The dried precipitate was purified by silica gel (500 g) chromatography using CHCl \n3\n : MeOH (9: 1, 2 L) as the eluting solvent. The solvent was removed in vacuo to give a yellow crystalline residue which was recrystallized from 70% EtOH (322 ml) to give 5- [5-amino-3- (4-fluorophenyl) -2-pyrazinyl] -1-Isopropyl-2 (1H) -pyridone was obtained as yellow crystals (19.4 g). \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.00 (6H, d, J = 6.8 Hz), 4.93 (1H, m), 6.33 (1H, d, J = 9.2 Hz), 6.63 (2H, s), 7.17-7.26 (3H, m), 7.38-7.46 (3H, m), 7.93 (1H, s) \n MS (ESI \n+\n ): 325 [M + H] \n+\n , 347 [M + Na] \n+\n \n IR (KBr): 3166, 1666, 1604, 1533, 1467, 1222 cm \n-1\n \n mp: 257.7 ℃ (IPA-H \n2\n O)\n\n\n\n\n\n\n \n \n実施例４２\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボン酸（７０ｍｇ）、メチルアミン塩酸塩（１４．８ｍｇ）、１−エチル−３−［３’−（ジメチルアミノ）プロピル］−カルボジイミド（３４．１ｍｇ）と１−ヒドロキシ−ベンゾトリアゾール（２９．７ｍｇ）のＣＨ\n２\nＣｌ\n２\n（０．７ｍｌ）中の混合物を２５℃で４時間攪拌した。水とＥｔＯＡｃを混合物に注いだ。有機層を分離し、水、ＮａＨＣＯ\n３\n飽和水溶液と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去した。残留物をシリカゲルカラムクロマトグラフィー（ｎ−ヘキサン−ＥｔＯＡｃ、次いでＣＨ\n２\nＣｌ\n２\n−ＭｅＯＨ）で精製し、ＭｅＯＨ−ＩＰＥから結晶化して、３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−Ｎ−メチル−５−フェニル−２−ピラジンカルボキサミド（４０ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.93 (6H, d, J=6.8 Hz), 2.84 (3H, d, J=4.8 Hz), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.38 (1H, d, J=9.4 Hz), 7.26 (1H, d, J=2.5 Hz), 7.42 (5H, m), 7.62 (2H, brs), 7.79 (1H, dd, J=2.5, 9.4 Hz), 8.69 (1H, m)\n\nMS(ESI\n+\n) : 364[M+H]\n+\n \n\n  下記の４個の化合物を実施例４２と同様の方法にしたがって得た。\n\n \nExample 42\n \n 3-amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxylic acid (70 mg), methylamine hydrochloride (14.8 mg), 1 A mixture of ethyl-3- [3 ′-(dimethylamino) propyl] -carbodiimide (34.1 mg) and 1-hydroxy-benzotriazole (29.7 mg) in CH \n2\n Cl \n2\n (0.7 ml) at 25 ° C. For 4 hours. Water and EtOAc were poured into the mixture. The organic layer was separated, washed with water, saturated aqueous NaHCO \n3\n and brine, and dried over MgSO \n4\n . The solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane-EtOAc, then CH \n2\n Cl \n2\n -MeOH), crystallized from MeOH-IPE to give 3-amino-6- (1-isopropyl-6-oxo-1 , 6-Dihydro-3-pyridyl) -N-methyl-5-phenyl-2-pyrazinecarboxamide (40 mg) was obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.93 (6H, d, J = 6.8 Hz), 2.84 (3H, d, J = 4.8 Hz), 4.89 (1H, qq, J = 6.8, 6.8 Hz), 6.38 (1H, d, J = 9.4 Hz), 7.26 (1H, d, J = 2.5 Hz), 7.42 (5H, m), 7.62 (2H, brs), 7.79 (1H, dd, J = 2.5, 9.4 Hz ), 8.69 (1H, m) \n MS (ESI \n+\n ): 364 [M + H] \n+\n \n The following four compounds were obtained in the same manner as in Example 42.\n\n\n\n\n\n\n \n \n実施例４３\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−Ｎ，Ｎ−ジメチル−５−フェニル−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.93 (6H, d, J=6.7 Hz), 3.04 (3H, s), 3.10 (3H, s), 4.89 (1H, qq, J=6.7, 6.7 Hz), 6.36 (1H, d, J=9.4 Hz), 6.73 (2H, brs), 7.21 (1H, d, J=2.5 Hz), 7.3-7.6 (6H, m)\n\nMS(ESI\n-\n) : 376[M-H]\n-\n\n\n \nExample 43\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -N, N-dimethyl-5-phenyl-2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.93 (6H, d, J = 6.7 Hz), 3.04 (3H, s), 3.10 (3H, s), 4.89 (1H, qq, J = 6.7, 6.7 Hz ), 6.36 (1H, d, J = 9.4 Hz), 6.73 (2H, brs), 7.21 (1H, d, J = 2.5 Hz), 7.3-7.6 (6H, m) \n \nMS (ESI -): 376 [\n MH] -\n\n\n\n\n\n\n \n \n実施例４４\n \n\n  ５−［５−アミノ−６−（４−モルホリニルカルボニル）−３−フェニル−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.95 (6H, d, J=6.8 Hz), 3.63 (4H, brs), 3.70 (4H, brs), 4.86 (1H, qq, J=6.8, 6.8 Hz), 6.36 (1H, d, J=9.4 Hz), 6.78 (2H, brs), 7.24 (1H, d, J=2.4 Hz), 7.3-7.5 (6H, m)\n\nMS(ESI\n+\n) : 420[M+H]\n+\n\n\n \nExample 44\n \n 5- [5-Amino-6- (4-morpholinylcarbonyl) -3-phenyl-2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.95 (6H, d, J = 6.8 Hz), 3.63 (4H, brs), 3.70 (4H, brs), 4.86 (1H, qq, J = 6.8, 6.8 Hz ), 6.36 (1H, d, J = 9.4 Hz), 6.78 (2H, brs), 7.24 (1H, d, J = 2.4 Hz), 7.3-7.5 (6H, m) \n MS (ESI \n+\n ): 420 [M + H] \n+\n \n\n\n\n\n\n\n \n \n実施例４５\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−Ｎ−（２−ピリジルメチル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.94 (6H, d, J=6.8 Hz), 4.64 (2H, d, J=6.0 Hz), 4.87 (1H, qq, J=6.8, 6.8 Hz), 6.39 (1H, d, J=9.4 Hz), 7.1-7.9 (12H, m), 8.52 (1H, distorted d, J=4.1 Hz), 9.37 (1H, t, J=6.0 Hz).\n\nMS(ESI\n+\n) : 441[M+H]\n+\n\n\n \nExample 45\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-N- (2-pyridylmethyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.94 (6H, d, J = 6.8 Hz), 4.64 (2H, d, J = 6.0 Hz), 4.87 (1H, qq, J = 6.8, 6.8 Hz), 6.39 (1H, d, J = 9.4 Hz), 7.1-7.9 (12H, m), 8.52 (1H, distorted d, J = 4.1 Hz), 9.37 (1H, t, J = 6.0 Hz). \n MS (ESI \n+\n ): 441 [M + H] \n+\n \n\n\n\n\n\n\n \n \n実施例４６\n \n\n  ３−アミノ−Ｎ−（シアノメチル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.92 (6H, d, J=6.8 Hz), 4.34 (2H, d, J=5.9 Hz), 4.88 (1H, qq, J=6.8, 6.8 Hz), 6.41 (1H, d, J=9.4 Hz), 7.24 (1H, d, J=2.4 Hz), 7.3-7.5 (5H, m), 7.61 (2H, brs), 7.83 (1H, dd, J=2.4, 9.4 Hz), 9.27 (1H, brt, J=5.9 Hz)\n\nMS(ESI\n+\n) : 389[M+H]\n+\n, 411[M+Na]\n+\n\n\n \nExample 46\n \n 3-Amino-N- (cyanomethyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.92 (6H, d, J = 6.8 Hz), 4.34 (2H, d, J = 5.9 Hz), 4.88 (1H, qq, J = 6.8, 6.8 Hz), 6.41 (1H, d, J = 9.4 Hz), 7.24 (1H, d, J = 2.4 Hz), 7.3-7.5 (5H, m), 7.61 (2H, brs), 7.83 (1H, dd, J = 2.4, 9.4 Hz), 9.27 (1H, brt, J = 5.9 Hz) \n MS (ESI \n+\n ): 389 [M + H] \n+\n , 411 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例４７\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボン酸（７０ｍｇ）とＮＥｔ\n３\n（４０．４ｍｇ）のＴＨＦ（０．７ｍｌ）中の混合物に、イソブチルクロロホルメート（３２．７ｍｇ）を氷浴冷却下に加えた。同温で１．５時間攪拌後、混合物をＴＨＦ（０．７ｍｌ）と水（１．４ｍｌ）の混合物中の水素化ホウ素ナトリウム（３０．２ｍｇ）の混合物に氷浴冷却下に注いだ。同温で２．５時間攪拌後、混合物を水とＥｔＯＡｃで希釈し、有機層を分離して、水と食塩水で洗浄して、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去した。残留物をシリカゲルカラムクロマトグラフィー（ＣＨ\n２\nＣｌ\n２\n：ＭｅＯＨ＝２５：１〜１０：１）で精製した。所望の画分をＩＰＥで粉末化して、５−［５−アミノ−６−（ヒドロキシメチル）−３−フェニル−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（２４ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.95 (6H, d, J=6.8 Hz), 4.59 (2H, d, J=5.6 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 5.34 (1H, t, J=5.6 Hz), 6.3-6.4 (3H, m), 7.20 (1H, d, J=2.4 Hz), 7.2-7.5 (5H, m), 7.50 (1H, dd, J=2.4, 9.4 Hz)\n\nMS(ESI\n+\n) : 337[M+H]\n+\n, 359[M+Na]\n+\n \n\n  下記の３個の化合物を実施例４２と同様の方法にしたがって得た。\n\n \nExample 47\n \n 3-amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxylic acid (70 mg) and NEt \n3\n (40.4 mg) in THF (0 To the mixture in 3 ml) was added isobutyl chloroformate (32.7 mg) under ice bath cooling. After stirring at the same temperature for 1.5 hours, the mixture was poured into a mixture of sodium borohydride (30.2 mg) in a mixture of THF (0.7 ml) and water (1.4 ml) under ice bath cooling. After stirring at the same temperature for 2.5 hours, the mixture was diluted with water and EtOAc, the organic layer was separated, washed with water and brine, and dried over MgSO \n4\n . The solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (CH \n2\n Cl \n2\n : MeOH = 25: 1 to 10: 1). The desired fraction was triturated with IPE to give 5- [5-amino-6- (hydroxymethyl) -3-phenyl-2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone (24 mg). . \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.95 (6H, d, J = 6.8 Hz), 4.59 (2H, d, J = 5.6 Hz), 4.90 (1H, qq, J = 6.8, 6.8 Hz), 5.34 (1H, t, J = 5.6 Hz), 6.3-6.4 (3H, m), 7.20 (1H, d, J = 2.4 Hz), 7.2-7.5 (5H, m), 7.50 (1H, dd, J = (2.4, 9.4 Hz) \n MS (ESI \n+\n ): 337 [M + H] \n+\n , 359 [M + Na] \n+\n \n The following three compounds were obtained in the same manner as in Example 42.\n\n\n\n\n\n\n \n \n実施例４８\n \n\n  ５−［５−アミノ−６−（１−アゼチジニルカルボニル）−３−フェニル−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.92 (6H, d, J=6.8 Hz), 2.25 (2H, m), 4.09 (2H, t, J=7.6 Hz), 4.70 (2H, t, J=7.6 Hz), 4.91 (1H, qq, J=6.8, 6.8 Hz), 6.36 (1H, d, J=9.4 Hz), 7.29 (1H, d, J=2.4 Hz), 7.3-7.6 (6H, m), 7.62 (2H, brs)\n\nMS(ESI\n+\n) : 390[M+H]\n+\n\n\n \nExample 48\n \n 5- [5-Amino-6- (1-azetidinylcarbonyl) -3-phenyl-2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.92 (6H, d, J = 6.8 Hz), 2.25 (2H, m), 4.09 (2H, t, J = 7.6 Hz), 4.70 (2H, t, J = 7.6 Hz), 4.91 (1H, qq, J = 6.8, 6.8 Hz), 6.36 (1H, d, J = 9.4 Hz), 7.29 (1H, d, J = 2.4 Hz), 7.3-7.6 (6H, m ), 7.62 (2H, brs) \n MS (ESI \n+\n ): 390 [M + H] \n+\n \n\n\n\n\n\n\n \n \n実施例４９\n \n\n  ３−アミノ−Ｎ−（２−ヒドロキシエチル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.93 (6H, d, J=6.8 Hz), 3.4-3.5 (2H, m), 3.5-3.6 (2H, m), 4.7-5.0 (2H, m), 6.39 (1H, d, J=9.4 Hz), 7.26 (1H, 2.4 Hz), 7.3-7.5 (5H, m), 7.63 (2H, brs), 7.75 (1H, dd, J=2.4, 9.4 Hz), 8.63 (1H, t, J=5.8 Hz)\n\nMS(ESI\n+\n) : 394[M+H]\n+\n, 416[M+Na]\n+\n\n\n \nExample 49\n \n 3-Amino-N- (2-hydroxyethyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.93 (6H, d, J = 6.8 Hz), 3.4-3.5 (2H, m), 3.5-3.6 (2H, m), 4.7-5.0 (2H, m) , 6.39 (1H, d, J = 9.4 Hz), 7.26 (1H, 2.4 Hz), 7.3-7.5 (5H, m), 7.63 (2H, brs), 7.75 (1H, dd, J = 2.4, 9.4 Hz) , 8.63 (1H, t, J = 5.8 Hz) \n MS (ESI \n+\n ): 394 [M + H] \n+\n , 416 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例５０\n \n\n  ３−アミノ−Ｎ−シクロプロピル−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.6-0.8 (4H, m), 0.93 (6H, d, J=6.8 Hz), 2.84 (1H, m), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.37 (1H, d, J=9.4 Hz), 7.29 (1H, d, J=2.4 Hz), 7.3-7.5 (5H, m), 7.61 (2H, brs), 7.75 (1H, dd, J=2.4, 9.4 Hz), 8.57 (1H, t, J=4.2 Hz)\n\nMS(ESI\n+\n) : 390[M+H]\n+\n, 412[M+Na]\n+\n\n\n \nExample 50\n \n 3-Amino-N-cyclopropyl-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.6-0.8 (4H, m), 0.93 (6H, d, J = 6.8 Hz), 2.84 (1H, m), 4.89 (1H, qq, J = 6.8, 6.8 Hz), 6.37 (1H, d, J = 9.4 Hz), 7.29 (1H, d, J = 2.4 Hz), 7.3-7.5 (5H, m), 7.61 (2H, brs), 7.75 (1H, dd, J = 2.4, 9.4 Hz), 8.57 (1H, t, J = 4.2 Hz) \n MS (ESI \n+\n ): 390 [M + H] \n+\n , 412 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例５１\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボン酸\n\n  表題の化合物を実施例４０と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.95 (6H, d, J=6.8 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 6.37 (1H, d, J=9.4 Hz), 7.31 (1H, d, J=2.4 Hz), 7.2-7.6 (7H, m), 7.59 (1H, dd, J=2.4, 9.4 Hz), 13.0 (1H, brs)\n\nMS(ESI\n-\n) : 349[M-H]\n-\n\n\n \nExample 51\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxylic acid The title compound was obtained in a similar manner to Example 40. . \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.95 (6H, d, J = 6.8 Hz), 4.90 (1H, qq, J = 6.8, 6.8 Hz), 6.37 (1H, d, J = 9.4 Hz), 7.31 (1H, d, J = 2.4 Hz), 7.2-7.6 (7H, m), 7.59 (1H, dd, J = 2.4, 9.4 Hz), 13.0 (1H, brs) \n \nMS (ESI -): 349 [\n MH] -\n\n\n\n\n\n\n \n \n実施例５２\n \n\n  ５−（５−アミノ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン\n\n  表題の化合物を実施例４１と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.95 (6H, d, J=6.8 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 6.32 (1H, d, J=9.4 Hz), 6.60 (2H, brs), 7.21 (1H, d, J=2.4 Hz), 7.2-7.5 (6H, m), 7.93 (1H, s)\n\nMS(ESI\n+\n) : 307[M+H]\n+\n, 329[M+Na]\n+\n\n\n \nExample 52\n \n 5- (5-Amino-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone The title compound was obtained in the same manner as in Example 41. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.95 (6H, d, J = 6.8 Hz), 4.90 (1H, qq, J = 6.8, 6.8 Hz), 6.32 (1H, d, J = 9.4 Hz), 6.60 (2H, brs), 7.21 (1H, d, J = 2.4 Hz), 7.2-7.5 (6H, m), 7.93 (1H, s) \n MS (ESI \n+\n ): 307 [M + H] \n+\n , 329 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例５３\n \n\n  ５−（５−アミノ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（１００ｍｇ）とＮ−ブロモスクシンイミド（８７．１ｍｇ）のＤＭＦ中の混合物を攪拌しながら５０℃で２０分間加熱した。飽和ＮａＨＣＯ\n３\n水溶液とＥｔＯＡｃを混合物に注いだ。有機層を分離し、水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去した。残留物をシリカゲルカラムクロマトグラフィー（ｎ−ヘキサン：ＥｔＯＡｃ＝１０：１〜２：１）で精製した。所望の生成物をＩＰＥで再結晶し、真空乾燥して、５−（５−アミノ−６−ブロモ−３−フェニル−２−ピラジニル）−３−ブロモ−１−イソプロピル−２（１Ｈ）−ピリドン（５７ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.94 (6H, d, J=6.8 Hz), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.97 (2H, brs), 7.24 (1H, d, J=2.4 Hz), 7.2-7.6 (5H, m), 7.92 (1H, d, J=2.4 Hz)\n\nMS(ESI\n+\n) : 463[M+H]\n+\n\n\n \nExample 53\n \n A mixture of 5- (5-amino-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (100 mg) and N-bromosuccinimide (87.1 mg) in DMF was stirred at 50 ° C. For 20 minutes. Saturated aqueous NaHCO \n3\n solution and EtOAc were poured into the mixture. The organic layer was separated, washed with water and brine and dried over MgSO \n4\n . The solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane: EtOAc = 10: 1 to 2: 1). The desired product is recrystallized from IPE and dried in vacuo to give 5- (5-amino-6-bromo-3-phenyl-2-pyrazinyl) -3-bromo-1-isopropyl-2 (1H) -pyridone (57 mg) was obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.94 (6H, d, J = 6.8 Hz), 4.89 (1H, qq, J = 6.8, 6.8 Hz), 6.97 (2H, brs), 7.24 (1H, d , J = 2.4 Hz), 7.2-7.6 (5H, m), 7.92 (1H, d, J = 2.4 Hz) \n MS (ESI \n+\n ): 463 [M + H] \n+\n \n\n\n\n\n\n\n \n \n実施例５４\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−Ｎ−メトキシ−Ｎ−メチル−５−フェニル−２−ピラジンカルボキサミド\n\n  表題の化合物を実施例４２と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.94 (6H, d, J=6.8 Hz), 3.36 (3H, s), 3.75 (3H, s), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.36 (1H, d, J=9.3 Hz), 6.79 (2H, brs), 7.24 (1H, d, J=2.4 Hz), 7.3-7.6 (6H, m)\n\nMS(ESI\n+\n) : 394[M+H]\n+\n\n\n \nExample 54\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -N-methoxy-N-methyl-5-phenyl-2-pyrazinecarboxamide The title compound is Obtained according to a similar method. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.94 (6H, d, J = 6.8 Hz), 3.36 (3H, s), 3.75 (3H, s), 4.89 (1H, qq, J = 6.8, 6.8 Hz ), 6.36 (1H, d, J = 9.3 Hz), 6.79 (2H, brs), 7.24 (1H, d, J = 2.4 Hz), 7.3-7.6 (6H, m) \n MS (ESI \n+\n ): 394 [M + H] \n+\n \n\n\n\n\n\n\n \n \n実施例５５\n \n\n  ５−（５−アミノ−６−クロロ−３−フェニル−２−ピラジニル）−３−クロロ−１−イソプロピル−２（１Ｈ）−ピリドン\n\n  表題の化合物を実施例５３と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.95 (6H, d, J=6.8 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 7.05 (2H, brs), 7.22 (1H, d, J=2.4 Hz), 7.2-7.6 (5H, m), 7.74 (1H, d, J=2.4 Hz)\n\nMS(ESI\n+\n) : 375[M+H]\n+\n, 397[M+Na]\n+\n\n\n \nExample 55\n \n 5- (5-Amino-6-chloro-3-phenyl-2-pyrazinyl) -3-chloro-1-isopropyl-2 (1H) -pyridone The title compound was obtained according to a method similar to that of Example 53. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.95 (6H, d, J = 6.8 Hz), 4.90 (1H, qq, J = 6.8, 6.8 Hz), 7.05 (2H, brs), 7.22 (1H, d , J = 2.4 Hz), 7.2-7.6 (5H, m), 7.74 (1H, d, J = 2.4 Hz) \n MS (ESI \n+\n ): 375 [M + H] \n+\n , 397 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例５６\n \n\n  ５−｛５−アミノ−６−［（３−メトキシ−１−アゼチジニル）カルボニル］−３−フェニル−２−ピラジニル｝−１−イソプロピル−２（１Ｈ）−ピリドン\n\n  表題の化合物を実施例１と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.00 (6H, d, J=6.8 Hz), 3.24 (3H, s), 3.8-4.0 (1H, m), 4.2-4.5 (2H, m), 4.4-4.6 (1H, m), 4.8-5.1 (2H, m), 6.35 (1H, J=9.2 Hz), 7.3-7.5 (7H, m), 7.62 (2H, brs)\n\nMS(ESI\n+\n) : 420[M+H]\n+\n\n\n \nExample 56\n \n 5- {5-Amino-6-[(3-methoxy-1-azetidinyl) carbonyl] -3-phenyl-2-pyrazinyl} -1-isopropyl-2 (1H) -pyridone The title compound is the same as in Example 1. According to the method of \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.00 (6H, d, J = 6.8 Hz), 3.24 (3H, s), 3.8-4.0 (1H, m), 4.2-4.5 (2H, m), 4.4 -4.6 (1H, m), 4.8-5.1 (2H, m), 6.35 (1H, J = 9.2 Hz), 7.3-7.5 (7H, m), 7.62 (2H, brs) \n MS (ESI \n+\n ): 420 [M + H] \n+\n \n\n\n\n\n\n\n \n \n実施例５７\n \n\n  氷浴冷却下に、３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−Ｎ−メトキシ−Ｎ−メチル−５−フェニル−２−ピラジンカルボキサミド（２００ｍｇ）のＴＨＦ（４．０ｍｌ）中の懸濁液に、ＴＨＦ中３．０Ｍ塩化メチルマグネシウム溶液（０．８５ｍｌ）を滴下した。混合物を同温で５時間攪拌した。混合物を塩化アンモニウム飽和水溶液（２０ｍｌ）に注ぎ、有機層をＥｔＯＡｃ（５０ｍｌ）で抽出し、水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去した。残留物をシリカゲルカラムクロマトグラフィー（ＣＨ\n２\nＣｌ\n２\n：ＭｅＯＨ＝５０：１〜１５：１）で精製した。所望の画分をＭｅＯＨから再結晶し、真空乾燥して、５−（６−アセチル−５−アミノ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（１１１ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.95 (6H, d, J=6.8 Hz), 2.66 (3H, s), 4.91 (1H, qq, J=6.8, 6.8 Hz), 6.41 (1H, d, J=9.4 Hz), 7.30 (1H, d, J=2.4 Hz), 7.3-7.6 (5H, m), 7.61 (1H, dd, J=2.4, 9.4 Hz), 7.81 (2H, brs)\n\nMS(ESI\n+\n) : 249[M+H]\n+\n, 371[M+Na]\n+\n\n\n \nExample 57\n \n Under cooling in an ice bath, 3-amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -N-methoxy-N-methyl-5-phenyl-2-pyrazinecarboxamide (200 mg ) In THF (4.0 ml) was added dropwise 3.0 M methylmagnesium chloride solution in THF (0.85 ml). The mixture was stirred at the same temperature for 5 hours. The mixture was poured into saturated aqueous ammonium chloride (20 ml) and the organic layer was extracted with EtOAc (50 ml), washed with water and brine, and dried over MgSO \n4\n . The solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (CH \n2\n Cl \n2\n : MeOH = 50: 1 to 15: 1). The desired fraction was recrystallized from MeOH and dried in vacuo to give 5- (6-acetyl-5-amino-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (111 mg). Obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.95 (6H, d, J = 6.8 Hz), 2.66 (3H, s), 4.91 (1H, qq, J = 6.8, 6.8 Hz), 6.41 (1H, d , J = 9.4 Hz), 7.30 (1H, d, J = 2.4 Hz), 7.3-7.6 (5H, m), 7.61 (1H, dd, J = 2.4, 9.4 Hz), 7.81 (2H, brs) \n MS (ESI \n+\n ): 249 [M + H] \n+\n , 371 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例５８\n \n\n  ３−アミノ−Ｎ−［２−（ジメチルアミノ）エチル］−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジン−カルボキサミド\n\n  表題の化合物を実施例４２と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.97 (6H, d, J=6.8 Hz), 2.20 (6H, s), 2.42 (2H, t, J=6.6 Hz), 3.3-3.5 (2H, m), 4.91 (1H, qq, J=6.8, 6.8 Hz), 6.37 (1H, d, J=9.4 Hz), 7.31 (1H, d, J=2.4 Hz), 7.3-7.5 (5H, m), 7.66 (1H, dd, J=2.4, 9.4 Hz), 8.62 (1H, t, J=5.7 Hz)\n\nMS(ESI\n+\n) : 421[M+H]\n+\n\n\n \nExample 58\n \n 3-Amino-N- [2- (dimethylamino) ethyl] -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazine-carboxamide Title compound Was obtained in the same manner as in Example 42. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.97 (6H, d, J = 6.8 Hz), 2.20 (6H, s), 2.42 (2H, t, J = 6.6 Hz), 3.3-3.5 (2H, m ), 4.91 (1H, qq, J = 6.8, 6.8 Hz), 6.37 (1H, d, J = 9.4 Hz), 7.31 (1H, d, J = 2.4 Hz), 7.3-7.5 (5H, m), 7.66 (1H, dd, J = 2.4, 9.4 Hz), 8.62 (1H, t, J = 5.7 Hz) \n MS (ESI \n+\n ): 421 [M + H] \n+\n \n\n\n\n\n\n\n \n \n実施例５９\n \n\n  ３−アミノ−６−（１−メチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボニトリル\n\n  表題の化合物を実施例１と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.40 (3H, s), 6.17 (1H, d, J=9.4 Hz), 6.97 (1H, dd, J=2.6, 9.4 Hz), 7.40-7.49 (7H, m), 7.81 (1H, d, J=2.6 Hz)\n\nMS(ESI\n+\n) : 304[M+H]\n+\n, 326[M+Na]\n+\n \n\nIR(KBr) : 3386, 2221, 1670, 1590, 1542, 1205 cm\n-1\n\n\n \nExample 59\n \n 3-Amino-6- (1-methyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarbonitrile The title compound was obtained in the same manner as in Example 1. . \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.40 (3H, s), 6.17 (1H, d, J = 9.4 Hz), 6.97 (1H, dd, J = 2.6, 9.4 Hz), 7.40-7.49 (7H , m), 7.81 (1H, d, J = 2.6 Hz) \n MS (ESI \n+\n ): 304 [M + H] \n+\n , 326 [M + Na] \n+\n \n IR (KBr): 3386, 2221, 1670, 1590, 1542, 1205 cm \n-1\n \n\n\n\n\n\n\n \n \n実施例６０\n \n\n  ３−アミノ−５−クロロ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド（５００ｍｇ）、（４−メトキシフェニル）ホウ素酸（７４０ｍｇ）とＰｄ（ＰＰｈ\n３\n）\n４\n（５６．３ｍｇ）の２ＭＮａ\n２\nＣＯ\n３\n水溶液（３．２５ｍｌ）とジオキサン（２０ｍｌ）中の混合物を３時間還流した。水（４０ｍｌ）とＥｔＯＡｃ（３０ｍｌ）を反応混合物に注ぎ、水溶液をＥｔＯＡｃで抽出した。有機層を水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。濾過後、溶媒を減圧除去した。残留固形物を、ＣＨＣｌ\n３\n：ＭｅＯＨ（２５：１）を溶離溶媒として用いるシリカゲルカラムに入れた。溶離溶媒を留去し、残留物をＩＰＥで懸濁し、濾過して、３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（４−メトキシフェニル）−２−ピラジンカルボキサミド（５１２ｍｇ）を黄色粉末として得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.05 (6H, d, J=7.0 Hz), 4.94 (1H, sept, J=7.0 Hz), 6.32 (1H, d, J=9.5 Hz), 6.98 (2H, d, J=9.0 Hz), 7.39-7.64 (7H, m), 8.15(1H, brs)\n\nMS(ESI\n+\n) : 380[M+H]\n+\n, 421[M+H+MeCN]\n+\n \n\n  下記の１８個の化合物を実施例６０と同様の方法にしたがって得た。\n\n \nExample 60\n \n 3-amino-5-chloro-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide (500 mg), (4-methoxyphenyl) boronic acid (740 mg) and A mixture of Pd (PPh \n3\n ) \n4\n (56.3 mg) in 2M Na \n2\n CO \n3\n aqueous solution (3.25 ml) and dioxane (20 ml) was refluxed for 3 hours. Water (40 ml) and EtOAc (30 ml) were poured into the reaction mixture and the aqueous solution was extracted with EtOAc. The organic layer was washed with water and brine and dried over MgSO \n4\n . After filtration, the solvent was removed under reduced pressure. The residual solid was loaded onto a silica gel column using CHCl \n3\n : MeOH (25: 1) as the eluting solvent. The elution solvent was distilled off, the residue was suspended in IPE, filtered and 3-amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (4- Methoxyphenyl) -2-pyrazinecarboxamide (512 mg) was obtained as a yellow powder. \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.05 (6H, d, J = 7.0 Hz), 4.94 (1H, sept, J = 7.0 Hz), 6.32 (1H, d, J = 9.5 Hz), 6.98 ( 2H, d, J = 9.0 Hz), 7.39-7.64 (7H, m), 8.15 (1H, brs) \n MS (ESI \n+\n ): 380 [M + H] \n+\n , 421 [M + H + MeCN] \n+\n \n The following 18 compounds were obtained in the same manner as in Example 60.\n\n\n\n\n\n\n \n \n実施例６１\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（２−メトキシフェニル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.89 (6H, brs), 3.48 (3H, s), 4.88 (1H, sept, J=6.8 Hz), 6.32 (1H, d, J=9.5 Hz), 7.00-7.13 (2H, m), 7.22 (1H, d, J=2.5 Hz), 7.37-7.79 (6H, m), 8.16 (1H, brs)\n\n \nExample 61\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (2-methoxyphenyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.89 (6H, brs), 3.48 (3H, s), 4.88 (1H, sept, J = 6.8 Hz), 6.32 (1H, d, J = 9.5 Hz), 7.00-7.13 (2H, m), 7.22 (1H, d, J = 2.5 Hz), 7.37-7.79 (6H, m), 8.16 (1H, brs)\n\n\n\n\n\n\n \n \n実施例６２\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（３−メトキシフェニル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.00 (6H, d, J=7.0 Hz), 3.71 (3H, s), 4.92 (1H, sept, J=7.0 Hz), 6.33 (1H, d, J=9.5 Hz ), 6.94-7.02 (3H, m), 7.30-7.39 (2H, m), 7.65-7.71 (4H, m), 8.20 (1H, brs)\n\n \nExample 62\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (3-methoxyphenyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.00 (6H, d, J = 7.0 Hz), 3.71 (3H, s), 4.92 (1H, sept, J = 7.0 Hz), 6.33 (1H, d, J = 9.5 Hz), 6.94-7.02 (3H, m), 7.30-7.39 (2H, m), 7.65-7.71 (4H, m), 8.20 (1H, brs)\n\n\n\n\n\n\n \n \n実施例６３\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（２−メチルフェニル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.88 (6H, d, J=7.0 Hz), 1.99 (3H, s), 4.85 (1H, sept, J=7.0 Hz), 6.33 (1H, d, J=9.5 Hz), 7.11 (1H, d, J=2.5 Hz), 7.32 (4H, brs), 7.70 (3H, brs), 7.89 (1H, dd, J=2.5, 9.5 Hz), 8.23 (1H, brs)\n\nMS(ESI\n+\n) : 364[M+H]\n+\n, 405[M+H+MeCN]\n+\n\n\n \nExample 63\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (2-methylphenyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.88 (6H, d, J = 7.0 Hz), 1.99 (3H, s), 4.85 (1H, sept, J = 7.0 Hz), 6.33 (1H, d, J = 9.5 Hz), 7.11 (1H, d, J = 2.5 Hz), 7.32 (4H, brs), 7.70 (3H, brs), 7.89 (1H, dd, J = 2.5, 9.5 Hz), 8.23 (1H, brs ) \n MS (ESI \n+\n ): 364 [M + H] \n+\n , 405 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例６４\n \n\n  ３−アミノ−５−（２，３−ジフルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.97 (6H, d, J=7.0 Hz), 4.92 (1H, sept, J=7.0 Hz), 6.37 (1H, d, J=9.0 Hz), 7.34-7.79 (8H, m), 8.26 (1H, brs)\n\nMS(ESI\n+\n) : 386[M+H]\n+\n, 427[M+H+MeCN]\n+\n\n\n \nExample 64\n \n 3-Amino-5- (2,3-difluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.97 (6H, d, J = 7.0 Hz), 4.92 (1H, sept, J = 7.0 Hz), 6.37 (1H, d, J = 9.0 Hz), 7.34- 7.79 (8H, m), 8.26 (1H, brs) \n MS (ESI \n+\n ): 386 [M + H] \n+\n , 427 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例６５\n \n\n  ３−アミノ−５−（２，４−ジフルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.99 (6H, d, J=6.8 Hz), 4.93 (1H, sept, J=6.8 Hz), 6.36 (1H, d, J=9.0 Hz), 7.24-7.35 (3H, m), 7.65-7.77 (5H, m), 8.23 (1H, brs)\n\nMS(ESI\n+\n) : 386[M+H]\n+\n, 427[M+H+MeCN]\n+\n\n\n \nExample 65\n \n 3-Amino-5- (2,4-difluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.99 (6H, d, J = 6.8 Hz), 4.93 (1H, sept, J = 6.8 Hz), 6.36 (1H, d, J = 9.0 Hz), 7.24- 7.35 (3H, m), 7.65-7.77 (5H, m), 8.23 (1H, brs) \n MS (ESI \n+\n ): 386 [M + H] \n+\n , 427 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例６６\n \n\n  ３−アミノ−５−（２，５−ジフルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.99 (6H, d, J=7.0 Hz), 4.92 (1H, sept, J=7.0 Hz), 6.37 (1H, d, J=9.5 Hz), 7.24-7.40 (3H, m), 7.48-7.79 (5H, m), 8.25 (1H, brs)\n\nMS(ESI\n+\n) : 386[M+H]\n+\n, 427[M+H+MeCN]\n+\n\n\n \nExample 66\n \n 3-Amino-5- (2,5-difluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.99 (6H, d, J = 7.0 Hz), 4.92 (1H, sept, J = 7.0 Hz), 6.37 (1H, d, J = 9.5 Hz), 7.24- 7.40 (3H, m), 7.48-7.79 (5H, m), 8.25 (1H, brs) \n MS (ESI \n+\n ): 386 [M + H] \n+\n , 427 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例６７\n \n\n  ３−アミノ−５−（２−フリル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.25 (6H, d, J=6.8 Hz), 5.07 (1H, sept, J=6.8 Hz), 6.39 (1H, d, J=9.0 Hz), 6.61 (1H, dd, J=1.1, 3.5 Hz), 6.79 (1H, d, J=3.5 Hz), 7.55 (1H, dd, J=2.5, 9.5 Hz), 7.66 (3H, brs), 7.79 (2H, brs), 8.09 (1H, brs)\n\nMS(ESI\n+\n) : 340[M+H]\n+\n, 381[M+H+MeCN]\n+\n\n\n \nExample 67\n \n 3-Amino-5- (2-furyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.25 (6H, d, J = 6.8 Hz), 5.07 (1H, sept, J = 6.8 Hz), 6.39 (1H, d, J = 9.0 Hz), 6.61 ( 1H, dd, J = 1.1, 3.5 Hz), 6.79 (1H, d, J = 3.5 Hz), 7.55 (1H, dd, J = 2.5, 9.5 Hz), 7.66 (3H, brs), 7.79 (2H, brs ), 8.09 (1H, brs) \n MS (ESI \n+\n ): 340 [M + H] \n+\n , 381 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例６８\n \n\n  ３−アミノ−５−（３−フリル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.25 (6H, d, J=6.8 Hz), 5.07 (1H, sept, J=6.8 Hz), 6.39 (1H, d, J=9.0 Hz), 6.62 (1H, dd, J=2.0, 3.5 Hz), 6.79 (1H, d, J=3.5 Hz), 7.55(1H, dd, J=2.5, 9.5 Hz), 7.66 (3H, brs), 7.99 (2H, s), 8.09 (1H, brs)\n\nMS(ESI\n+\n) : 340[M+H]\n+\n, 381[M+H+MeCN]\n+\n\n\n \nExample 68\n \n 3-Amino-5- (3-furyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.25 (6H, d, J = 6.8 Hz), 5.07 (1H, sept, J = 6.8 Hz), 6.39 (1H, d, J = 9.0 Hz), 6.62 ( 1H, dd, J = 2.0, 3.5 Hz), 6.79 (1H, d, J = 3.5 Hz), 7.55 (1H, dd, J = 2.5, 9.5 Hz), 7.66 (3H, brs), 7.99 (2H, s ), 8.09 (1H, brs) \n MS (ESI \n+\n ): 340 [M + H] \n+\n , 381 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例６９\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（２−チエニル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.23 (6H, d, J=6.8 Hz), 5.07 (1H, sept, J=6.8 Hz), 6.42 (1H, d, J=9.5 Hz), 7.04-7.06 (1H, m), 7.16-7.17 (1H, m), 7.49 (1H, d, J=2.5 Hz), 7.54 (1H, d, J=2.5 Hz), 7.65 (2H, brs), 7.69 (1H, d, J=5.5 Hz), 7.87 (1H, d, J=2.5 Hz), 8.06 (1H, brs)\n\nMS(ESI\n+\n) : 356[M+H]\n+\n, 397[M+H+MeCN]\n+\n\n\n \nExample 69\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (2-thienyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.23 (6H, d, J = 6.8 Hz), 5.07 (1H, sept, J = 6.8 Hz), 6.42 (1H, d, J = 9.5 Hz), 7.04- 7.06 (1H, m), 7.16-7.17 (1H, m), 7.49 (1H, d, J = 2.5 Hz), 7.54 (1H, d, J = 2.5 Hz), 7.65 (2H, brs), 7.69 (1H , d, J = 5.5 Hz), 7.87 (1H, d, J = 2.5 Hz), 8.06 (1H, brs) \n MS (ESI \n+\n ): 356 [M + H] \n+\n , 397 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例７０\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（３−チエニル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.12 (6H, d, J=7.0 Hz), 4.98 (1H, sept, J=7.0 Hz), 6.36 (1H, d, J=9.0 Hz), 7.12 (1H, dd, J=1.3, 5.0 Hz), 7.54-7.71 (7H, m), 8.14 (1H, brs)\n\nMS(ESI\n+\n) : 356[M+H]\n+\n, 397[M+H+MeCN]\n+\n\n\n \nExample 70\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (3-thienyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.12 (6H, d, J = 7.0 Hz), 4.98 (1H, sept, J = 7.0 Hz), 6.36 (1H, d, J = 9.0 Hz), 7.12 ( 1H, dd, J = 1.3, 5.0 Hz), 7.54-7.71 (7H, m), 8.14 (1H, brs) \n MS (ESI \n+\n ): 356 [M + H] \n+\n , 397 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例７１\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（５−メチル−２−チエニル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.26 (6H, d, J=6.5 Hz), 2.44 (3H, s), 5.08 (1H, sept, J=6.8 Hz), 6.41 (1H, d, J=9.5 Hz), 6.76 ( 1H, d, J=2.5 Hz), 6.98 (1H, d, J=3.5 Hz), 7.47 (1H, d, J=2.5 Hz), 7.52 (1H, d, J=2.5 Hz), 7.61 (2H, brs), 7.89 (1H, d, J=2.5 Hz), 8.01 (1H, brs)\n\nMS(ESI\n+\n) : 370[M+H]\n+\n, 411[M+H+MeCN]\n+\n\n\n \nExample 71\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (5-methyl-2-thienyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.26 (6H, d, J = 6.5 Hz), 2.44 (3H, s), 5.08 (1H, sept, J = 6.8 Hz), 6.41 (1H, d, J = 9.5 Hz), 6.76 (1H, d, J = 2.5 Hz), 6.98 (1H, d, J = 3.5 Hz), 7.47 (1H, d, J = 2.5 Hz), 7.52 (1H, d, J = 2.5 Hz), 7.61 (2H, brs), 7.89 (1H, d, J = 2.5 Hz), 8.01 (1H, brs) \n MS (ESI \n+\n ): 370 [M + H] \n+\n , 411 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例７２\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（１Ｈ−ピラゾール−４−イル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.23 (6H, d, J=7.0 Hz), 5.06 (1H, sept, J=7.0 Hz), 6.40 (1H, d, J=9.5 Hz), 7.50 (1H, dd, J=2.5, 9.5 Hz), 7.57 (5H, brs), 7.80 (1H, d, J=2.5 Hz), 8.01 (1H, brs), 13.06 (1H, brs)\n\nMS(ESI\n+\n) : 362[M+Na]\n+\n, 701[2M+Na]\n+\n\n\n \nExample 72\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (1H-pyrazol-4-yl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.23 (6H, d, J = 7.0 Hz), 5.06 (1H, sept, J = 7.0 Hz), 6.40 (1H, d, J = 9.5 Hz), 7.50 ( 1H, dd, J = 2.5, 9.5 Hz), 7.57 (5H, brs), 7.80 (1H, d, J = 2.5 Hz), 8.01 (1H, brs), 13.06 (1H, brs) \n MS (ESI \n+\n ): 362 [M + Na] \n+\n , 701 [2M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例７３\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−［（Ｅ）−２−フェニルビニル］−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.32 (6H, d, J=6.5 Hz), 5.12 (1H, sept, J=6.5 Hz), 6.50 (1H, d, J=9.5 Hz), 7.20-7.43 (5H, m), 7.59-7.83 (6H, m), 7.90 (1H, d, J=2.5 Hz), 8.10 (1H, brs)\n\nMS(ESI\n+\n) : 398[M+Na]\n+\n, 773[2M+Na]\n+\n\n\n \nExample 73\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-[(E) -2-phenylvinyl] -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.32 (6H, d, J = 6.5 Hz), 5.12 (1H, sept, J = 6.5 Hz), 6.50 (1H, d, J = 9.5 Hz), 7.20- 7.43 (5H, m), 7.59-7.83 (6H, m), 7.90 (1H, d, J = 2.5 Hz), 8.10 (1H, brs) \n MS (ESI \n+\n ): 398 [M + Na] \n+\n , 773 [2M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例７４\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（３−ピリジル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.98 (6H, d, J=7.0 Hz), 4.93 (1H, sept, J=7.0 Hz), 6.36 (1H, d, J=9.5 Hz), 7.37-7.46 (3H, m), 7.66-7.75 (4H, m), 8.26 (1H, brs), 8.61-8.64 (2H, m)\n\nMS(ESI\n+\n) : 351[M+H]\n+\n, 392[M+H+MeCN]\n+\n\n\n \nExample 74\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (3-pyridyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.98 (6H, d, J = 7.0 Hz), 4.93 (1H, sept, J = 7.0 Hz), 6.36 (1H, d, J = 9.5 Hz), 7.37- 7.46 (3H, m), 7.66-7.75 (4H, m), 8.26 (1H, brs), 8.61-8.64 (2H, m) \n MS (ESI \n+\n ): 351 [M + H] \n+\n , 392 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例７５\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（４−ピリジル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.00 (6H, d, J=7.0 Hz), 4.93 (1H, sept, J=7.0 Hz), 6.35 (1H, d, J=9.5 Hz), 7.42-7.89 (7H, m), 8.23 (1H, brs), 8.57 (1H, dd, J=2.0, 5.0 Hz), 8.64 (1H, d, J=2.0 Hz)\n\nMS(ESI\n+\n) : 351[M+H]\n+\n, 392[M+H+MeCN]\n+\n\n\n \nExample 75\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (4-pyridyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.00 (6H, d, J = 7.0 Hz), 4.93 (1H, sept, J = 7.0 Hz), 6.35 (1H, d, J = 9.5 Hz), 7.42- 7.89 (7H, m), 8.23 (1H, brs), 8.57 (1H, dd, J = 2.0, 5.0 Hz), 8.64 (1H, d, J = 2.0 Hz) \n MS (ESI \n+\n ): 351 [M + H] \n+\n , 392 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例７６\n \n\n  ３−アミノ−５−（４−フルオロフェニル）−６−（１−メチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.46 (3H, s), 6.17 (1H, d, J=9.5 Hz), 7.00 (1H, dd, J=2.5, 9.5 Hz), 7.25 (2H, t, J=9 Hz), 7.51-7.73 (5H, m), 8.15 (1H, d, J=2.5 Hz), 8.27 (1H, brs)\n\nMS(ESI\n+\n) : 362[M+Na]\n+\n, 701[2M+Na]\n+\n\n\n \nExample 76\n \n 3-Amino-5- (4-fluorophenyl) -6- (1-methyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.46 (3H, s), 6.17 (1H, d, J = 9.5 Hz), 7.00 (1H, dd, J = 2.5, 9.5 Hz), 7.25 (2H, t , J = 9 Hz), 7.51-7.73 (5H, m), 8.15 (1H, d, J = 2.5 Hz), 8.27 (1H, brs) \n MS (ESI \n+\n ): 362 [M + Na] \n+\n , 701 [2M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例７７\n \n\n  ３−アミノ−５−（２−フリル）−６−（１−メチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.50 (3H, s), 6.33 (1H, d, J=9.0 Hz), 6.63 (1H, dd, J=1.8, 3.5 Hz), 6.83 (1H, d, J=3.5 Hz), 7.28 (1H, dd, J=2.5, 9.5 Hz), 7.69-7.79 (4H, m), 8.10 (1H, d, J=2.5 Hz), 8.16 (1H, brs)\n\nMS(ESI\n+\n) : 334[M+Na]\n+\n\n\n \nExample 77\n \n 3-Amino-5- (2-furyl) -6- (1-methyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.50 (3H, s), 6.33 (1H, d, J = 9.0 Hz), 6.63 (1H, dd, J = 1.8, 3.5 Hz), 6.83 (1H, d , J = 3.5 Hz), 7.28 (1H, dd, J = 2.5, 9.5 Hz), 7.69-7.79 (4H, m), 8.10 (1H, d, J = 2.5 Hz), 8.16 (1H, brs) \n MS (ESI \n+\n ): 334 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例７８\n \n\n  ３−アミノ−６−（１−メチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（２−チエニル）−２−ピラジンカルボキサミド\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.50 (3H, s), 6.35 (1H, d, J=9.5 Hz), 7.04-7.09 (1H, m), 7.19-7.21 (1H, m), 7.35 (1H, dd, J=2.5, 9.5 Hz), 7.66 (1H, brs), 7.70-7.72 (3H, m), 8.12-8.13 (2H, m)\n\nMS(ESI\n+\n) : 350[M+Na]\n+\n\n\n \nExample 78\n \n 3-Amino-6- (1-methyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (2-thienyl) -2-pyrazinecarboxamide \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.50 (3H, s), 6.35 (1H, d, J = 9.5 Hz), 7.04-7.09 (1H, m), 7.19-7.21 (1H, m), 7.35 (1H, dd, J = 2.5, 9.5 Hz), 7.66 (1H, brs), 7.70-7.72 (3H, m), 8.12-8.13 (2H, m) \n MS (ESI \n+\n ): 350 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例７９\n \n\n  ３−アミノ−５−クロロ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド（２００ｍｇ）、エチニルベンゼン（３３１ｍｇ）、ＮＥｔ\n３\n（６５８ｍｇ）、トリフェニルホスフィン（１７ｍｇ）、ＣｕＩ（６．２ｍｇ）とＰｄＣｌ\n２\n（ＰＰｈ\n３\n）\n２\n（２３ｍｇ）のＤＭＦ（２ｍｌ）中の混合物を８０℃で１８時間加熱した。水（２０ｍｌ）とＥｔＯＡｃ（２０ｍｌ）を反応混合物に注ぎ、水溶液をＥｔＯＡｃで抽出した。有機層を水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。濾過後、溶媒を減圧除去した。残留固形物を、ＣＨＣｌ\n３\n−ＭｅＯＨ（９７：３）を溶離溶媒として用いるシリカゲルカラムに入れた。溶離溶媒を留去し、残留物をＩＰＥで懸濁し、濾過して、３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（フェニルエチニル）−２−ピラジンカルボキサミド（２１８ｍｇ）を黄色粉末として得た。\n\nMS(ESI\n+\n) : 396[M+Na]\n+\n, 769[2M+Na]\n+\n\n\n \nExample 79\n \n 3-amino-5-chloro-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide (200 mg), ethynylbenzene (331 mg), NEt \n3\n (658 mg), A mixture of triphenylphosphine (17 mg), CuI (6.2 mg) and PdCl \n2\n (PPh \n3\n ) \n2\n (23 mg) in DMF (2 ml) was heated at 80 ° C. for 18 hours. Water (20 ml) and EtOAc (20 ml) were poured into the reaction mixture and the aqueous solution was extracted with EtOAc. The organic layer was washed with water and brine and dried over MgSO \n4\n . After filtration, the solvent was removed under reduced pressure. The residual solid was loaded onto a silica gel column using CHCl \n3\n -MeOH (97: 3) as the eluting solvent. The elution solvent was distilled off and the residue was suspended in IPE, filtered and 3-amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (phenylethynyl). ) -2-pyrazinecarboxamide (218 mg) was obtained as a yellow powder. \n MS (ESI \n+\n ): 396 [M + Na] \n+\n , 769 [2M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例８０\n \n\n  ３−アミノ−５−クロロ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド（２００ｍｇ）、２−（トリブチルスタニル）ピリジン（３１１ｍｇ）とＰｄ（ＰＰｈ\n３\n）\n４\n（２２．５ｍｇ）のトルエン溶液を５時間還流した。水（２０ｍｌ）とＥｔＯＡｃ（１５ｍｌ）を反応混合物に注ぎ、水溶液をＥｔＯＡｃで抽出した。有機層を水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。濾過後、溶媒を減圧除去した。残留固形物を、ＣＨＣｌ\n３\n−ＭｅＯＨ（９７：３）を溶離溶媒として用いるシリカゲルカラムに入れた。溶離溶媒を留去し、残留物をＩＰＥで懸濁し、濾過して、３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（２−ピリジル）−２−ピラジンカルボキサミド（６４ｍｇ）を黄色粉末として得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.01 (6H, d, J=6.5 Hz), 4.93 (1H, sept, J=6.5 Hz), 6.30 (1H, d, J=9.5 Hz), 7.35-7.46 (2H, m), 7.59-7.75 (5H, m), 7.96 (1H, dt, J=1.7, 7.8 Hz), 8.24 (1H, brs), 8.55 (1H, d, J=4.5 Hz)\n\nMS(ESI\n+\n) : 351[M+H]\n+\n\n\n \nExample 80\n \n 3-amino-5-chloro-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide (200 mg), 2- (tributylstannyl) pyridine (311 mg) and A toluene solution of Pd (PPh \n3\n ) \n4\n (22.5 mg) was refluxed for 5 hours. Water (20 ml) and EtOAc (15 ml) were poured into the reaction mixture and the aqueous solution was extracted with EtOAc. The organic layer was washed with water and brine and dried over MgSO \n4\n . After filtration, the solvent was removed under reduced pressure. The residual solid was loaded onto a silica gel column using CHCl \n3\n -MeOH (97: 3) as the eluting solvent. The elution solvent was distilled off, the residue was suspended in IPE, filtered and 3-amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (2- Pyridyl) -2-pyrazinecarboxamide (64 mg) was obtained as a yellow powder. \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.01 (6H, d, J = 6.5 Hz), 4.93 (1H, sept, J = 6.5 Hz), 6.30 (1H, d, J = 9.5 Hz), 7.35- 7.46 (2H, m), 7.59-7.75 (5H, m), 7.96 (1H, dt, J = 1.7, 7.8 Hz), 8.24 (1H, brs), 8.55 (1H, d, J = 4.5 Hz) \n MS (ESI \n+\n ): 351 [M + H] \n+\n \n\n\n\n\n\n\n \n \n実施例８１\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（４−メトキシフェニル）−２−ピラジンカルボキサミド（２１０ｍｇ）のジオキサン（２ｍｌ）中の懸濁液に、ＮａＯＨ水溶液（２Ｍ、４ｍｌ）を加え、この溶液を１００℃で４時間加熱した。この反応混合物を室温まで冷却し、この溶液のｐＨを２ＮＨＣｌ水溶液で２．５に調整した。沈殿物を濾取し、水で洗浄して、３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（４−メトキシフェニル）−２−ピラジンカルボン酸（２０３ｍｇ）を黄色粉末として得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.03 (1H, d, J=7 Hz), 3.77 (3H, s), 4.94 (1H, sept, J=7.0 Hz), 6.36 (1H, d, J=9.5 Hz), 6.98 (2H, d, J=9.0 Hz), 7.41-7.56 (6H, m), 12.91 (1H, brs)\n\nMS(ESI\n+\n) : 381[M+H]\n+\n, 422[M+H+MeCN]\n+\n \n\n  下記の２４個の化合物を実施例８１と同様の方法にしたがって得た。\n\n \nExample 81\n \n Suspension of 3-amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (4-methoxyphenyl) -2-pyrazinecarboxamide (210 mg) in dioxane (2 ml) To the suspension was added aqueous NaOH (2M, 4 ml) and the solution was heated at 100 ° C. for 4 hours. The reaction mixture was cooled to room temperature and the pH of the solution was adjusted to 2.5 with 2N aqueous HCl. The precipitate was filtered off and washed with water to give 3-amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (4-methoxyphenyl) -2- Pyrazinecarboxylic acid (203 mg) was obtained as a yellow powder. \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.03 (1H, d, J = 7 Hz), 3.77 (3H, s), 4.94 (1H, sept, J = 7.0 Hz), 6.36 (1H, d, J = 9.5 Hz), 6.98 (2H, d, J = 9.0 Hz), 7.41-7.56 (6H, m), 12.91 (1H, brs) \n MS (ESI \n+\n ): 381 [M + H] \n+\n , 422 [M + H + MeCN] \n+\n \n The following 24 compounds were obtained in the same manner as in Example 81.\n\n\n\n\n\n\n \n \n実施例８２\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（２−メトキシフェニル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.91 (6H, brs), 3.48 (3H, s), 4.87 (1H, sept, J=6.8 Hz), 6.35 (1H, d, J=9.5 Hz), 7.01 (1H, d, J=8 Hz), 7.10 (1H, t, J=7.5 Hz), 7.19 (1H, d, J=2.5 Hz), 7.38-7.49 (4H, m), 7.62 (1H, dd, J=2.5, 9.0 Hz), 12.93 (1H, brs)\n\nMS(ESI\n+\n) : 381[M+H]\n+\n, 422[M+H+MeCN]\n+\n\n\n \nExample 82\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (2-methoxyphenyl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.91 (6H, brs), 3.48 (3H, s), 4.87 (1H, sept, J = 6.8 Hz), 6.35 (1H, d, J = 9.5 Hz), 7.01 (1H, d, J = 8 Hz), 7.10 (1H, t, J = 7.5 Hz), 7.19 (1H, d, J = 2.5 Hz), 7.38-7.49 (4H, m), 7.62 (1H, dd , J = 2.5, 9.0 Hz), 12.93 (1H, brs) \n MS (ESI \n+\n ): 381 [M + H] \n+\n , 422 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例８３\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（３−メトキシフェニル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.99 (6H, d, J=7 Hz), 3.70 (3H, s), 4.92 (1H, sept, J=7.0 Hz), 6.37 (1H, d, J=9.5 Hz), 6.95-7.04 (3H, m), 7.30-7.38 (2H, m), 7.50 (2H, brs), 7.58 (1H, dd, J=2.5, 9.0 Hz), 13 (1H, brs)\n\nMS(ESI\n+\n) : 381[M+H]\n+\n, 422[M+H+MeCN]\n+\n\n\n \nExample 83\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (3-methoxyphenyl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.99 (6H, d, J = 7 Hz), 3.70 (3H, s), 4.92 (1H, sept, J = 7.0 Hz), 6.37 (1H, d, J = 9.5 Hz), 6.95-7.04 (3H, m), 7.30-7.38 (2H, m), 7.50 (2H, brs), 7.58 (1H, dd, J = 2.5, 9.0 Hz), 13 (1H, brs) \n MS (ESI \n+\n ): 381 [M + H] \n+\n , 422 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例８４\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（２−メチルフェニル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.88 (6H, d, J=7.0 Hz), 1.99 (3H, s), 4.85 (1H, t, J=7.0 Hz), 6.37 (1H, d, J=9.5 Hz), 7.09 (1H, d, J=2.5 Hz), 7.26 - 7.40 (4H, m), 7.49 (2H, brs), 7.73 (1H, dd, J=2.5, 9.5 Hz), 13.05 (1H, brs)\n\n \nExample 84\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (2-methylphenyl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.88 (6H, d, J = 7.0 Hz), 1.99 (3H, s), 4.85 (1H, t, J = 7.0 Hz), 6.37 (1H, d, J = 9.5 Hz), 7.09 (1H, d, J = 2.5 Hz), 7.26-7.40 (4H, m), 7.49 (2H, brs), 7.73 (1H, dd, J = 2.5, 9.5 Hz), 13.05 (1H , brs)\n\n\n\n\n\n\n \n \n実施例８５\n \n\n  ３−アミノ−５−（２，３−ジフルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.95 (6H, d, J=3.5 Hz), 4.92 (1H, sept, J=3.5 Hz), 6.40 (1H, d, J=4.7 Hz), 7.30 (1H, d, J=1.1 Hz), 7.34-7.63 (6H, m), 13.20 (1H, brs)\n\nMS(ESI\n+\n) : 387[M+H]\n+\n, 428[M+H+MeCN]\n+\n\n\n \nExample 85\n \n 3-Amino-5- (2,3-difluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.95 (6H, d, J = 3.5 Hz), 4.92 (1H, sept, J = 3.5 Hz), 6.40 (1H, d, J = 4.7 Hz), 7.30 ( 1H, d, J = 1.1 Hz), 7.34-7.63 (6H, m), 13.20 (1H, brs) \n MS (ESI \n+\n ): 387 [M + H] \n+\n , 428 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例８６\n \n\n  ３−アミノ−５−（２，４−ジフルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.97 (6H, d, J=3.4 Hz), 4.92 (1H, sept, J=3.4 Hz), 6.39 (1H, d, J=4.8 Hz), 7.26-7.33 (3H, m), 7.56 (2H, brs), 7.61 (1H, dd, J=1.3, 4.8 Hz), 7.68-7.74 (1H, m), 13.15 (1H, brs)\n\nMS(ESI\n+\n) : 387[M+H]\n+\n, 428[M+H+MeCN]\n+\n\n\n \nExample 86\n \n 3-Amino-5- (2,4-difluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.97 (6H, d, J = 3.4 Hz), 4.92 (1H, sept, J = 3.4 Hz), 6.39 (1H, d, J = 4.8 Hz), 7.26- 7.33 (3H, m), 7.56 (2H, brs), 7.61 (1H, dd, J = 1.3, 4.8 Hz), 7.68-7.74 (1H, m), 13.15 (1H, brs) \n MS (ESI \n+\n ): 387 [M + H] \n+\n , 428 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例８７\n \n\n  ３−アミノ−５−（２，５−ジフルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.97 (6H, d, J=3.5 Hz), 4.92 (1H, sept, J=3.5 Hz), 6.4 (1H, d, J=4.8 Hz), 7.25-7.38 (3H, m), 7.51-7.55 (1H, m), 7.58 (2H, brs), 7.62 (1H, dd, J=1.3, 4.8 Hz), 13.19 (1H, brs)\n\nMS(ESI\n+\n) : 387[M+H]\n+\n, 428[M+H+MeCN]\n+\n\n\n \nExample 87\n \n 3-Amino-5- (2,5-difluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.97 (6H, d, J = 3.5 Hz), 4.92 (1H, sept, J = 3.5 Hz), 6.4 (1H, d, J = 4.8 Hz), 7.25- 7.38 (3H, m), 7.51-7.55 (1H, m), 7.58 (2H, brs), 7.62 (1H, dd, J = 1.3, 4.8 Hz), 13.19 (1H, brs) \n MS (ESI \n+\n ): 387 [M + H] \n+\n , 428 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例８８\n \n\n  ３−アミノ−５−（２−フリル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.24 (6H, d, J=6.5 Hz), 5.09 (1H, sept, J=6.5 Hz), 6.43 (1H, d, J=9 Hz), 6.62 (1H, dd, J=2, 3.5 Hz), 6.77 (1H, d, J=3 Hz), 7.45-7.51 (3H, m), 7.75-7.82 (2H, m)\n\n \nExample 88\n \n 3-Amino-5- (2-furyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.24 (6H, d, J = 6.5 Hz), 5.09 (1H, sept, J = 6.5 Hz), 6.43 (1H, d, J = 9 Hz), 6.62 ( 1H, dd, J = 2, 3.5 Hz), 6.77 (1H, d, J = 3 Hz), 7.45-7.51 (3H, m), 7.75-7.82 (2H, m)\n\n\n\n\n\n\n \n \n実施例８９\n \n\n  ３−アミノ−５−（３−フリル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.21 (6H, d, J=3.5 Hz), 5.06 (1H, sept, J=3.5 Hz), 6.43 (1H, d, J=4.8 Hz), 6.54 (1H, d, J=0.9 Hz), 7.44 (2H, brs), 7.48 (1H, dd, J=1.3, 4.8 Hz), 7.72-7.77 (3H, m), 12.95 (1H, brs)\n\nMS(ESI\n+\n) : 341[M+H]\n+\n, 382[M+H+MeCN]\n+\n\n\n \nExample 89\n \n 3-Amino-5- (3-furyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.21 (6H, d, J = 3.5 Hz), 5.06 (1H, sept, J = 3.5 Hz), 6.43 (1H, d, J = 4.8 Hz), 6.54 ( 1H, d, J = 0.9 Hz), 7.44 (2H, brs), 7.48 (1H, dd, J = 1.3, 4.8 Hz), 7.72-7.77 (3H, m), 12.95 (1H, brs) \n MS (ESI \n+\n ): 341 [M + H] \n+\n , 382 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例９０\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（２−チエニル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.22 (6H, d, J=7.0 Hz), 5.08 (1H, sept, J=7.0 Hz), 6.46 (1H, d, J=9.0 Hz), 7.05-7.09 (1H, m), 7.2 (1H, dd, J=1.0, 4.0 Hz), 7.42-7.48 (3H, m), 7.73 (1H, dd, J=1.0, 5.0 Hz), 7.83 (1H, d, J=2.5 Hz), 13.00 (1H, brs)\n\nMS(ESI\n+\n) : 357[M+H]\n+\n, 398[M+H+MeCN]\n+\n\n\n \nExample 90\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (2-thienyl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.22 (6H, d, J = 7.0 Hz), 5.08 (1H, sept, J = 7.0 Hz), 6.46 (1H, d, J = 9.0 Hz), 7.05- 7.09 (1H, m), 7.2 (1H, dd, J = 1.0, 4.0 Hz), 7.42-7.48 (3H, m), 7.73 (1H, dd, J = 1.0, 5.0 Hz), 7.83 (1H, d, J = 2.5 Hz), 13.00 (1H, brs) \n MS (ESI \n+\n ): 357 [M + H] \n+\n , 398 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例９１\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（３−チエニル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.10 (6H, d, J=6.5 Hz), 4.98 (1H, sept, J=6.5 Hz), 6.37-6.43 (1H, m), 7.13 (1H, dd, J=1.5, 5.0 Hz), 7.46-7.60 (5H, m), 7.72 (1H, dd, J=1.3, 3 Hz)\n\nMS(ESI\n+\n) : 357[M+H]\n+\n, 398[M+H+MeCN]\n+\n\n\n \nExample 91\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (3-thienyl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.10 (6H, d, J = 6.5 Hz), 4.98 (1H, sept, J = 6.5 Hz), 6.37-6.43 (1H, m), 7.13 (1H, dd , J = 1.5, 5.0 Hz), 7.46-7.60 (5H, m), 7.72 (1H, dd, J = 1.3, 3 Hz) \n MS (ESI \n+\n ): 357 [M + H] \n+\n , 398 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例９２\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（５−メチル−２−チエニル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.25 (6H, d, J=7.0 Hz), 5.09 (1H, sept, J=7.0 Hz), 2.44 (3H, s), 6.45 (1H, d, J=9.5 Hz), 6.77-6.78 (1H, m), 7.01 (1H, d, J=3.5 Hz), 7.40-7.46 (3H, m), 7.85 (1H, d, J=2.5 Hz), 12.98 (1H, brs)\n\nMS(ESI\n+\n) : 371[M+H]\n+\n, 412[M+H+MeCN]\n+\n\n\n \nExample 92\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (5-methyl-2-thienyl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.25 (6H, d, J = 7.0 Hz), 5.09 (1H, sept, J = 7.0 Hz), 2.44 (3H, s), 6.45 (1H, d, J = 9.5 Hz), 6.77-6.78 (1H, m), 7.01 (1H, d, J = 3.5 Hz), 7.40-7.46 (3H, m), 7.85 (1H, d, J = 2.5 Hz), 12.98 (1H , brs) \n MS (ESI \n+\n ): 371 [M + H] \n+\n , 412 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例９３\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（１Ｈ−ピラゾール−４−イル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.23 (1H, d, J=7.0 Hz), 5.07 (1H, sept, J=7.0 Hz), 6.44 (1H, d, J=9.0 Hz), 7.37 (2H, brs), 7.43 (1H, dd, J=2.5, 9.0 Hz), 7.66 (2H, s), 7.77 (1H, d, J=2.5 Hz), 12.99 (1H, brs)\n\nMS(ESI\n-\n) : 339[M-H]\n-\n\n\n \nExample 93\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (1H-pyrazol-4-yl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.23 (1H, d, J = 7.0 Hz), 5.07 (1H, sept, J = 7.0 Hz), 6.44 (1H, d, J = 9.0 Hz), 7.37 ( 2H, brs), 7.43 (1H, dd, J = 2.5, 9.0 Hz), 7.66 (2H, s), 7.77 (1H, d, J = 2.5 Hz), 12.99 (1H, brs) \n \nMS (ESI -): 339 [\n MH] -\n\n\n\n\n\n\n \n \n実施例９４\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−［（Ｅ）−２−フェニルビニル］−２−ピラジンカルボン酸\n\nMS(ESI\n-\n) : 375[M-H]\n-\n\n\n \nExample 94\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-[(E) -2-phenylvinyl] -2-pyrazinecarboxylic acid \n \nMS (ESI -): 375 [\n MH] -\n\n\n\n\n\n\n \n \n実施例９５\n \n\n  ３−アミノ−５−（４−フルオロフェニル）−６−（１−メチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.43 (3H, s), 6.22 (1H, d, J=9.5 Hz), 7.05 (1H, dd, J=2.8, 9.5 Hz), 7.26 (2H, t, J=8.8 Hz), 7.50 (2H, brs), 7.55 (2H, dd, J=5.5, 9.0 Hz), 7.92 (1H, d, J=2.5 Hz)\n\n \nExample 95\n \n 3-Amino-5- (4-fluorophenyl) -6- (1-methyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.43 (3H, s), 6.22 (1H, d, J = 9.5 Hz), 7.05 (1H, dd, J = 2.8, 9.5 Hz), 7.26 (2H, t , J = 8.8 Hz), 7.50 (2H, brs), 7.55 (2H, dd, J = 5.5, 9.0 Hz), 7.92 (1H, d, J = 2.5 Hz)\n\n\n\n\n\n\n \n \n実施例９６\n \n\n  ３−アミノ−５−（２−フリル）−６−（１−メチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボン酸\n\nMS(ESI\n-\n) : 311[M-H]\n-\n\n\n \nExample 96\n \n 3-Amino-5- (2-furyl) -6- (1-methyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxylic acid \n \nMS (ESI -): 311 [\n MH] -\n\n\n\n\n\n\n \n \n実施例９７\n \n\n  ３−アミノ−６−（１−メチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（２−チエニル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.49 (3H, s), 6.40 (1H, d, J=9.5 Hz), 7.08 (1H, dd, J=4.0, 5.0 Hz), 7.22 (1H, dd, J=1.0, 4.0 Hz), 7.36 (1H, dd, J=2.8, 9.5 Hz), 7.48 (2H, brs), 7.74 (1H, dd, J=1.0, 5.0 Hz), 7.97 (1H, d, J=2.5 Hz)\n\n \nExample 97\n \n 3-Amino-6- (1-methyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (2-thienyl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.49 (3H, s), 6.40 (1H, d, J = 9.5 Hz), 7.08 (1H, dd, J = 4.0, 5.0 Hz), 7.22 (1H, dd , J = 1.0, 4.0 Hz), 7.36 (1H, dd, J = 2.8, 9.5 Hz), 7.48 (2H, brs), 7.74 (1H, dd, J = 1.0, 5.0 Hz), 7.97 (1H, d, (J = 2.5 Hz)\n\n\n\n\n\n\n \n \n実施例９８\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（フェニルエチニル）−２−ピラジンカルボン酸\n\nMS(ESI\n-\n) : 373[M-H]\n-\n\n\n \nExample 98\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (phenylethynyl) -2-pyrazinecarboxylic acid \n \nMS (ESI -): 373 [\n MH] -\n\n\n\n\n\n\n \n \n実施例９９\n \n\n  ３−アミノ−５−（２−フルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.92 (1H, d, J=7.0 Hz), 4.88 (1H, sept, J=7.0 Hz), 6.38 (1H, d, J=9.5 Hz), 7.18-7.69 (8H, m), 13.12 (1H, brs)\n\nMS(ESI\n+\n) : 369[M+H]\n+\n, 410[M+H+MeCN]\n+\n\n\n \nExample 99\n \n 3-Amino-5- (2-fluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.92 (1H, d, J = 7.0 Hz), 4.88 (1H, sept, J = 7.0 Hz), 6.38 (1H, d, J = 9.5 Hz), 7.18- 7.69 (8H, m), 13.12 (1H, brs) \n MS (ESI \n+\n ): 369 [M + H] \n+\n , 410 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１００\n \n\n  ３−アミノ−５−（３−フルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.99 (6H, d, J=6.5 Hz), 4.93 (1H, t, J=6.5 Hz), 6.38 (1H, d, J=9.0 Hz), 7.22-7.60 (8H, m), 13.07 (1H, brs)\n\nMS(ESI\n+\n) : 369[M+H]\n+\n, 410[M+H+MeCN]\n+\n\n\n \nExample 100\n \n 3-Amino-5- (3-fluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.99 (6H, d, J = 6.5 Hz), 4.93 (1H, t, J = 6.5 Hz), 6.38 (1H, d, J = 9.0 Hz), 7.22- 7.60 (8H, m), 13.07 (1H, brs) \n MS (ESI \n+\n ): 369 [M + H] \n+\n , 410 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１０１\n \n\n  ３−アミノ−５−（３−クロロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.99 (1H, d, J=7.0 Hz), 4.94 (1H, sept, J=7.0 Hz), 6.39 (1H, d, J=9.5 Hz), 7.37-7.62 (8H, m), 13.06 (1H, brs)\n\nMS(ESI\n+\n) : 385[M+H]\n+\n, 426[M+H+MeCN]\n+\n\n\n \nExample 101\n \n 3-Amino-5- (3-chlorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.99 (1H, d, J = 7.0 Hz), 4.94 (1H, sept, J = 7.0 Hz), 6.39 (1H, d, J = 9.5 Hz), 7.37- 7.62 (8H, m), 13.06 (1H, brs) \n MS (ESI \n+\n ): 385 [M + H] \n+\n , 426 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１０２\n \n\n  ３−アミノ−５−（４−クロロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.00 (6H, d, J=7.0 Hz ), 4.94 (1H, t, J=7.0 Hz), 6.38 (1H, d, J=9.5 Hz), 7.34-7.59 (8H, m), 13.04 (1H, brs)\n\nMS(ESI\n+\n) : 385[M+H]\n+\n, 426[M+H+MeCN]\n+\n\n\n \nExample 102\n \n 3-Amino-5- (4-chlorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.00 (6H, d, J = 7.0 Hz), 4.94 (1H, t, J = 7.0 Hz), 6.38 (1H, d, J = 9.5 Hz), 7.34- 7.59 (8H, m), 13.04 (1H, brs) \n MS (ESI \n+\n ): 385 [M + H] \n+\n , 426 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１０３\n \n\n  ３−アミノ−５−（３，４−ジフルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.03 (6H, d, J=7.0 Hz), 4.96 (1H, sept, J=6.8 Hz), 6.39 (1H, d, J=9.0 Hz), 7.30-7.61 (7H, m), 13.06 (1H, brs)\n\nMS(ESI\n+\n) : 387[M+H]\n+\n, 428[M+H+MeCN]\n+\n\n\n \nExample 103\n \n 3-Amino-5- (3,4-difluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.03 (6H, d, J = 7.0 Hz), 4.96 (1H, sept, J = 6.8 Hz), 6.39 (1H, d, J = 9.0 Hz), 7.30- 7.61 (7H, m), 13.06 (1H, brs) \n MS (ESI \n+\n ): 387 [M + H] \n+\n , 428 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１０４\n \n\n  ３−アミノ−５−（３，５−ジフルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.03 (1H, d, J=6.5 Hz), 4.97 (1H, sept, J=6.5 Hz), 6.40 (1H, d, J=9.5 Hz), 7.16-7.59 (7H, m), 13.16 (1H, brs)\n\nMS(ESI\n+\n) : 387[M+H]\n+\n, 428[M+H+MeCN]\n+\n\n\n \nExample 104\n \n 3-Amino-5- (3,5-difluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.03 (1H, d, J = 6.5 Hz), 4.97 (1H, sept, J = 6.5 Hz), 6.40 (1H, d, J = 9.5 Hz), 7.16- 7.59 (7H, m), 13.16 (1H, brs) \n MS (ESI \n+\n ): 387 [M + H] \n+\n , 428 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１０５\n \n\n  ３−アミノ−６−（１−メチル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボン酸\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.42 (3H, s), 6.18 (1H, d, J=9.0 Hz), 7.03 (1H, dd, J=2.8, 9.0 Hz), 7.38-7.53 (7H, m), 7.91 (1H, d, J=2.5 Hz)\n\n \nExample 105\n \n 3-Amino-6- (1-methyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxylic acid \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.42 (3H, s), 6.18 (1H, d, J = 9.0 Hz), 7.03 (1H, dd, J = 2.8, 9.0 Hz), 7.38-7.53 (7H , m), 7.91 (1H, d, J = 2.5 Hz)\n\n\n\n\n\n\n \n \n実施例１０６\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（４−メトキシフェニル）−２−ピラジンカルボン酸の１，２−ジクロロベンゼン（３ｍｌ）中懸濁液を２００℃に加熱し、４時間攪拌した。この反応混合物を室温まで冷却した。この溶液にＩＰＥを加え、室温で１時間攪拌した。沈殿物を濾取し、ＩＰＥで洗浄した。残留固形物を、ＣＨＣｌ\n３\n−ＭｅＯＨ（２０：１）を溶離溶媒として用いるシリカゲルカラムに入れた。溶離溶媒を留去し、残留物をＥｔＯＨ−水から再結晶して精製して、５−［５−アミノ−３−（４−メトキシフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（８８ｍｇ）を淡褐色結晶として得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.02 (6H, d, J=7.0 Hz), 3.75 (3H, s), 4.94 (1H, sept, J=7.0 Hz), 6.31 (1H, d, J=9.5 Hz), 6.55 (2H, brs), 6.94 (2H, d, J=9.0 Hz), 7.29-7.42 (4H, m), 7.87 (1H, s)\n\nMS(ESI\n+\n) : 337[M+H]\n+\n, 378[M+H+MeCN]\n+\n \n\n  下記の２４個の化合物を実施例１０６と同様の方法にしたがって得た。\n\n \nExample 106\n \n 1,2-dichlorobenzene of 3-amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (4-methoxyphenyl) -2-pyrazinecarboxylic acid (3 ml) The medium suspension was heated to 200 ° C. and stirred for 4 hours. The reaction mixture was cooled to room temperature. IPE was added to this solution and stirred at room temperature for 1 hour. The precipitate was collected by filtration and washed with IPE. The residual solid was loaded onto a silica gel column using CHCl \n3\n -MeOH (20: 1) as the eluting solvent. The elution solvent was distilled off and the residue was purified by recrystallization from EtOH-water to give 5- [5-amino-3- (4-methoxyphenyl) -2-pyrazinyl] -1-isopropyl-2 (1H ) -Pyridone (88 mg) was obtained as light brown crystals. \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.02 (6H, d, J = 7.0 Hz), 3.75 (3H, s), 4.94 (1H, sept, J = 7.0 Hz), 6.31 (1H, d, J = 9.5 Hz), 6.55 (2H, brs), 6.94 (2H, d, J = 9.0 Hz), 7.29-7.42 (4H, m), 7.87 (1H, s) \n MS (ESI \n+\n ): 337 [M + H] \n+\n , 378 [M + H + MeCN] \n+\n \n The following 24 compounds were obtained in the same manner as in Example 106.\n\n\n\n\n\n\n \n \n実施例１０７\n \n\n  ５−［５−アミノ−３−（２−メトキシフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.91 (6H, brs), 3.48 (3H, s), 4.87 (1H, sept, J=6.8 Hz), 6.31 (1H, d, J=9.0 Hz), 6.51 (2H, brs), 6.97-7.10 (3H, m), 7.33-7.51 (3H, m), 7.90 (1H, s)\n\nMS(ESI\n+\n) : 337[M+H]\n+\n, 378[M+H+MeCN]\n+\n\n\n \nExample 107\n \n 5- [5-Amino-3- (2-methoxyphenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.91 (6H, brs), 3.48 (3H, s), 4.87 (1H, sept, J = 6.8 Hz), 6.31 (1H, d, J = 9.0 Hz), 6.51 (2H, brs), 6.97-7.10 (3H, m), 7.33-7.51 (3H, m), 7.90 (1H, s) \n MS (ESI \n+\n ): 337 [M + H] \n+\n , 378 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１０８\n \n\n  ５−［５−アミノ−３−（３−メトキシフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.98 (6H, d, J=7.0 Hz), 3.69 (3H, s), 4.92 (1H, sept, J=7.0 Hz), 6.32 (1H, d, J=9.5 Hz), 6.61 (2H, brs), 6.89-6.95 (3H, m), 7.24-7.33 (3H, m), 7.43 (1H, dd, J=2.5, 9.5 Hz), 7.92 (1H, s)\n\n \nExample 108\n \n 5- [5-Amino-3- (3-methoxyphenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.98 (6H, d, J = 7.0 Hz), 3.69 (3H, s), 4.92 (1H, sept, J = 7.0 Hz), 6.32 (1H, d, J = 9.5 Hz), 6.61 (2H, brs), 6.89-6.95 (3H, m), 7.24-7.33 (3H, m), 7.43 (1H, dd, J = 2.5, 9.5 Hz), 7.92 (1H, s)\n\n\n\n\n\n\n \n \n実施例１０９\n \n\n  ５−［５−アミノ−３−（２−メチルフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.88 (6H, d, J=6.5 Hz), 1.97 (3H, s), 4.84 (1H, sept, J=6.5 Hz), 6.32 (1H, d, J=9.0 Hz), 6.58 (2H, brs), 7.02 (1H, d, J=2.5 Hz), 7.27 (4H, brs), 7.56 (1H, dd, J=2.5, 9.0 Hz), 7.95 (1H, s)\n\n \nExample 109\n \n 5- [5-Amino-3- (2-methylphenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.88 (6H, d, J = 6.5 Hz), 1.97 (3H, s), 4.84 (1H, sept, J = 6.5 Hz), 6.32 (1H, d, J = 9.0 Hz), 6.58 (2H, brs), 7.02 (1H, d, J = 2.5 Hz), 7.27 (4H, brs), 7.56 (1H, dd, J = 2.5, 9.0 Hz), 7.95 (1H, s )\n\n\n\n\n\n\n \n \n実施例１１０\n \n\n  ５−［５−アミノ−３−（２，３−ジフルオロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.96 (6H, d, J=7 Hz), 4.91 (1H, sept, J=7 Hz), 6.36 (1H, d, J=9.5 Hz), 6.75 (2H, brs), 7.2 (1H, d, J=2.5 Hz), 7.3-7.51 (4H, m), 8.01 (1H, s)\n\nMS(ESI\n+\n) : 343[M+H]\n+\n, 484[M+H+MeCN]\n+\n\n\n \nExample 110\n \n 5- [5-Amino-3- (2,3-difluorophenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.96 (6H, d, J = 7 Hz), 4.91 (1H, sept, J = 7 Hz), 6.36 (1H, d, J = 9.5 Hz), 6.75 ( 2H, brs), 7.2 (1H, d, J = 2.5 Hz), 7.3-7.51 (4H, m), 8.01 (1H, s) \n MS (ESI \n+\n ): 343 [M + H] \n+\n , 484 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１１１\n \n\n  ５−［５−アミノ−３−（２，４−ジフルオロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.97 (6H, d, J=7.0 Hz), 4.92 (1H, t, J=7.0 Hz), 6.35 (1H, d, J=9.0 Hz), 6.7 (2H, brs), 7.19-7.30 (3H, m), 7.47 (1H, dd, J=2.8, 9.0 Hz), 7.56-7.68 (1H, m), 7.97 (1H, s)\n\nMS(ESI\n+\n) : 343[M+H]\n+\n, 384[M+H+MeCN]\n+\n\n\n \nExample 111\n \n 5- [5-Amino-3- (2,4-difluorophenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.97 (6H, d, J = 7.0 Hz), 4.92 (1H, t, J = 7.0 Hz), 6.35 (1H, d, J = 9.0 Hz), 6.7 ( 2H, brs), 7.19-7.30 (3H, m), 7.47 (1H, dd, J = 2.8, 9.0 Hz), 7.56-7.68 (1H, m), 7.97 (1H, s) \n MS (ESI \n+\n ): 343 [M + H] \n+\n , 384 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１１２\n \n\n  ５−［５−アミノ−３−（２，５−ジフルオロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.97 (6H, d, J=6.8 Hz), 4.91 (1H, sept, J=6.8 Hz), 6.36 (1H, d, J=9.5 Hz), 6.73 (2H, brs), 7.21-7.30(3H, m), 7.44-7.52 (2H, m), 7.99 (1H, s)\n\nMS(ESI\n+\n) : 343[M+H]\n+\n, 384[M+H+MeCN]\n+\n\n\n \nExample 112\n \n 5- [5-Amino-3- (2,5-difluorophenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.97 (6H, d, J = 6.8 Hz), 4.91 (1H, sept, J = 6.8 Hz), 6.36 (1H, d, J = 9.5 Hz), 6.73 ( 2H, brs), 7.21-7.30 (3H, m), 7.44-7.52 (2H, m), 7.99 (1H, s) \n MS (ESI \n+\n ): 343 [M + H] \n+\n , 384 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１１３\n \n\n  ５−［５−アミノ−３−（２−フリル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.22 (6H, d, J=7.0 Hz), 5.06 (1H, sept, J=7.0 Hz), 6.38 (1H, d, J=9.0 Hz), 6.56 (1H, dd, J=1.8, 3.5 Hz), 6.65-6.66 (1H, m), 7.36 (3H, dd, J=2.8, 9.5 Hz), 7.58 (2H, d, J=2.5 Hz), 7.70 (1H, m), 7.87 (1H, s)\n\nMS(ESI\n+\n) : 297[M+H]\n+\n, 338[M+H+MeCN]\n+\n\n\n \nExample 113\n \n 5- [5-Amino-3- (2-furyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.22 (6H, d, J = 7.0 Hz), 5.06 (1H, sept, J = 7.0 Hz), 6.38 (1H, d, J = 9.0 Hz), 6.56 ( 1H, dd, J = 1.8, 3.5 Hz), 6.65-6.66 (1H, m), 7.36 (3H, dd, J = 2.8, 9.5 Hz), 7.58 (2H, d, J = 2.5 Hz), 7.70 (1H , m), 7.87 (1H, s) \n MS (ESI \n+\n ): 297 [M + H] \n+\n , 338 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１１４\n \n\n  ５−［５−アミノ−３−（３−フリル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.19 (6H, d, J=6.5 Hz), 5.04 (1H, sept, J=6.5 Hz), 6.4 (1H, d, J=12.0 Hz), 6.42 (1H, brs), 6.54 (2H, brs), 7.39 (1H, dd, J=2.5, 9.5 Hz), 7.59 (1H, d, J=2.5 Hz), 7.65-7.69 (2H, m), 7.84 (1H, brs)\n\nMS(ESI\n+\n) : 297[M+H]\n+\n, 338[M+H+MeCN]\n+\n\n\n \nExample 114\n \n 5- [5-Amino-3- (3-furyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.19 (6H, d, J = 6.5 Hz), 5.04 (1H, sept, J = 6.5 Hz), 6.4 (1H, d, J = 12.0 Hz), 6.42 ( 1H, brs), 6.54 (2H, brs), 7.39 (1H, dd, J = 2.5, 9.5 Hz), 7.59 (1H, d, J = 2.5 Hz), 7.65-7.69 (2H, m), 7.84 (1H , brs) \n MS (ESI \n+\n ): 297 [M + H] \n+\n , 338 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１１５\n \n\n  ５−［５−アミノ−３−（２−チエニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.20 (6H, d, J=6.5 Hz), 5.06 (1H, sept, J=6.5 Hz), 6.4 (1H, d, J=9.5 Hz), 6.63 (2H, brs), 6.99-7.04 (2H, m), 7.36 (1H, dd, J=2.5, 9.5 Hz), 7.59 (1H, dd, J=2.0, 4.5 Hz), 7.68 (1H, d, J=2.0 Hz), 7.84 (1H, s)\n\nMS(ESI\n+\n) : 313[M+H]\n+\n, 354[M+H+MeCN]\n+\n\n\n \nExample 115\n \n 5- [5-Amino-3- (2-thienyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.20 (6H, d, J = 6.5 Hz), 5.06 (1H, sept, J = 6.5 Hz), 6.4 (1H, d, J = 9.5 Hz), 6.63 ( 2H, brs), 6.99-7.04 (2H, m), 7.36 (1H, dd, J = 2.5, 9.5 Hz), 7.59 (1H, dd, J = 2.0, 4.5 Hz), 7.68 (1H, d, J = 2.0 Hz), 7.84 (1H, s) \n MS (ESI \n+\n ): 313 [M + H] \n+\n , 354 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１１６\n \n\n  ５−［５−アミノ−３−（３−チエニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.09 (6H, d, J=6.5 Hz), 4.97 (1H, sept, J=6.5 Hz), 6.35 (1H, d, J=9.5 Hz), 6.56 (2H, brs), 7.04 (1H, dd, J=1.3, 5.0 Hz), 7.38-7.44 (2H, m), 7.51-7.58 (2H, m), 7.87 (1H, s)\n\nMS(ESI\n+\n) : 313[M+H]\n+\n, 354[M+H+MeCN]\n+\n\n\n \nExample 116\n \n 5- [5-Amino-3- (3-thienyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.09 (6H, d, J = 6.5 Hz), 4.97 (1H, sept, J = 6.5 Hz), 6.35 (1H, d, J = 9.5 Hz), 6.56 ( 2H, brs), 7.04 (1H, dd, J = 1.3, 5.0 Hz), 7.38-7.44 (2H, m), 7.51-7.58 (2H, m), 7.87 (1H, s) \n MS (ESI \n+\n ): 313 [M + H] \n+\n , 354 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１１７\n \n\n  ５−［５−アミノ−３−（５−メチル−２−チエニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.22 (6H, d, J=6.5 Hz), 2.41 (3H, s), 5.07 (1H, sept, J=6.5 Hz), 6.40 (1H, d, J=9.5 Hz), 6.57 (2H, brs), 6.69-6.70 (1H, m), 6.84 (1H, d, J=3.5 Hz), 7.35 (1H, dd, J=2.5, 9.0 Hz), 7.70 (1H, d, J=2.5 Hz), 7.79 (1H, s)\n\nMS(ESI\n+\n) : 327[M+H]\n+\n, 368[M+H+MeCN]\n+\n\n\n \nExample 117\n \n 5- [5-Amino-3- (5-methyl-2-thienyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.22 (6H, d, J = 6.5 Hz), 2.41 (3H, s), 5.07 (1H, sept, J = 6.5 Hz), 6.40 (1H, d, J = 9.5 Hz), 6.57 (2H, brs), 6.69-6.70 (1H, m), 6.84 (1H, d, J = 3.5 Hz), 7.35 (1H, dd, J = 2.5, 9.0 Hz), 7.70 (1H , d, J = 2.5 Hz), 7.79 (1H, s) \n MS (ESI \n+\n ): 327 [M + H] \n+\n , 368 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１１８\n \n\n  ５−［５−アミノ−３−（１Ｈ−ピラゾール−４−イル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.20 (6H, d, J=6.5 Hz), 5.05 (1H, sept, J=6.5 Hz), 6.38 (1H, d, J=9.0 Hz), 6.45 (2H, brs), 7.34 (1H, dd, J=2.5, 9.0 Hz), 7.50-7.62 (3H, m), 7.77 (1H, s), 12.92 (1H, brs)\n\nMS(ESI\n+\n) : 319[M+Na]\n+\n, 615[2M+Na]\n+\n\n\n \nExample 118\n \n 5- [5-Amino-3- (1H-pyrazol-4-yl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.20 (6H, d, J = 6.5 Hz), 5.05 (1H, sept, J = 6.5 Hz), 6.38 (1H, d, J = 9.0 Hz), 6.45 ( 2H, brs), 7.34 (1H, dd, J = 2.5, 9.0 Hz), 7.50-7.62 (3H, m), 7.77 (1H, s), 12.92 (1H, brs) \n MS (ESI \n+\n ): 319 [M + Na] \n+\n , 615 [2M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１１９\n \n\n  ５−｛５−アミノ−３−［（Ｅ）−２−フェニルビニル］−２−ピラジニル｝−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.30 (6H, d, J=7.0 Hz), 5.13 (1H, sept, J=7.0 Hz), 6.49 (1H, d, J=9.5 Hz), 6.58 (2H, brs), 7.16 (1H, d, J=15.6 Hz), 7.29-7.40 (3H, m), 7.53-7.65 (4H, m), 7.74 (1H, d, J=2.0 Hz), 7.88 (1H, s)\n\nMS(ESI\n+\n) : 333[M+H]\n+\n, 355[M+Na]\n+\n, 687[2M+Na]\n+\n\n\n \nExample 119\n \n 5- {5-Amino-3-[(E) -2-phenylvinyl] -2-pyrazinyl} -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.30 (6H, d, J = 7.0 Hz), 5.13 (1H, sept, J = 7.0 Hz), 6.49 (1H, d, J = 9.5 Hz), 6.58 ( 2H, brs), 7.16 (1H, d, J = 15.6 Hz), 7.29-7.40 (3H, m), 7.53-7.65 (4H, m), 7.74 (1H, d, J = 2.0 Hz), 7.88 (1H , s) \n MS (ESI \n+\n ): 333 [M + H] \n+\n , 355 [M + Na] \n+\n , 687 [2M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１２０\n \n\n  ５−［５−アミノ−３−（４−フルオロフェニル）−２−ピラジニル］−１−メチル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.40 (3H, s), 6.20 (1H, d, J=9.5 Hz), 6.62 (2H, brs), 7.01 (1H, dd, J=2.5, 9.5 Hz), 7.21 (1H, t, J=8.5 Hz ), 7.46 (1H, dd, J=5.5, 8.5 Hz), 7.74 (1H, d, J=2.5 Hz), 7.90 (1H, s)\n\nMS(ESI\n+\n) : 297[M+H]\n+\n, 319[M+Na]\n+\n, 615[2M+Na]\n+\n\n\n \nExample 120\n \n 5- [5-Amino-3- (4-fluorophenyl) -2-pyrazinyl] -1-methyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.40 (3H, s), 6.20 (1H, d, J = 9.5 Hz), 6.62 (2H, brs), 7.01 (1H, dd, J = 2.5, 9.5 Hz) ), 7.21 (1H, t, J = 8.5 Hz), 7.46 (1H, dd, J = 5.5, 8.5 Hz), 7.74 (1H, d, J = 2.5 Hz), 7.90 (1H, s) \n MS (ESI \n+\n ): 297 [M + H] \n+\n , 319 [M + Na] \n+\n , 615 [2M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１２１\n \n\n  ５−［５−アミノ−３−（２−フリル）−２−ピラジニル］−１−メチル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.46 (3H, s), 6.33 (1H, d, J=9.5 Hz), 6.57 (1H, dd, J=1.5, 3.5 Hz), 6.65-6.68 (3H, m), 7.22 (1H, dd, J=2.5, 9.5 Hz), 7.69 (1H, s), 7.78 (1H, d, J=2.5 Hz), 7.85 (1H, s)\n\nMS(ESI\n+\n) : 269[M+H]\n+\n, 291[M+Na]\n+\n, 559[2M+Na]\n+\n\n\n \nExample 121\n \n 5- [5-Amino-3- (2-furyl) -2-pyrazinyl] -1-methyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.46 (3H, s), 6.33 (1H, d, J = 9.5 Hz), 6.57 (1H, dd, J = 1.5, 3.5 Hz), 6.65-6.68 (3H , m), 7.22 (1H, dd, J = 2.5, 9.5 Hz), 7.69 (1H, s), 7.78 (1H, d, J = 2.5 Hz), 7.85 (1H, s) \n MS (ESI \n+\n ): 269 [M + H] \n+\n , 291 [M + Na] \n+\n , 559 [2M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１２２\n \n\n  ５−［５−アミノ−３−（２−チエニル）−２−ピラジニル］−１−メチル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.46 (3H, s), 6.36 (1H, d, J=9.5 Hz), 6.64 (2H, brs), 6.99-7.07 (2H, m), 7.28 (1H, dd, J=2.5, 9.5 Hz), 7.60 (1H, d, J=3.5 Hz), 7.82 (1H, s), 7.85 (1H, d, J=2.5 Hz)\n\nMS(ESI\n+\n) : 307[M+Na]\n+\n, 591[2M+Na]\n+\n\n\n \nExample 122\n \n 5- [5-Amino-3- (2-thienyl) -2-pyrazinyl] -1-methyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.46 (3H, s), 6.36 (1H, d, J = 9.5 Hz), 6.64 (2H, brs), 6.99-7.07 (2H, m), 7.28 (1H , dd, J = 2.5, 9.5 Hz), 7.60 (1H, d, J = 3.5 Hz), 7.82 (1H, s), 7.85 (1H, d, J = 2.5 Hz) \n MS (ESI \n+\n ): 307 [M + Na] \n+\n , 591 [2M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１２３\n \n\n  ５−［５−アミノ−３−（フェニルエチニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.26 (6H, d, J=7.0 Hz), 5.06 (1H, t, J=7.0 Hz), 6.49 (1H, d, J=9.5 Hz), 6.75 (2H, brs), 7.43-7.54 (5H, m), 7.91 (1H, dd, J=2.5, 9.5 Hz), 7.95 (1H, s), 8.17 (1H, d, J=2.5 Hz)\n\nMS(ESI\n+\n) : 331[M+H]\n+\n, 353[M+Na]\n+\n, 683[2M+Na]\n+\n\n\n \nExample 123\n \n 5- [5-Amino-3- (phenylethynyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.26 (6H, d, J = 7.0 Hz), 5.06 (1H, t, J = 7.0 Hz), 6.49 (1H, d, J = 9.5 Hz), 6.75 ( 2H, brs), 7.43-7.54 (5H, m), 7.91 (1H, dd, J = 2.5, 9.5 Hz), 7.95 (1H, s), 8.17 (1H, d, J = 2.5 Hz) \n MS (ESI \n+\n ): 331 [M + H] \n+\n , 353 [M + Na] \n+\n , 683 [2M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１２４\n \n\n  ５−［５−アミノ−３−（２−フルオロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.92 (6H, d, J=7.0 Hz), 4.88 (1H, sept, J=7.0 Hz), 6.34 (1H, d, J=9.5 Hz), 6.67 (2H, brs), 7.15-7.60 (6H, m), 7.97 (1H, s)\n\nMS(ESI\n+\n) : 325[M+H]\n+\n, 366[M+H+MeCN]\n+\n\n\n \nExample 124\n \n 5- [5-Amino-3- (2-fluorophenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.92 (6H, d, J = 7.0 Hz), 4.88 (1H, sept, J = 7.0 Hz), 6.34 (1H, d, J = 9.5 Hz), 6.67 ( 2H, brs), 7.15-7.60 (6H, m), 7.97 (1H, s) \n MS (ESI \n+\n ): 325 [M + H] \n+\n , 366 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１２５\n \n\n  ５−［５−アミノ−３−（３−フルオロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.00 (6H, d, J=6.8 Hz), 4.94 (1H, sept, J=6.8 Hz), 6.35 (1H, d, J=9.0 Hz), 6.68 (2H, brs), 7.28-7.48 (6H, m), 7.95 (1H, s)\n\nMS(ESI\n+\n) : 341[M+H]\n+\n, 382[M+H+MeCN]\n+\n\n\n \nExample 125\n \n 5- [5-Amino-3- (3-fluorophenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.00 (6H, d, J = 6.8 Hz), 4.94 (1H, sept, J = 6.8 Hz), 6.35 (1H, d, J = 9.0 Hz), 6.68 ( 2H, brs), 7.28-7.48 (6H, m), 7.95 (1H, s) \n MS (ESI \n+\n ): 341 [M + H] \n+\n , 382 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１２６\n \n\n  ５−［５−アミノ−３−（３−クロロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.00 (6H, d, J=6.8 Hz), 4.94 (1H, sept, J=6.8 Hz), 6.35 (1H, d, J=9.0 Hz), 6.68 (2H, brs), 7.28-7.48 (6H, m), 7.95 (1H, s)\n\nMS(ESI\n+\n) : 341[M+H]\n+\n, 382[M+H+MeCN]\n+\n\n\n \nExample 126\n \n 5- [5-Amino-3- (3-chlorophenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.00 (6H, d, J = 6.8 Hz), 4.94 (1H, sept, J = 6.8 Hz), 6.35 (1H, d, J = 9.0 Hz), 6.68 ( 2H, brs), 7.28-7.48 (6H, m), 7.95 (1H, s) \n MS (ESI \n+\n ): 341 [M + H] \n+\n , 382 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１２７\n \n\n  ５−［５−アミノ−３−（４−クロロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.00 (6H, d, J=6.8 Hz), 4.93 (1H, sept, J=6.8 Hz), 6.34 (1H, d, J=9.5 Hz), 6.65 (2H, brs), 7.25 (1H, d, J=2.5 Hz), 7.38-7.48 (5H, m), 7.93 (1H, s)\n\nMS(ESI\n+\n) : 341[M+H]\n+\n, 382[M+H+MeCN]\n+\n\n\n \nExample 127\n \n 5- [5-Amino-3- (4-chlorophenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.00 (6H, d, J = 6.8 Hz), 4.93 (1H, sept, J = 6.8 Hz), 6.34 (1H, d, J = 9.5 Hz), 6.65 ( 2H, brs), 7.25 (1H, d, J = 2.5 Hz), 7.38-7.48 (5H, m), 7.93 (1H, s) \n MS (ESI \n+\n ): 341 [M + H] \n+\n , 382 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１２８\n \n\n  ５−［５−アミノ−３−（３，４−ジフルオロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.03 (6H, d, J=6.8 Hz), 4.96 (1H, sept, J=6.8 Hz), 6.35 (1H, d, J=9.5 Hz), 6.68 (2H, brs), 7.20-7.53 (6H, m), 7.95 (1H, s)\n\nMS(ESI\n+\n) : 343[M+H]\n+\n, 384[M+H+MeCN]\n+\n\n\n \nExample 128\n \n 5- [5-Amino-3- (3,4-difluorophenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.03 (6H, d, J = 6.8 Hz), 4.96 (1H, sept, J = 6.8 Hz), 6.35 (1H, d, J = 9.5 Hz), 6.68 ( 2H, brs), 7.20-7.53 (6H, m), 7.95 (1H, s) \n MS (ESI \n+\n ): 343 [M + H] \n+\n , 384 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１２９\n \n\n  ５−［５−アミノ−３−（３，５−ジフルオロフェニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.04 (6H, d, J=6.8 Hz), 4.96 (1H, sept, J=6.8 Hz), 6.37 (1H, d, J=9.0 Hz), 6.72 (2H, brs), 7.07-7.46 (5H, m), 7.97 (1H, s)\n\nMS(ESI\n+\n) : 343[M+H]\n+\n, 384[M+H+MeCN]\n+\n\n\n \nExample 129\n \n 5- [5-Amino-3- (3,5-difluorophenyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.04 (6H, d, J = 6.8 Hz), 4.96 (1H, sept, J = 6.8 Hz), 6.37 (1H, d, J = 9.0 Hz), 6.72 ( 2H, brs), 7.07-7.46 (5H, m), 7.97 (1H, s) \n MS (ESI \n+\n ): 343 [M + H] \n+\n , 384 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１３０\n \n\n  ５−（５−アミノ−３−フェニル−２−ピラジニル）−１−メチル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 3.38 (3H, s), 6.16 (1H, d, J=4.8 Hz), 6.60 (2H, brs), 6.99 (1H, dd, J=1.4, 4.8 Hz), 7.36-7.42 (5H, m), 7.72 (1H, d, J=1.4 Hz), 7.90 (1H, s)\n\n \nExample 130\n \n 5- (5-Amino-3-phenyl-2-pyrazinyl) -1-methyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 3.38 (3H, s), 6.16 (1H, d, J = 4.8 Hz), 6.60 (2H, brs), 6.99 (1H, dd, J = 1.4, 4.8 Hz) ), 7.36-7.42 (5H, m), 7.72 (1H, d, J = 1.4 Hz), 7.90 (1H, s)\n\n\n\n\n\n\n \n \n実施例１３１\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−（２−ピリジル）−２−ピラジン−カルボキサミド（５２ｍｇ）のジオキサン（０．５ｍｌ）中の懸濁液に、ＮａＯＨ水溶液（２Ｍ、１ｍｌ）を加え、この溶液を１００℃で４時間加熱した。この反応混合物を室温まで冷却し、この溶液のｐＨを２ＮＨＣｌ水溶液で２．５に調整した。この溶液を減圧留去して、黄色固形物を得た。この黄色固形物の１，２−ジクロロベンゼン（２ｍｌ）中の懸濁液を２００℃に加熱し、４時間攪拌した。この反応混合物を室温まで冷却した。この溶液にＩＰＥを加え、室温で１時間攪拌した。沈殿物を濾取し、ＩＰＥで洗浄した。残留固形物を、ＣＨＣｌ\n３\n−ＭｅＯＨ−２８％アンモニア水溶液（１５：１：０．１）を溶離溶媒として用いるシリカゲルカラムに入れた。溶離溶媒を留去し、残留物をＥｔＯＡｃ−ＩＰＥから再結晶して精製して、５−［５−アミノ−３−（２−ピリジル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（５ｍｇ）を淡黄色結晶として得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.13 (6H, d, J=7.0 Hz), 5.18 (1H, t, J=7.0 Hz), 6.48 (1H, d, J=9.0 Hz), 7.29-7.38 (3H, m), 7.46 (1H, d, J=7.5 Hz), 7.75 (1H, dt, J=1.7, 7.5 Hz), 8.09 (1H, s), 8.71 (1H, d, J=4.5 Hz)\n\nMS(ESI\n+\n) : 308[M+H]\n+\n, 349[M+H+MeCN]\n+\n \n\n  下記の２個の化合物を実施例１３１と同様の方法にしたがって得た。\n\n \nExample 131\n \n 3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5- (2-pyridyl) -2-pyrazine-carboxamide (52 mg) in dioxane (0.5 ml). To the suspension was added aqueous NaOH (2M, 1 ml) and the solution was heated at 100 ° C. for 4 h. The reaction mixture was cooled to room temperature and the pH of the solution was adjusted to 2.5 with 2N aqueous HCl. This solution was distilled off under reduced pressure to obtain a yellow solid. A suspension of this yellow solid in 1,2-dichlorobenzene (2 ml) was heated to 200 ° C. and stirred for 4 hours. The reaction mixture was cooled to room temperature. IPE was added to this solution and stirred at room temperature for 1 hour. The precipitate was collected by filtration and washed with IPE. The residual \nsolid,\n CHCl 3 -MeOH-28% aqueous ammonia (15: 1: 0.1) was placed in a silica gel column using as eluting solvent. The elution solvent was distilled off and the residue was purified by recrystallization from EtOAc-IPE to give 5- [5-amino-3- (2-pyridyl) -2-pyrazinyl] -1-isopropyl-2 (1H). -Pyridone (5 mg) was obtained as pale yellow crystals. \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.13 (6H, d, J = 7.0 Hz), 5.18 (1H, t, J = 7.0 Hz), 6.48 (1H, d, J = 9.0 Hz), 7.29- 7.38 (3H, m), 7.46 (1H, d, J = 7.5 Hz), 7.75 (1H, dt, J = 1.7, 7.5 Hz), 8.09 (1H, s), 8.71 (1H, d, J = 4.5 Hz) ) \n MS (ESI \n+\n ): 308 [M + H] \n+\n , 349 [M + H + MeCN] \n+\n \n The following two compounds were obtained in the same manner as in Example 131.\n\n\n\n\n\n\n \n \n実施例１３２\n \n\n  ５−［５−アミノ−３−（３−ピリジル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.98 (6H, d, J=7.0 Hz), 4.92 (1H, t, J=7.0 Hz), 6.35 (1H, d, J=9.5 Hz), 6.71 (2H, brs), 7.3 (1H, d, J=2.5 Hz), 7.38-7.46 (2H, m), 7.79 (1H, dt, J=2.5, 4.0 Hz), 7.97 (1H, s), 8.51 (1H, dd, J=1.5, 5.0 Hz), 8.56 (1H, d, J=1.5 Hz)\n\nMS(ESI\n+\n) : 308[M+H]\n+\n, 349[M+H+MeCN]\n+\n\n\n \nExample 132\n \n 5- [5-Amino-3- (3-pyridyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.98 (6H, d, J = 7.0 Hz), 4.92 (1H, t, J = 7.0 Hz), 6.35 (1H, d, J = 9.5 Hz), 6.71 ( 2H, brs), 7.3 (1H, d, J = 2.5 Hz), 7.38-7.46 (2H, m), 7.79 (1H, dt, J = 2.5, 4.0 Hz), 7.97 (1H, s), 8.51 (1H , dd, J = 1.5, 5.0 Hz), 8.56 (1H, d, J = 1.5 Hz) \n MS (ESI \n+\n ): 308 [M + H] \n+\n , 349 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１３３\n \n\n  ５−［５−アミノ−３−（４−ピリジル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.96 (6H, d, J=7.0 Hz), 4.92 (1H, t, J=7.0 Hz), 6.36 (1H, d, J=9.5 Hz), 6.74 (2H, brs), 7.25 (1H, d, J=2.5 Hz), 7.36-7.48 (3H, m), 7.99 (1H, brs), 8.56-8.59 (2H, m)\n\nMS(ESI\n+\n) : 308[M+H]\n+\n, 349[M+H+MeCN]\n+\n\n\n \nExample 133\n \n 5- [5-Amino-3- (4-pyridyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.96 (6H, d, J = 7.0 Hz), 4.92 (1H, t, J = 7.0 Hz), 6.36 (1H, d, J = 9.5 Hz), 6.74 ( 2H, brs), 7.25 (1H, d, J = 2.5 Hz), 7.36-7.48 (3H, m), 7.99 (1H, brs), 8.56-8.59 (2H, m) \n MS (ESI \n+\n ): 308 [M + H] \n+\n , 349 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１３４\n \n\n  ３−アミノ−５−クロロ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−２−ピラジンカルボキサミド（５００ｍｇ）、（４−メトキシフェニル）ホウ素酸（７４０ｍｇ）とＰｄ（ＰＰｈ\n３\n）\n４\n（５６．３ｍｇ）の２ＭＮａ\n２\nＣＯ\n３\n水溶液（３．２５ｍｌ）とジオキサン（２０ｍｌ）中の溶液を３時間還流した。水（４０ｍｌ）とＥｔＯＡｃ（３０ｍｌ）を反応混合物に注ぎ、水溶液をＥｔＯＡｃで抽出した。有機層を水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。濾過後、溶媒を減圧除去した。残留固形物を、ＣＨＣｌ\n３\n−ＭｅＯＨ（９７：３）を溶離溶媒として用いるシリカゲルカラムに入れた。溶離溶媒を留去し、残留物をＩＰＥで懸濁し、濾過して、黄色粉末を得た。この黄色粉末のジオキサン（０．５ｍｌ）中の懸濁液に、ＮａＯＨ水溶液（２Ｍ、１ｍｌ）を加え、この溶液を１００℃で４時間加熱した。この反応混合物を室温まで冷却し、この溶液のｐＨを２ＮＨＣｌ水溶液で２．５に調整した。この溶液を減圧留去して、黄色固形物を得た。この黄色固形物の１，２−ジクロロベンゼン（２ｍｌ）中懸濁液を２００℃に加熱し、４時間攪拌した。この反応混合物を室温まで冷却した。この溶液にＩＰＥを加え、室温で１時間攪拌した。沈殿物を濾取し、ＩＰＥで洗浄した。残留固形物を、ＣＨＣｌ\n３\n−ＭｅＯＨ（９７：３）を溶離溶媒として用いるシリカゲルカラムに入れた。溶離溶媒を留去し、残留物をＧＰＣ（ゲル浸透クロマトグラフィー）で精製して、５−［５−アミノ−３−（５−クロロ−２−チエニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（２５ｍｇ）と５−［５−アミノ−３−（５’−クロロ−２，２’−ビチエン−５−イル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（２６ｍｇ）を黄色粉末として得た。\n\n \nExample 134\n \n 3-amino-5-chloro-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -2-pyrazinecarboxamide (500 mg), (4-methoxyphenyl) boronic acid (740 mg) and A solution of Pd (PPh \n3\n ) \n4\n (56.3 mg) in 2M Na \n2\n CO \n3\n aqueous solution (3.25 ml) and dioxane (20 ml) was refluxed for 3 hours. Water (40 ml) and EtOAc (30 ml) were poured into the reaction mixture and the aqueous solution was extracted with EtOAc. The organic layer was washed with water and brine and dried over MgSO \n4\n . After filtration, the solvent was removed under reduced pressure. The residual solid was loaded onto a silica gel column using CHCl \n3\n -MeOH (97: 3) as the eluting solvent. The elution solvent was distilled off and the residue was suspended in IPE and filtered to give a yellow powder. To a suspension of this yellow powder in dioxane (0.5 ml) was added aqueous NaOH (2M, 1 ml) and the solution was heated at 100 ° C. for 4 hours. The reaction mixture was cooled to room temperature and the pH of the solution was adjusted to 2.5 with 2N aqueous HCl. This solution was distilled off under reduced pressure to obtain a yellow solid. A suspension of this yellow solid in 1,2-dichlorobenzene (2 ml) was heated to 200 ° C. and stirred for 4 hours. The reaction mixture was cooled to room temperature. IPE was added to this solution and stirred at room temperature for 1 hour. The precipitate was collected by filtration and washed with IPE. The residual solid was loaded onto a silica gel column using CHCl \n3\n -MeOH (97: 3) as the eluting solvent. The elution solvent was distilled off and the residue was purified by GPC (gel permeation chromatography) to give 5- [5-amino-3- (5-chloro-2-thienyl) -2-pyrazinyl] -1-isopropyl- 2 (1H) -pyridone (25 mg) and 5- [5-amino-3- (5′-chloro-2,2′-bithien-5-yl) -2-pyrazinyl] -1-isopropyl-2 (1H) -Pyridone (26 mg) was obtained as a yellow powder.\n\n\n\n\n\n\n \n\n  ５−［５−アミノ−３−（５−クロロ−２−チエニル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.24 (6H, d, J=7.0 Hz), 5.08 (1H, sept, J=7.0 Hz), 6.43 (1H, d, J=9.0 Hz), 6.7 (2H, brs), 6.86 (1H, d, J=11.4 Hz), 7.02 (1H, d, J=4.0 Hz), 7.38 (1H, dd, J=2.5, 9.0 Hz), 7.77 (1H, d, J=2.5 Hz), 7.85 (1H, brs)\n\nMS(ESI\n+\n) : 347[M+H]\n+\n, 388[M+H+MeCN]\n+\n \n\n  ５−［５−アミノ−３−（５’−クロロ−２，２’−ビチエン−５−イル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.24 (6H, d, J=6.5 Hz), 5.09 (1H, sept, J=6.5 Hz), 6.44 (1H, d, J=9.5 Hz), 6.69 (2H, brs), 6.93 (1H, d, J=3.5 Hz), 7.12-7.21 (3H, m), 7.40 (1H, dd, J=2.5, 9.5 Hz), 7.78 (1H, d, J=2.5 Hz), 7.85 (1H, s)\n\nMS(ESI\n+\n) : 429[M+H]\n+\n, 470[M+H+MeCN]\n+\n\n\n5- [5-Amino-3- (5-chloro-2-thienyl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.24 (6H, d, J = 7.0 Hz), 5.08 (1H, sept, J = 7.0 Hz), 6.43 (1H, d, J = 9.0 Hz), 6.7 ( 2H, brs), 6.86 (1H, d, J = 11.4 Hz), 7.02 (1H, d, J = 4.0 Hz), 7.38 (1H, dd, J = 2.5, 9.0 Hz), 7.77 (1H, d, J = 2.5 Hz), 7.85 (1H, brs) \n MS (ESI \n+\n ): 347 [M + H] \n+\n , 388 [M + H + MeCN] \n+\n \n 5- [5-Amino-3- (5′-chloro-2,2′-bithien-5-yl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.24 (6H, d, J = 6.5 Hz), 5.09 (1H, sept, J = 6.5 Hz), 6.44 (1H, d, J = 9.5 Hz), 6.69 ( 2H, brs), 6.93 (1H, d, J = 3.5 Hz), 7.12-7.21 (3H, m), 7.40 (1H, dd, J = 2.5, 9.5 Hz), 7.78 (1H, d, J = 2.5 Hz ), 7.85 (1H, s) \n MS (ESI \n+\n ): 429 [M + H] \n+\n , 470 [M + H + MeCN] \n+\n \n\n\n\n\n\n\n \n \n実施例１３５\n \n\n  ３−アミノ−５−（４−フルオロフェニル）−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−Ｎ−メチル−２−ピラジンカルボキサミド\n\n  表題の化合物を製造例４２と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.98 (6H, d, J=7.0 Hz), 2.84 (3H, d, J=5.0 Hz), 4.92 (1H, sept, J=7.0 Hz), 6.39 (1H, d, J=9.0 Hz), 7.21-7.78 (8H, m), 8.68 (1H, d, J=5.0 Hz)\n\nMS(ESI\n+\n) : 382[M+H]\n+\n, 404[M+Na]\n+\n, 785[2M+Na]\n+\n\n\n \nExample 135\n \n 3-Amino-5- (4-fluorophenyl) -6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -N-methyl-2-pyrazinecarboxamide The title compound was prepared in Preparation Example 42. According to the same method as above. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.98 (6H, d, J = 7.0 Hz), 2.84 (3H, d, J = 5.0 Hz), 4.92 (1H, sept, J = 7.0 Hz), 6.39 ( 1H, d, J = 9.0 Hz), 7.21-7.78 (8H, m), 8.68 (1H, d, J = 5.0 Hz) \n MS (ESI \n+\n ): 382 [M + H] \n+\n , 404 [M + Na] \n+\n , 785 [2M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１３６\n \n\n  ３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボン酸（３５０ｍｇ）のＭｅＯＨ（７．０ｍｌ）中の懸濁液に、塩化チオニル（０．１４６ｍ）を氷浴冷却下に滴下した。同温で１時間攪拌後、混合物を室温まで加温させた。混合物を６時間攪拌し、次いで攪拌しながら１５時間還流した。冷却後、溶媒を減圧除去した。水を残留物に注ぎ、混合物のｐＨを１ＮＮａＯＨ水溶液で１０に調整した。沈殿物を濾過により分離し、水で洗浄し、真空乾燥して、３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボン酸メチル（２４４ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.91 (6H, d, J=6.8 Hz), 3.89 (3H, s), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.41 (1H, d, J=9.3 Hz), 7.21 (1H, d, J=2.4 Hz), 7.30-7.50 (7H, m), 7.56 (1H, dd, J=2.4, 9.3 Hz)\n\nMS(ESI\n+\n) : 365[M+H]\n+\n, 387[M+Na]\n+\n\n\n \nExample 136\n \n Suspension of 3-amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxylic acid (350 mg) in MeOH (7.0 ml) To the solution, thionyl chloride (0.146 m) was added dropwise with cooling in an ice bath. After stirring at the same temperature for 1 hour, the mixture was allowed to warm to room temperature. The mixture was stirred for 6 hours and then refluxed with stirring for 15 hours. After cooling, the solvent was removed under reduced pressure. Water was poured into the residue and the pH of the mixture was adjusted to 10 with 1N aqueous NaOH. The precipitate was separated by filtration, washed with water, dried in vacuo, and 3-amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2- Methyl pyrazinecarboxylate (244 mg) was obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.91 (6H, d, J = 6.8 Hz), 3.89 (3H, s), 4.89 (1H, qq, J = 6.8, 6.8 Hz), 6.41 (1H, d , J = 9.3 Hz), 7.21 (1H, d, J = 2.4 Hz), 7.30-7.50 (7H, m), 7.56 (1H, dd, J = 2.4, 9.3 Hz) \n MS (ESI \n+\n ): 365 [M + H] \n+\n , 387 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１３７\n \n\n  塩化メチルマグネシウム（３Ｍ溶液、０．４６ｍｌ）を、３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジンカルボン酸メチル（１００ｍｇ）のＴＨＦ（１０ｍｌ）中の懸濁液に氷浴冷却下に加えた。同温で７．５時間攪拌後、飽和塩化アンモニウム水溶液（１ｍｌ）を混合物に注いだ。水とＥｔＯＡｃを混合物に注ぎ、有機層を分離し、水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去した。残留物をＭｅＯＨ−ＩＰＥから再結晶し、減圧乾燥して、５−［５−アミノ−６−（１−ヒドロキシ−１−メチルエチル）−３−フェニル−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（４１ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.93 (6H, d, J=6.8 Hz), 1.56 (6H, s), 4.89 (1H, qq, J=6.8, 6.8 Hz), 5.76 (1H, brs), 6.37 (1H, d, J=9.3 Hz), 6.59 (2H, brs), 7.17 (1H, d, J=2.4 Hz), 7.20-7.50 (5H, m), 7.53 (1H, dd, J=2.4, 9.3 Hz)\n\nMS(ESI\n+\n) : 365[M+H]\n+\n\n\n \nExample 137\n \n Methyl magnesium chloride (3M solution, 0.46 ml) was added to methyl 3-amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinecarboxylate ( 100 mg) in THF (10 ml) was added with ice bath cooling. After stirring at the same temperature for 7.5 hours, a saturated aqueous ammonium chloride solution (1 ml) was poured into the mixture. Water and EtOAc were poured into the mixture and the organic layer was separated, washed with water and brine and dried over MgSO \n4\n . The solvent was removed under reduced pressure. The residue was recrystallized from MeOH-IPE and dried under reduced pressure to give 5- [5-amino-6- (1-hydroxy-1-methylethyl) -3-phenyl-2-pyrazinyl] -1-isopropyl-2. (1H) -pyridone (41 mg) was obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.93 (6H, d, J = 6.8 Hz), 1.56 (6H, s), 4.89 (1H, qq, J = 6.8, 6.8 Hz), 5.76 (1H, brs ), 6.37 (1H, d, J = 9.3 Hz), 6.59 (2H, brs), 7.17 (1H, d, J = 2.4 Hz), 7.20-7.50 (5H, m), 7.53 (1H, dd, J = (2.4, 9.3 Hz) \n MS (ESI \n+\n ): 365 [M + H] \n+\n \n\n\n\n\n\n\n \n \n実施例１３８\n \n\n  ５−（６−アセチル−５−アミノ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（８２ｍｇ）のＴＨＦ−ＭｅＯＨ（１：１、２．０ｍｌ）中の溶液に、水素化ホウ素ナトリウム（８．９ｍｇ）を加えた。混合物を室温で４時間攪拌した。１ＮＨＣｌ（０．０５ｍｌ）を混合物に注いだ。水とＥｔＯＡｃを混合物に注ぎ、有機層を分離し、水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去した。残留物をカラムクロマトグラフィーで精製した。所望の生成物をＥｔＯＨから再結晶し、真空乾燥して、５−［５−アミノ−６−（１−ヒドロキシエチル）−３−フェニル−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（１６ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.93 (3H, d, J=6.7 Hz), 0.94 (3H, d, J=6.7 Hz), 1.46 (3H, d, J=6.5 Hz), 4.70-5.00 (2H, m), 5.57 (1H, d, J=5.4 Hz), 6.35 (1H, d, J=9.4 Hz), 6.40 (2H, brs), 7.18 (1H, d, J=2.5 Hz), 7.40 (5H, m), 7.53 (1H, dd, J=2.5, 9.4 Hz)\n\nMS(ESI\n+\n) : 351[M+H]\n+\n\n\n \nExample 138\n \n To a solution of 5- (6-acetyl-5-amino-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (82 mg) in THF-MeOH (1: 1, 2.0 ml). , Sodium borohydride (8.9 mg) was added. The mixture was stirred at room temperature for 4 hours. 1N HCl (0.05 ml) was poured into the mixture. Water and EtOAc were poured into the mixture and the organic layer was separated, washed with water and brine and dried over MgSO \n4\n . The solvent was removed under reduced pressure. The residue was purified by column chromatography. The desired product is recrystallized from EtOH and dried in vacuo to give 5- [5-amino-6- (1-hydroxyethyl) -3-phenyl-2-pyrazinyl] -1-isopropyl-2 (1H)- Pyridone (16 mg) was obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.93 (3H, d, J = 6.7 Hz), 0.94 (3H, d, J = 6.7 Hz), 1.46 (3H, d, J = 6.5 Hz), 4.70- 5.00 (2H, m), 5.57 (1H, d, J = 5.4 Hz), 6.35 (1H, d, J = 9.4 Hz), 6.40 (2H, brs), 7.18 (1H, d, J = 2.5 Hz), 7.40 (5H, m), 7.53 (1H, dd, J = 2.5, 9.4 Hz) \n MS (ESI \n+\n ): 351 [M + H] \n+\n \n\n\n\n\n\n\n \n \n実施例１３９\n \n\n  ＮａＨ（純度６０％、１８ｍｇ）を、５−［５−アミノ−６−（ヒドロキシメチル）−３−フェニル−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（１００ｍｇ）のＤＭＦ（１．０ｍｌ）中の懸濁液に氷浴冷却下に加えた。１０分間攪拌後、ＭｅＩ（１２７ｍｇ）を混合物に加えた。同温で１０分間攪拌後、混合物を２５℃まで加温させた。３．５時間攪拌後、ＥｔＯＡｃと水を混合物に注ぎ、有機層を分離し、水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去し、残留物をカラムクロマトグラフィーで精製し、ＩＰＥで粉末化し、真空乾燥して、５−［５−アミノ−６−（メトキシメチル）−３−フェニル−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（４０ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.93 (6H, d, J=6.7 Hz), 3.36 (3H, s), 4.53 (2H, s), 4.89 (1H, qq, J=6.7, 6.7 Hz), 6.36 (1H, d, J=9.4 Hz), 6.41 (1H, brs), 7.17 (1H, d, J=2.5 Hz), 7.2-7.5 (4H, m), 7.50 (1H, dd, J=2.5, 9.4 Hz)\n\nMS(ESI\n+\n) : 351[M+H]\n+\n, 373[M+Na]\n+\n\n\n \nExample 139\n \n NaH (purity 60%, 18 mg) was added to 5- [5-amino-6- (hydroxymethyl) -3-phenyl-2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone (100 mg) in DMF (1 0.0 ml) was added to the suspension under ice bath cooling. After stirring for 10 minutes, MeI (127 mg) was added to the mixture. After stirring at the same temperature for 10 minutes, the mixture was warmed to 25 ° C. After stirring for 3.5 hours, EtOAc and water were poured into the mixture and the organic layer was separated, washed with water and brine and dried over MgSO \n4\n . The solvent was removed under reduced pressure and the residue was purified by column chromatography, triturated with IPE and dried in vacuo to give 5- [5-amino-6- (methoxymethyl) -3-phenyl-2-pyrazinyl] -1 -Isopropyl-2 (1H) -pyridone (40 mg) was obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.93 (6H, d, J = 6.7 Hz), 3.36 (3H, s), 4.53 (2H, s), 4.89 (1H, qq, J = 6.7, 6.7 Hz ), 6.36 (1H, d, J = 9.4 Hz), 6.41 (1H, brs), 7.17 (1H, d, J = 2.5 Hz), 7.2-7.5 (4H, m), 7.50 (1H, dd, J = (2.5, 9.4 Hz) \n MS (ESI \n+\n ): 351 [M + H] \n+\n , 373 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１４０\n \n\n  ５−｛５−アミノ−６−［（ベンジルオキシ）メチル］−３−フェニル−２−ピラジニル｝−１−イソプロピル−２（１Ｈ）−ピリドン\n\n  表題の化合物を製造例１３９と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.93 (6H, d, J=6.8 Hz), 4.62 (2H, s), 4.67 (2H, s), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.35 (1H, d, J=9.4 Hz), 6.45 (2H, brs), 7.18 (1H, d, J=2.4 Hz), 7.20-7.40 (10H, m), 7.49 (1H, dd, J=2.4, 9.4 Hz)\n\nMS(ESI\n+\n) : 427[M+H]\n+\n, 449[M+Na]\n+\n\n\n \nExample 140\n \n 5- {5-Amino-6-[(benzyloxy) methyl] -3-phenyl-2-pyrazinyl} -1-isopropyl-2 (1H) -pyridone The title compound is obtained in the same manner as in Production Example 139. It was. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.93 (6H, d, J = 6.8 Hz), 4.62 (2H, s), 4.67 (2H, s), 4.89 (1H, qq, J = 6.8, 6.8 Hz ), 6.35 (1H, d, J = 9.4 Hz), 6.45 (2H, brs), 7.18 (1H, d, J = 2.4 Hz), 7.20-7.40 (10H, m), 7.49 (1H, dd, J = (2.4, 9.4 Hz) \n MS (ESI \n+\n ): 427 [M + H] \n+\n , 449 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１４１\n \n\n  Ｎ−ブロモスクシンイミド（１．８３ｇ）を、５−（５−アミノ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（３．０ｇ）のＤＭＦ（９０ｍｌ）中の溶液に氷浴冷却下に加えた。混合物を同温で２時間攪拌した。水とＣＨ\n２\nＣｌ\n２\nを混合物に注ぎ、有機層を分離し、飽和チオ硫酸ナトリウム水溶液、飽和ＮａＨＣＯ\n３\n水溶液、水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去した。残留物をカラムクロマトグラフィー（シリカゲル、トルエン−ＥｔＯＡｃ）で精製し、ＥｔＯＨから再結晶し、真空乾燥して、５−（５−アミノ−６−ブロモ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（３．０ｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.93 (6H, d, J=6.8 Hz), 4.88 (1H, qq, J=6.8, 6.8 Hz), 6.35 (1H, d, J=9.4 Hz), 6.89 (2H, brs), 7.20 (1H, d, J=2.5 Hz), 7.30-7.50 (6H, m)\n\nMS(ESI\n+\n) : 385[M+H]\n+\n, 407[M+Na]\n+\n\n\n \nExample 141\n \n A solution of N-bromosuccinimide (1.83 g) in 5- (5-amino-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (3.0 g) in DMF (90 ml). Was added under ice bath cooling. The mixture was stirred at the same temperature for 2 hours. Water and CH \n2\n Cl \n2\n were poured into the mixture and the organic layer was separated, washed with saturated aqueous sodium thiosulfate, saturated aqueous NaHCO \n3\n , water and brine, and dried over MgSO \n4\n . The solvent was removed under reduced pressure. The residue was purified by column chromatography (silica gel, toluene-EtOAc), recrystallized from EtOH and dried in vacuo to give 5- (5-amino-6-bromo-3-phenyl-2-pyrazinyl) -1- Isopropyl-2 (1H) -pyridone (3.0 g) was obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.93 (6H, d, J = 6.8 Hz), 4.88 (1H, qq, J = 6.8, 6.8 Hz), 6.35 (1H, d, J = 9.4 Hz), 6.89 (2H, brs), 7.20 (1H, d, J = 2.5 Hz), 7.30-7.50 (6H, m) \n MS (ESI \n+\n ): 385 [M + H] \n+\n , 407 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１４２\n \n\n  ５−（５−アミノ−６−ブロモ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（１００ｍｇ）とＰｄ（ＰＰｈ\n３\n）\n４\n（１５ｍｇ）のＴＨＦ（１．０ｍｌ）中の懸濁液に、塩化メチル亜鉛のＴＨＦ中の溶液（２．０Ｍ、０．７５ｍｌ）を加えた。混合物を２５℃で７．５時間攪拌し、次いで６０℃で１．５時間加熱した。冷却後、ＥｔＯＡｃと水を混合物に注ぎ、有機層を分離し、水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去した。残留物をＭｅＯＨ−ＩＰＥから結晶化し、真空乾燥して、５−（５−アミノ−６−メチル−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（９５ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.94 (6H, d, J=6.8 Hz), 2.38 (3H, s), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.33 (1H, d, J=9.4 Hz), 6.38 (2H, s), 7.15 (1H, d, J=2.4 Hz), 7.20-7.50 (5H, m), 7.49 (1H, dd, J=2.4, 9.4 Hz)\n\nMS(ESI\n+\n) : 321[M+H]\n+\n, 343[M+Na]\n+\n\n\n \nExample 142\n \n 5- (5-amino-6-bromo-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (100 mg) and Pd (PPh \n3\n ) \n4\n (15 mg) in THF (1.0 ml) To the suspension in was added a solution of methylzinc chloride in THF (2.0 M, 0.75 ml). The mixture was stirred at 25 ° C. for 7.5 hours and then heated at 60 ° C. for 1.5 hours. After cooling, EtOAc and water were poured into the mixture and the organic layer was separated, washed with water and brine and dried over MgSO \n4\n . The solvent was removed under reduced pressure. The residue was crystallized from MeOH-IPE and dried in vacuo to give 5- (5-amino-6-methyl-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (95 mg). It was. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.94 (6H, d, J = 6.8 Hz), 2.38 (3H, s), 4.89 (1H, qq, J = 6.8, 6.8 Hz), 6.33 (1H, d , J = 9.4 Hz), 6.38 (2H, s), 7.15 (1H, d, J = 2.4 Hz), 7.20-7.50 (5H, m), 7.49 (1H, dd, J = 2.4, 9.4 Hz) \n MS (ESI \n+\n ): 321 [M + H] \n+\n , 343 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１４３\n \n\n  ５−（５−アミノ−６−ブロモ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（１００ｍｇ）、フェニルホウ素酸（７９ｍｇ）、Ｐｄ（ＰＰｈ\n３\n）\n４\n（９ｍｇ）、Ｎａ\n２\nＣＯ\n３\n（１１０ｍｇ）の水（０．８ｍｌ）とジオキサン（２．０ｍｌ）中の溶液からなる混合物を攪拌しながら９０℃で１時間加熱した。冷却後、ＥｔＯＡｃと水を混合物に注ぎ、有機層を分離し、水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去した。残留物をＭｅＯＨ−ＩＰＥから再結晶し、真空乾燥して、５−（５−アミノ−３，６−ジフェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（８４ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.94 (6H, d, J=6.8 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 6.30-6.40 (3H, m), 7.24 (dH, d, J=2.0 Hz), 7.30-7.70 (9H, m), 7.80-7.90 (2H, m)\n\nMS(ESI\n+\n) : 383[M+H]\n+\n, 405[M+Na]\n+\n\n\n \nExample 143\n \n 5- (5-Amino-6-bromo-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (100 mg), phenylboronic acid (79 mg), Pd (PPh \n3\n ) \n4\n (9 mg) A mixture of a solution of Na \n2\n CO \n3\n (110 mg) in water (0.8 ml) and dioxane (2.0 ml) was heated at 90 ° C. with stirring for 1 hour. After cooling, EtOAc and water were poured into the mixture and the organic layer was separated, washed with water and brine and dried over MgSO \n4\n . The solvent was removed under reduced pressure. The residue was recrystallized from MeOH-IPE and dried in vacuo to give 5- (5-amino-3,6-diphenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (84 mg). . \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.94 (6H, d, J = 6.8 Hz), 4.90 (1H, qq, J = 6.8, 6.8 Hz), 6.30-6.40 (3H, m), 7.24 (dH , d, J = 2.0 Hz), 7.30-7.70 (9H, m), 7.80-7.90 (2H, m) \n MS (ESI \n+\n ): 383 [M + H] \n+\n , 405 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１４４\n \n\n  ５−［５−アミノ−６−（２−フリル）−３−フェニル−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n  表題の化合物を製造例１４３と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.95 (6H, d, J=6.8 Hz), 4.91 (1H, qq, J=6.8, 6.8 Hz), 6.38 (1H, d, J=9.4 Hz), 6.60-6.80 (3H, m), 7.19 (1H, d, J=3.4 Hz), 7.27 (1H, d, J=2.4 Hz), 7.30-7.50 (5H, m), 7.59 (1H, dd, J=2.4, 9.4 Hz), 7.89 (1H, d, J=1.1 Hz)\n\nMS(ESI\n+\n) : 373[M+H]\n+\n, 395[M+Na]\n+\n\n\n \nExample 144\n \n 5- [5-Amino-6- (2-furyl) -3-phenyl-2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone The title compound was obtained in the same manner as in Production Example 143. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.95 (6H, d, J = 6.8 Hz), 4.91 (1H, qq, J = 6.8, 6.8 Hz), 6.38 (1H, d, J = 9.4 Hz), 6.60-6.80 (3H, m), 7.19 (1H, d, J = 3.4 Hz), 7.27 (1H, d, J = 2.4 Hz), 7.30-7.50 (5H, m), 7.59 (1H, dd, J = 2.4, 9.4 Hz), 7.89 (1H, d, J = 1.1 Hz) \n MS (ESI \n+\n ): 373 [M + H] \n+\n , 395 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１４５\n \n\n  ５−（５−アミノ−６−ブロモ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（１００ｍｇ）、アクリルアミド（５５ｍｇ）、Ｐｄ（ＯＡｃ）\n２\n（３ｍｇ）、トリス（２−メチルフェニル）ホスフィン（８ｍｇ）、ＮＥｔ\n３\n（０．１１ｍｌ）とＤＭＦ（１．０ｍｌ）の混合物を攪拌しながら６０℃で１時間、次いで９０℃で５時間加熱した。冷却後、ＥｔＯＡｃと水を混合物に注ぎ、有機層を分離し、水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去した。残留物をＥｔＯＡｃから再結晶し、真空乾燥して、（２Ｅ）−３−［３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジニル］アクリルアミド（７０ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.93 (6H, d, J=6.8 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 6.40 (1H, d, J=9.4 Hz), 6.81 (2H, brs), 7.08 (1H, d, J=14.9 Hz), 7.10-7.20 (2H, m), 7.20-7.50 (5H, m), 7.62 (1H, dd, J=2.5, 9.3 Hz), 7.70 (1H, brs), 7.75 (1H, d, J=14.9 Hz)\n\nMS(ESI\n+\n) : 376[M+H]\n+\n, 398[M+Na]\n+\n\n\n \nExample 145\n \n 5- (5-amino-6-bromo-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (100 mg), acrylamide (55 mg), Pd (OAc) \n2\n (3 mg), tris ( A mixture of 2-methylphenyl) phosphine (8 mg), NEt \n3\n (0.11 ml) and DMF (1.0 ml) was heated with stirring at 60 ° C. for 1 hour and then at 90 ° C. for 5 hours. After cooling, EtOAc and water were poured into the mixture and the organic layer was separated, washed with water and brine and dried over MgSO \n4\n . The solvent was removed under reduced pressure. The residue was recrystallized from EtOAc, dried in vacuo and (2E) -3- [3-amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl -2-Pyrazinyl] acrylamide (70 mg) was obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.93 (6H, d, J = 6.8 Hz), 4.90 (1H, qq, J = 6.8, 6.8 Hz), 6.40 (1H, d, J = 9.4 Hz), 6.81 (2H, brs), 7.08 (1H, d, J = 14.9 Hz), 7.10-7.20 (2H, m), 7.20-7.50 (5H, m), 7.62 (1H, dd, J = 2.5, 9.3 Hz) , 7.70 (1H, brs), 7.75 (1H, d, J = 14.9 Hz) \n MS (ESI \n+\n ): 376 [M + H] \n+\n , 398 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１４６\n \n\n  （２Ｅ）−３−［３−アミノ−６−（１−イソプロピル−６−オキソ−１，６−ジヒドロ−３−ピリジル）−５−フェニル−２−ピラジニル］−Ｎ，Ｎ−ジメチルアクリルアミド\n\n  表題の化合物を製造例１４５と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.96 (6H, d, J=6.7 Hz), 2.96 (3H, s), 3.16 (3H, s), 4.92 (1H, qq, J=6.7, 6.7 Hz), 6.36 (1H, d, J=9.4 Hz), 6.84 (2H, brs), 7.30-7.60 (8H, m), 7.79 (1H, d, J=14.6 Hz)\n\nMS(ESI\n+\n) : 404[M+H]\n+\n, 426[M+Na]\n+\n\n\n \nExample 146\n \n (2E) -3- [3-Amino-6- (1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl) -5-phenyl-2-pyrazinyl] -N, N-dimethylacrylamide The compound was obtained in the same manner as in Production Example 145. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.96 (6H, d, J = 6.7 Hz), 2.96 (3H, s), 3.16 (3H, s), 4.92 (1H, qq, J = 6.7, 6.7 Hz ), 6.36 (1H, d, J = 9.4 Hz), 6.84 (2H, brs), 7.30-7.60 (8H, m), 7.79 (1H, d, J = 14.6 Hz) \n MS (ESI \n+\n ): 404 [M + H] \n+\n , 426 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１４７\n \n\n  ５−（５−アミノ−６−ブロモ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（５００ｍｇ）、エチニル（トリメチル）シラン（２５５ｍｇ）、ＰｄＣｌ\n２\n（ＰＰｈ\n３\n）\n２\n（４６ｍｇ）、ＣｕＩ（１２ｍｇ）とＣＨ\n２\nＣｌ\n２\n（１０ｍｌ）の混合物に、ＮＥｔ\n３\n（０．２ｍｌ）を氷浴冷却下に加えた。混合物を２５℃まで加温させ、１５時間攪拌した。水とＥｔＯＡｃを混合物に注ぎ、有機層を分離し、水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去した。残留物をカラムクロマトグラフィー（シリカゲル；ＣＨ\n２\nＣｌ\n２\n−ＭｅＯＨ）で精製し、ＥｔＯＨから再結晶し、真空乾燥して、５−｛５−アミノ−３−フェニル−６−［（トリメチルシリル）エチニル］−２−ピラジニル｝−１−イソプロピル−２（１Ｈ）−ピリドン（３７３ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.29 (9H, s), 0.94 (6H, d, J=6.7 Hz), 4.89 (1H, qq, J=6.7, 6.7 Hz), 6.34 (1H, d, J=9.4 Hz), 6.70 (2H, brs), 7.21 (1H, d, J=2.4 Hz), 7.30-7.50 (5H, m), 7.47 (1H, dd, J=2.5, 9.4 Hz)\n\nMS(ESI\n+\n) : 403[M+H]\n+\n, 425[M+Na]\n+\n\n\n \nExample 147\n \n 5- (5-Amino-6-bromo-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (500 mg), ethynyl (trimethyl) silane (255 mg), PdCl \n2\n (PPh \n3\n ) \n2\n NEt \n3\n (0.2 ml) was added to a mixture of (46 mg), CuI (12 mg) and CH \n2\n Cl \n2\n (10 ml) under ice bath cooling. The mixture was warmed to 25 ° C. and stirred for 15 hours. Water and EtOAc were poured into the mixture and the organic layer was separated, washed with water and brine and dried over MgSO \n4\n . The solvent was removed under reduced pressure. The residue was purified by column chromatography (silica gel; CH \n2\n Cl \n2\n -MeOH), recrystallized from EtOH, dried in vacuo, and 5- {5-amino-3-phenyl-6-[(trimethylsilyl) ethynyl] -2-Pyrazinyl} -1-isopropyl-2 (1H) -pyridone (373 mg) was obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.29 (9H, s), 0.94 (6H, d, J = 6.7 Hz), 4.89 (1H, qq, J = 6.7, 6.7 Hz), 6.34 (1H, d , J = 9.4 Hz), 6.70 (2H, brs), 7.21 (1H, d, J = 2.4 Hz), 7.30-7.50 (5H, m), 7.47 (1H, dd, J = 2.5, 9.4 Hz) \n MS (ESI \n+\n ): 403 [M + H] \n+\n , 425 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１４８\n \n\n  ５−｛５−アミノ−３−フェニル−６−［（トリメチルシリル）エチニル］−２−ピラジニル｝−１−イソプロピル−２（１Ｈ）−ピリドン（３００ｍｇ）とＭｅＯＨ中の飽和Ｋ\n２\nＣＯ\n３\n（４．５ｍｌ）の混合物を２５℃で３時間攪拌した。水とＥｔＯＡｃを混合物に注ぎ、有機層を分離し、水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去した。残留物をショートカラム（シリカゲル；ＣＨ\n２\nＣｌ\n２\n）で精製し、ＥｔＯＨから再結晶して、５−（５−アミノ−６−エチニル−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（１００ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.95 (6H, d, J=6.8 Hz), 4.71 (1H, s), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.34 (1H, d, J=9.3 Hz), 6.75 (2H, brs), 7.22 (1H, d, J=2.5 Hz), 7.30-7.50 (6H, m)\n\nMS(ESI\n+\n) : 331[M+H]\n+\n, 353[M+Na]\n+\n\n\n \nExample 148\n \n 5- {5-Amino-3-phenyl-6-[(trimethylsilyl) ethynyl] -2-pyrazinyl} -1-isopropyl-2 (1H) -pyridone (300 mg) and saturated K \n2\n CO \n3 in\n MeOH (4. 5 ml) was stirred at 25 ° C. for 3 hours. Water and EtOAc were poured into the mixture and the organic layer was separated, washed with water and brine and dried over MgSO \n4\n . The solvent was removed under reduced pressure. The residue was purified on a short column (silica gel; CH \n2\n Cl \n2\n ) and recrystallized from EtOH to give 5- (5-amino-6-ethynyl-3-phenyl-2-pyrazinyl) -1-isopropyl-2 ( 1H) -pyridone (100 mg) was obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.95 (6H, d, J = 6.8 Hz), 4.71 (1H, s), 4.89 (1H, qq, J = 6.8, 6.8 Hz), 6.34 (1H, d , J = 9.3 Hz), 6.75 (2H, brs), 7.22 (1H, d, J = 2.5 Hz), 7.30-7.50 (6H, m) \n MS (ESI \n+\n ): 331 [M + H] \n+\n , 353 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１４９\n \n\n  ５−（５−アミノ−６−ブロモ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（１００ｍｇ）、ナトリウムメトキシド（７０ｍｇ）とＣｕＩ（５ｍｇ）のＮＭＰ（１．０ｍｌ）中の混合物を１００℃で２．５時間加熱した。冷却後、ＥｔＯＡｃと水を混合物に注ぎ、有機層を分離し、水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去した。残留物をＭｅＯＨ−ＩＰＥから再結晶して、５−（５−アミノ−６−メトキシ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（５８ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.94 (6H, d, J=6.7 Hz), 3.98 (3H, s), 4.90 (1H, qq, J=6.7, 6.7 Hz), 6.35 (1H, d, J=9.4 Hz), 6.49 (2H, brs), 7.19 (1H, d, J=9.4 Hz), 7.20-7.40 (5H, m), 7.52 (1H, dd, J=2.5, 9.4 Hz)\n\nMS(ESI\n+\n) : 337[M+H]\n+\n, 359[M+Na]\n+\n\n\n \nExample 149\n \n 5- (5-amino-6-bromo-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (100 mg), sodium methoxide (70 mg) and CuI (5 mg) NMP (1. The mixture in 0 ml) was heated at 100 ° C. for 2.5 hours. After cooling, EtOAc and water were poured into the mixture and the organic layer was separated, washed with water and brine and dried over MgSO \n4\n . The solvent was removed under reduced pressure. The residue was recrystallized from MeOH-IPE to give 5- (5-amino-6-methoxy-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (58 mg). \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.94 (6H, d, J = 6.7 Hz), 3.98 (3H, s), 4.90 (1H, qq, J = 6.7, 6.7 Hz), 6.35 (1H, d , J = 9.4 Hz), 6.49 (2H, brs), 7.19 (1H, d, J = 9.4 Hz), 7.20-7.40 (5H, m), 7.52 (1H, dd, J = 2.5, 9.4 Hz) \n MS (ESI \n+\n ): 337 [M + H] \n+\n , 359 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１５０\n \n\n  ５−（５−アミノ−６−メトキシ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（８０ｍｇ）、濃ＨＣｌ（０．８ｍｌ）とジオキサン（１．６ｍｌ）の混合物を攪拌しながら１００℃で３時間加熱した。冷却後、混合物のｐＨを８に調整し、生じた沈殿物を濾過分離し、真空乾燥して、５−（５−アミノ−６−ヒドロキシ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（３６ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 1.08 (6H, d, J=6.8 Hz), 4.94 (1H, qq, J=6.8, 6.8 Hz), 6.26 (1H, d, J=9.4 Hz), 6.76 (2H, brs), 7.13 (1H, dd, J=2.2, 9.4 Hz), 7.1-7.3 (5H, m), 7.46 (1H, d, J=2.2 Hz), 11.91 (1H, brs)\n\nMS(ESI\n+\n) : 323[M+H]\n+\n, 345[M+Na]\n+\n\n\n \nExample 150\n \n 5- (5-Amino-6-methoxy-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (80 mg), a mixture of concentrated HCl (0.8 ml) and dioxane (1.6 ml) The mixture was heated at 100 ° C. for 3 hours with stirring. After cooling, the pH of the mixture is adjusted to 8, and the resulting precipitate is filtered off and dried in vacuo to give 5- (5-amino-6-hydroxy-3-phenyl-2-pyrazinyl) -1-isopropyl- 2 (1H) -pyridone (36 mg) was obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 1.08 (6H, d, J = 6.8 Hz), 4.94 (1H, qq, J = 6.8, 6.8 Hz), 6.26 (1H, d, J = 9.4 Hz), 6.76 (2H, brs), 7.13 (1H, dd, J = 2.2, 9.4 Hz), 7.1-7.3 (5H, m), 7.46 (1H, d, J = 2.2 Hz), 11.91 (1H, brs) \n MS (ESI \n+\n ): 323 [M + H] \n+\n , 345 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１５１\n \n\n  フェノール（１４７ｍｇ）のＮＭＰ（１．０ｍｌ）中の溶液に、６０％ＮａＨ（５２ｍｇ）を氷浴冷却下に加えた。５分間攪拌後、５−（５−アミノ−６−ブロモ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（１００ｍｇ）を混合物に同温で加えた。次いで混合物を攪拌しながら１００℃で５．５時間加熱した。冷却後、ＥｔＯＡｃと水を混合物に注ぎ、有機層を分離し、水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去した。残留物をＭｅＯＨ−ＩＰＥから再結晶して、５−（５−アミノ−６−フェノキシ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（８８ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.90 (6H, d, J=6.8 Hz), 4.86 (1H, qq, J=6.8, 6.8 Hz), 6.23 (1H, d, J=10.1 Hz), 7.15 (2H, m), 7.20-7.50 (10H, m)\n\nMS(ESI\n+\n) : 399[M+H]\n+\n, 421[M+Na]\n+\n\n\n \nExample 151\n \n To a solution of phenol (147 mg) in NMP (1.0 ml) was added 60% NaH (52 mg) under ice bath cooling. After stirring for 5 minutes, 5- (5-amino-6-bromo-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (100 mg) was added to the mixture at the same temperature. The mixture was then heated at 100 ° C. with stirring for 5.5 hours. After cooling, EtOAc and water were poured into the mixture and the organic layer was separated, washed with water and brine and dried over MgSO \n4\n . The solvent was removed under reduced pressure. The residue was recrystallized from MeOH-IPE to give 5- (5-amino-6-phenoxy-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (88 mg). \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.90 (6H, d, J = 6.8 Hz), 4.86 (1H, qq, J = 6.8, 6.8 Hz), 6.23 (1H, d, J = 10.1 Hz), 7.15 (2H, m), 7.20-7.50 (10H, m) \n MS (ESI \n+\n ): 399 [M + H] \n+\n , 421 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１５２\n \n\n  ５−（５−アミノ−６−ブロモ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（１００ｍｇ）とＴＨＦ中のメチルアミン溶液（２．０Ｍ、１．０ｍｌ）の混合物をシールドチューブ内で攪拌しながら１００℃で２０時間加熱した。冷却後、溶媒を減圧除去し、残留物をＭｅＯＨ−ＩＰＥから再結晶して、５−［５−アミノ−６−（メチルアミノ）−３−フェニル−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（１３ｍｇ）を得た。濾液を真空濃縮し、残留物をＭｅＯＨ−ＩＰＥで洗浄し、所望の生成物（６０ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.94 (6H, d, J=6.7 Hz), 2.93 (3H, d, J=4.4 Hz), 4.90 (1H, qq, J=6.7, 6.7 Hz), 6.11 (2H, brs), 6.33 (1H, d, J=9.3 Hz), 6.49 (1H, m), 7.19 (1H, d, J=2.4 Hz), 7.10-7.40 (5H, m), 7.52 (1H, dd, J=2.4, 9.4 Hz)\n\nMS(ESI\n+\n) : 336[M+H]\n+\n, 358[M+Na]\n+\n\n\n \nExample 152\n \n Of 5- (5-amino-6-bromo-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (100 mg) and a solution of methylamine in THF (2.0 M, 1.0 ml). The mixture was heated at 100 ° C. for 20 hours with stirring in a shield tube. After cooling, the solvent was removed under reduced pressure and the residue was recrystallized from MeOH-IPE to give 5- [5-amino-6- (methylamino) -3-phenyl-2-pyrazinyl] -1-isopropyl-2 ( 1H) -pyridone (13 mg) was obtained. The filtrate was concentrated in vacuo and the residue was washed with MeOH-IPE to give the desired product (60 mg). \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.94 (6H, d, J = 6.7 Hz), 2.93 (3H, d, J = 4.4 Hz), 4.90 (1H, qq, J = 6.7, 6.7 Hz), 6.11 (2H, brs), 6.33 (1H, d, J = 9.3 Hz), 6.49 (1H, m), 7.19 (1H, d, J = 2.4 Hz), 7.10-7.40 (5H, m), 7.52 (1H , dd, J = 2.4, 9.4 Hz) \n MS (ESI \n+\n ): 336 [M + H] \n+\n , 358 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１５３\n \n\n  ５−（５−アミノ−６−ブロモ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（１００ｍｇ）、モルホリン（１１３ｍｇ）とＮＭＰ（１．０ｍｌ）の混合物を攪拌しながら１５０℃で一日間加熱した。冷却後、ＥｔＯＡｃと水を混合物に注ぎ、有機層を分離し、水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去し、残留物をＭｅＯＨ−ＩＰＥから再結晶し、真空乾燥して、５−［５−アミノ−６−（４−モルホリニル）−３−フェニル−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（８４ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.94 (6H, d, J=6.7 Hz), 3.10-3.20 (4H, m), 3.70-3.90 (4H, m), 4.90 (1H, qq, J=6.7, 6.7 Hz), 6.22 (2H, brs), 6.35 (1H, d, J=9.4 Hz), 7.19 (1H, d, J=2.4 Hz), 7.20-7.40 (5H, m), 7.54 (1H, dd, J=2.4, 9.4 Hz)\n\nMS(ESI\n+\n) : 392[M+H]\n+\n, 414[M+Na]\n+\n\n\n \nExample 153\n \n A mixture of 5- (5-amino-6-bromo-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (100 mg), morpholine (113 mg) and NMP (1.0 ml) was stirred. The mixture was heated at 150 ° C. for 1 day. After cooling, EtOAc and water were poured into the mixture and the organic layer was separated, washed with water and brine and dried over MgSO \n4\n . The solvent was removed under reduced pressure and the residue was recrystallized from MeOH-IPE and dried in vacuo to give 5- [5-amino-6- (4-morpholinyl) -3-phenyl-2-pyrazinyl] -1-isopropyl- 2 (1H) -pyridone (84 mg) was obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.94 (6H, d, J = 6.7 Hz), 3.10-3.20 (4H, m), 3.70-3.90 (4H, m), 4.90 (1H, qq, J = 6.7, 6.7 Hz), 6.22 (2H, brs), 6.35 (1H, d, J = 9.4 Hz), 7.19 (1H, d, J = 2.4 Hz), 7.20-7.40 (5H, m), 7.54 (1H, (dd, J = 2.4, 9.4 Hz) \n MS (ESI \n+\n ): 392 [M + H] \n+\n , 414 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１５４\n \n\n  ５−（５−アミノ−６−ブロモ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（１００ｍｇ）、ジメチルアミン塩酸塩（１０６ｍｇ）、Ｎ，Ｎ−ジイソプロピルエチルアミン（２０１ｍｇ）のＮＭＰ（１．０ｍｌ）中の混合物を攪拌しながら１５０℃で６５時間加熱した。冷却後、ＥｔＯＡｃと水を混合物に注ぎ、有機層を分離し、水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去した。残留物をＭｅＯＨ−ＩＰＥから再結晶し、真空乾燥して、５−［５−アミノ−６−（ジメチルアミノ）−３−フェニル−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（８ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.94 (6H, d, J=7.0 Hz), 2.83 (6H, s), 4.90 (1H, qq, J=7.0, 7.0 Hz), 6.16 (2H, brs), 6.34 (1H, d, J=9.5 Hz), 7.20 (1H, d, J=2.5 Hz), 7.20-7.40 (5H, m), 7.54 (1H, dd, J=2.5, 9.5 Hz)\n\nMS(ESI\n+\n) : 350[M+H]\n+\n, 372[M+Na]\n+\n\n\n \nExample 154\n \n 5- (5-Amino-6-bromo-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (100 mg), dimethylamine hydrochloride (106 mg), N, N-diisopropylethylamine (201 mg) ) In NMP (1.0 ml) was heated with stirring at 150 ° C. for 65 hours. After cooling, EtOAc and water were poured into the mixture and the organic layer was separated, washed with water and brine and dried over MgSO \n4\n . The solvent was removed under reduced pressure. The residue was recrystallized from MeOH-IPE, dried under vacuum, and 5- [5-amino-6- (dimethylamino) -3-phenyl-2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone ( 8 mg) was obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.94 (6H, d, J = 7.0 Hz), 2.83 (6H, s), 4.90 (1H, qq, J = 7.0, 7.0 Hz), 6.16 (2H, brs ), 6.34 (1H, d, J = 9.5 Hz), 7.20 (1H, d, J = 2.5 Hz), 7.20-7.40 (5H, m), 7.54 (1H, dd, J = 2.5, 9.5 Hz) \n MS (ESI \n+\n ): 350 [M + H] \n+\n , 372 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１５５\n \n\n  ピラゾール（１０６ｍｇ）のＮＭＰ（１．０ｍｌ）中の溶液に、６０％ＮａＨ（５２ｍｇ）を氷浴冷却下に加えた。５分間攪拌後、５−（５−アミノ−６−ブロモ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（１００ｍｇ）を混合物に加えた。次いで混合物を攪拌しながら１００℃で２時間加熱した。冷却後、ＥｔＯＡｃと水を混合物に注ぎ、有機層を分離し、水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去し、残留物をＭｅＯＨから再結晶し、真空乾燥して、５−［５−アミノ−３−フェニル−６−（１Ｈ−ピラゾール−１−イル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（６０ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.98 (6H, d, J=6.8 Hz), 4.92 (1H, qq, J=6.8, 6.8 Hz), 6.38 (1H, d, J=9.4 Hz), 6.68 (1H, m), 7.3-7.5 (6H, m), 7.5-7.7 (3H, m), 7.94 (1H, m), 8.78 (1H, m)\n\nMS(ESI\n-\n) : 371[M-H]\n-\n\n\n \nExample 155\n \n To a solution of pyrazole (106 mg) in NMP (1.0 ml) was added 60% NaH (52 mg) under ice bath cooling. After stirring for 5 minutes, 5- (5-amino-6-bromo-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (100 mg) was added to the mixture. The mixture was then heated at 100 ° C. with stirring for 2 hours. After cooling, EtOAc and water were poured into the mixture and the organic layer was separated, washed with water and brine and dried over MgSO \n4\n . The solvent was removed under reduced pressure and the residue was recrystallized from MeOH and dried in vacuo to give 5- [5-amino-3-phenyl-6- (1H-pyrazol-1-yl) -2-pyrazinyl] -1- Isopropyl-2 (1H) -pyridone (60 mg) was obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.98 (6H, d, J = 6.8 Hz), 4.92 (1H, qq, J = 6.8, 6.8 Hz), 6.38 (1H, d, J = 9.4 Hz), 6.68 (1H, m), 7.3-7.5 (6H, m), 7.5-7.7 (3H, m), 7.94 (1H, m), 8.78 (1H, m) \n \nMS (ESI -): 371 [\n MH] -\n\n\n\n\n\n\n \n \n実施例１５６\n \n\n  ５−［５−アミノ−３−フェニル−６−（１Ｈ−ピロール−１−イル）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン\n\n  表題の化合物を製造例１５５と同様の方法にしたがって得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.95 (6H, d, J=6.8 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 6.3-6.4 (3H, m), 6.49 (2H, brs), 7.28 (1H, d, J=2.4 Hz), 7.30-7.50 (7H, m), 7.53 (1H, dd, J=2.4, 9.4 Hz)\n\nMS(ESI\n+\n) : 372[M+H]\n+\n, 394[M+Na]\n+\n\n\n \nExample 156\n \n 5- [5-Amino-3-phenyl-6- (1H-pyrrol-1-yl) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone The title compound was prepared in the same manner as in Production Example 155. Thus obtained. \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.95 (6H, d, J = 6.8 Hz), 4.90 (1H, qq, J = 6.8, 6.8 Hz), 6.3-6.4 (3H, m), 6.49 (2H , brs), 7.28 (1H, d, J = 2.4 Hz), 7.30-7.50 (7H, m), 7.53 (1H, dd, J = 2.4, 9.4 Hz) \n MS (ESI \n+\n ): 372 [M + H] \n+\n , 394 [M + Na] \n+\n \n\n\n\n\n\n\n \n \n実施例１５７\n \n\n  ６０％ＮａＨ（５２ｍｇ）のＮＭＰ（１．０ｍｌ）中の懸濁液に、チオフェノール（１４３ｍｇ）を氷浴冷却下に加えた。１０分間攪拌後、５−（５−アミノ−６−ブロモ−３−フェニル−２−ピラジニル）−１−イソプロピル−２（１Ｈ）−ピリドン（１００ｍｇ）を混合物に同温で加えた。混合物を同温で１０分間攪拌し、次いで２５℃まで加温させた。２時間攪拌後、混合物を１００℃で１時間加熱した。冷却後、ＥｔＯＡｃと水を混合物に注ぎ、有機層を分離し、水と食塩水で洗浄し、ＭｇＳＯ\n４\nで乾燥した。溶媒を減圧除去した。残留物をＭｅＯＨ−ＩＰＥから再結晶して、５−［５−アミノ−３−フェニル−６−（フェニルチオ）−２−ピラジニル］−１−イソプロピル−２（１Ｈ）−ピリドン（９３ｍｇ）を得た。\n\n\n1\nH-NMR(DMSO-d\n6\n δ) : 0.93 (6H, d, J=6.8 Hz), 4.87 (1H, qq, J=6.8, 6.8 Hz), 6.18 (1H, d, J=9.4 Hz), 6.62 (2H, brs), 7.06 (1H, dd, J=2.4, 9.4 Hz), 7.17 (1H, d, J=2.4 Hz), 7.3-7.5 (8H, m), 7.5-7.6 (2H, m)\n\nMS(ESI\n+\n) : 415[M+H]\n+\n, 437[M+Na]\n+\n \n\n\n\n\n\n\n\n\n \nExample 157\n \n To a suspension of 60% NaH (52 mg) in NMP (1.0 ml), thiophenol (143 mg) was added under ice bath cooling. After stirring for 10 minutes, 5- (5-amino-6-bromo-3-phenyl-2-pyrazinyl) -1-isopropyl-2 (1H) -pyridone (100 mg) was added to the mixture at the same temperature. The mixture was stirred at the same temperature for 10 minutes and then allowed to warm to 25 ° C. After stirring for 2 hours, the mixture was heated at 100 ° C. for 1 hour. After cooling, EtOAc and water were poured into the mixture and the organic layer was separated, washed with water and brine and dried over MgSO \n4\n . The solvent was removed under reduced pressure. The residue was recrystallized from MeOH-IPE to give 5- [5-amino-3-phenyl-6- (phenylthio) -2-pyrazinyl] -1-isopropyl-2 (1H) -pyridone (93 mg). . \n \n1\n H-NMR (DMSO-d \n6\n δ): 0.93 (6H, d, J = 6.8 Hz), 4.87 (1H, qq, J = 6.8, 6.8 Hz), 6.18 (1H, d, J = 9.4 Hz), 6.62 (2H, brs), 7.06 (1H, dd, J = 2.4, 9.4 Hz), 7.17 (1H, d, J = 2.4 Hz), 7.3-7.5 (8H, m), 7.5-7.6 (2H, m) \n MS (ESI \n+\n ): 415 [M + H] \n+\n , 437 [M + Na] \n+"
  }
]